Next Article in Journal
Placenta-Related Parameters at Delivery in Relation to Folic Acid Supplementation in Different Pregnancies
Previous Article in Journal
Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Unveiling the Immunomodulatory Potential of Phenolic Compounds in Food Allergies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 16
Issue 11
10.3390/nu16111728
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials

by
Young-Min Lee
1 and
Yoona Kim
2,*
1
Department of Practical Science Education, Gyeongin National University of Education, Gyesan-ro 62, Gyeyang-gu, Incheon 21044, Republic of Korea
2
Department of Food and Nutrition, Institute of Agriculture and Life Science, Gyeongsang National University, Jinju 52828, Republic of Korea
*
Author to whom correspondence should be addressed.
Nutrients 2024, 16(11), 1728; https://doi.org/10.3390/nu16111728
Submission received: 8 May 2024 / Revised: 28 May 2024 / Accepted: 29 May 2024 / Published: 31 May 2024
(This article belongs to the Special Issue Immunomodulatory Effects of Dietary Polyphenols)
Browse Figure
Review Reports Versions Notes

Abstract

:
This review aimed to examine the effects of curcumin on chronic inflammatory metabolic disease by extensively evaluating meta-analyses of randomized controlled trials (RCTs). We performed a literature search of meta-analyses of RCTs published in English in PubMed®/MEDLINE up to 31 July 2023. We identified 54 meta-analyses of curcumin RCTs for inflammation, antioxidant, glucose control, lipids, anthropometric parameters, blood pressure, endothelial function, depression, and cognitive function. A reduction in C-reactive protein (CRP) levels was observed in seven of ten meta-analyses of RCTs. In five of eight meta-analyses, curcumin intake significantly lowered interleukin 6 (IL-6) levels. In six of nine meta-analyses, curcumin intake significantly lowered tumor necrosis factor α (TNF-α) levels. In five of six meta-analyses, curcumin intake significantly lowered malondialdehyde (MDA) levels. In 14 of 15 meta-analyses, curcumin intake significantly reduced fasting blood glucose (FBG) levels. In 12 of 12 meta-analyses, curcumin intake significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR). In seven of eight meta-analyses, curcumin intake significantly reduced glycated hemoglobin (HbA1c) levels. In eight of ten meta-analyses, curcumin intake significantly reduced insulin levels. In 14 of 19 meta-analyses, curcumin intake significantly reduced total cholesterol (TC) levels. Curcumin intake plays a protective effect on chronic inflammatory metabolic disease, possibly via improved levels of glucose homeostasis, MDA, TC, and inflammation (CRP, IL-6, TNF-α, and adiponectin). The safety and efficacy of curcumin as a natural product support the potential for the prevention and treatment of chronic inflammatory metabolic diseases.

1. Introduction

Chronic (non-communicable) diseases can be defined as long-term (3 months or more) health conditions that develop overtime [1]. Diabetes, cardiovascular disease, Alzheimer’s disease (AD), Parkinson’s disease, and cancer are included in chronic disease [1], which are major players of mortality responsible for 70% of all mortality worldwide [2]. Several contributors to chronic diseases are genetics, unhealthy dietary patterns, sedentary lifestyles, stress, alcohol intake, smoking, environmental pollutants, radiation exposure, infections, inflammation, and so on [3,4,5,6].
The development of chronic disease is especially associated with unregulated ongoing chronic inflammation conditions [7]. Chronic inflammation-related diseases include metabolic syndrome, type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), depression, and cognitive impairment [7,8]. Due to the relationship between oxidative stress and inflammation through activating transcription factors [9], anti-inflammatory activity, as well as antioxidant activity, could offer a benefit for the prevention and treatment of chronic inflammatory metabolic disease.
Turmeric is obtained from Curcuma longa L. (a tuberous herbaceous perennial plant, which has yellow flowers and broad leaves) and grows in tropical climates. Turmeric (Curcuma longa) is a curry spice and a herbal medicine that originated in India [10]. Turmeric as a yellow compound is widely used as food flavoring and coloring [11,12]. Turmeric comprises three bioactive curcuminoids [curcumin (2–5% of turmeric), demethoxycurcumin, and bisdemethoxycurcumin), protein, sugars, resins, and volatile oils (such as natlantone, turmerone, and zingiberene). In particular, curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-hepta-1,6-diene-3,5-dione, also called diferuloylmethane), is a major curcuminoid in the ginger family [13,14,15]. Curcumin is the main active component of Curcuma longa, which exerts antioxidant, anti-inflammatory, and anti-aging effects attributable to its lipophilic phenolic O-H and the CH-H hydrogen group [16,17,18,19]. The anti-inflammatory and antioxidant properties of curcumin can play a key role in the prevention and treatment of chronic inflammatory metabolic diseases [20,21].
The objective of this review was to clarify the effect of curcumin on chronic inflammatory metabolic disease by examining meta-analyses of randomized controlled trials (RCTs). The present study includes a meta-analysis of as many RCTs as possible to extensively investigate the effects of curcumin intake on chronic inflammatory metabolic diseases.

2. Materials and Methods

We investigated meta-analyses of the effects of curcumin on inflammatory diseases in human studies. A literature search was conducted in the PubMed®/MEDLINE® (https://www.ncbi.nlm.nih.gov/pubmed/) (accessed on 7 August 2023) database and was restricted to full articles in English up to 31 July 2023. The search terms included meta-analysis combined with curcumin. Reference lists of selected papers were also examined. The titles and abstracts of articles were initially screened, and then full texts of the literature were reviewed for final study selection. Inclusion criteria were glycemic control, glucose, lipids, blood pressure (BP), inflammatory markers, type 2 diabetes mellitus (T2DM), hypertension, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), endothelial function, flow-mediated dilation (FMD), obesity, body weight (BW), depression, and cognitive function. Meta-analyses of human studies were included, and non-English articles were excluded. Articles addressing skin, dermatitis, oral, periodontitis, gingivitis, quality of life, tumor, cancer, irritable bowel syndrome, bone, chronic obstructive pulmonary disease (COPD), coronavirus disease (COVID-19), nephropathy, colitis, arthritis, muscle, liver enzymes (function), and hemodialysis were excluded among the 212 articles searched with the terms curcumin and meta-analysis in PubMed®/MEDLINE®. Finally, fifty-four meta-analyses that specifically addressed these inclusion criteria were selected and included in this review. A flowchart of this study’s screening and selection process is reported in Figure 1.

3. Results

3.1. Identification and Selection of Studies

A total of 210 studies were initially identified, 209 from the database search and one from the manual search. The titles and abstracts of 208 studies were screened by two authors. Subsequently, 71 studies were excluded. The remaining 137 studies underwent double full-text review. Subsequently, 83 studies were excluded; 82 were excluded because of unrelated outcomes, and one non-English report was excluded. Finally, 54 studies were included in the systematic review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart for the selection process is presented in Figure 1.

3.2. Inflammatory Markers

The influence of curcumin on inflammatory markers in 20 meta-analyses of interventions is shown in Table 1. In the summary in Table 1, curcumin intake could significantly reduce major inflammatory markers.
In seven of ten meta-analyses, curcumin intake significantly lowered C-reactive protein (CRP) levels. In four of five meta-analyses, curcumin intake significantly lowered high-sensitivity C-reactive protein (hs-CRP) levels. In five of eight meta-analyses, curcumin intake significantly lowered interleukin 6 (IL-6) levels. In four of five meta-analyses, curcumin intake significantly increased adiponectin levels. In six of nine meta-analyses, curcumin intake significantly lowered tumor necrosis factor α (TNF-α) levels. In three of three meta-analyses, curcumin intake significantly lowered leptin levels.
A meta-analysis of RCTs by Dehzad et al. 2023 [42] showed the anti-inflammatory effect of curcumin/curcuminoids/turmeric. Subjects taking 60–2000 mg/day of curcumin or 150–1500 mg/day of curcuminoids or 900–3000 mg/day of turmeric showed reductions in CRP [weighted mean difference (WMD) = −0.58 mg/L; 95% confidence interval (CI) −0.74 to −0.41; I2 = 98.9%; p < 0.001], TNF-α (WMD = −3.48 pg/mL; 95% CI −4.38 to −2.58; I2 = 99.4%; p < 0.001) and IL-6 (WMD = −1.31 pg/mL; 95% CI −1.58 to −0.67; I2 = 88.2%, p < 0.001), with no difference in interleukin 1β (IL-1β) (WMD = −0.46 pg/mL; 95% CI −1.18 to 0.27; I2 = 75.8%; p < 0.001) in 46 publications [23,29,38,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85] for CRP, 23 publications [24,43,47,48,50,54,55,56,60,63,64,67,68,71,79,83,86,87,88,89,90,91,92] for TNF-α, and 20 publications for IL-6 [23,24,45,46,47,48,50,54,63,64,68,83,86,89,91,93,94,95,96,97].
Ferguson et al. 2020 [116] also observed a significant anti-inflammatory effect of curcumin ranging from 46–4560 mg/day of curcumin with decreases in CRP in twenty-two publications [27,38,43,45,46,48,50,51,52,53,57,60,63,65,66,67,70,103,106,107,117,118] (WMD = −1.55 mg/L; 95% CI −1.81 to −1.30), IL-6 in eleven publications [24,45,46,50,63,86,103,107,114,117,118] (WMD = −1.69 pg/mL; 95% CI −2.56 to −0.82), TNF-α in twelve publications [24,43,46,50,63,67,86,112,114,118,119,120] (WMD = −3.13 pg/mL; 95% CI −4.62 to −1.64), IL-8 in four publications [46,63,86,107] (WMD = −0.54 pg/mL; 95% CI −0.82 to −0.28), and monocyte chemoattractant protein-1 (MCP-1) in three publications [24,63,86] (WMD = −2.48 pg/mL; 95% CI −3.96 to −1.00), and there was no change in intracellular adhesion molecule-1 in two publications [120,121].
According to a meta-analysis of seven publications [25,43,44,45,46,47,106] conducted by Gorabi et al. 2022 [105], curcumin decreased CRP levels (WMD = 3.67 mg/L; 95% CI −6.96 to −0.38; p = 0.02; I2 = 99.5%; p < 0.001) in comparison with a placebo. Moreover, sub-analyses showed that curcumin at a dose of ≤ 1000 mg/day significantly decreased CRP levels (WMD = −2.77 mg/L; 95% CI −4.34 to −1.19; p < 0.001) compared with curcumin dose > 1000 mg/day. The intervention duration of > 10 weeks showed significantly decreased CRP levels (WMD = −3.48 mg/L; 95% CI −5.64 to −1.33; p < 0.001) compared with the placebo. Levels of hs-CRP were significantly decreased after curcumin at a dose of ≤2000 mg/day in a meta-analysis of 23 studies (22 publications) [27,29,38,48,49,50,51,52,53,54,55,56,57,58,59,60,61,103,107,108,109,110]. Moreover, a sub-analysis showed a significant effect of curcumin on hs-CRP in RCTs with ≤1000 mg/day and those with a ≤10-week intervention period [27,29,38,48,49,50,51,52,53,54,55,56,57,58,59,60,61,103,107,108,109,110].
Gorabi et al. 2021 [113] observed a significant reduction in TNF-α in 12 publications [24,43,46,47,50,54,55,56,86,87,103,114] (WMD = −1.61 pg/mL; 95% CI −2.72 to −0.51; p < 0.001) after intake of curcumin (80–1500 mg/day), curcuminoids (300–1500 mg/day), or turmeric (112–1500 mg/day) for 4–12 weeks. Consistently, Sahebkar et al. 2016 [137] also observed that 300–1500 mg/day of taking curcumin for 4–12 weeks significantly decreased TNF-α (WMD = −4.69 pg/mL; 95% CI −7.10 to −2.28; p < 0.001) in a meta-analysis of nine publications [24,63,86,87,114,123,134,138,139].
On the other hand, Gorabi et al. 2021 [113] observed no differences in IL-6 in twelve publications [24,45,46,47,48,50,54,86,103,107,109,114] (WMD = −0.33 pg/mL; 95% CI −0.99 to −0.34; p = 0.33) after intake of curcumin (80–1000 mg/day), curcuminoids (300–1500 mg/day), or turmeric (112–1500 mg/day) for 4–12 weeks and IL-8 in four publications [46,86,87,107] (WMD = 0.52 pg/mL; 95% CI −1.13 to 2.17; p = 0.53) after intake of curcuminoids (1000 mg/day) or turmeric (112–1500 mg/day) for 4–8 weeks. Moreover, White et al. 2019 [122] found no effect of curcumin intake ranging from 20 to 2000 mg/day on CRP in five publications [25,45,46,53,106], hs-CRP in six publications [27,51,52,54,57,103], IL-1β in two publications [86,98], IL-6 in seven publications [24,45,86,93,103,114,123], and TNF-α in seven publications [46,86,87,103,114,123,124] compared with the controls with a follow-up duration ranging from 4 to 13 weeks.
A meta-analysis by Dehazd et al. 2023 [28] examined the effect of curcumin on adiposity-associated adipokines. Curcumin intake of 50–1500 mg/day for 4–42 weeks significantly increased serum adiponectin levels in 11 publications [29,30,31,32,34,36,37,38,39,40,41] (WMD = 2.48 μg/mL; 95% CI 1.34 to 3.62; p < 0.001; I2 = 96.3%, p < 0.001). Simental-Mendía et al. 2019 [128] also observed that curcumin intake of 500–1500 mg/day for 4–36 weeks significantly increased adiponectin levels (WMD = 6.47 ng/mL; 95% CI 1.85 to 11.10; p = 0.010; I2 = 94.85%) in a meta-analysis of five publications [31,39,41,129,130]. Moreover, a meta-analysis by Clark et al. 2019 [127] showed elevated adiponectin levels after curcumin intake of 200–1500 mg/day for 6–39 weeks compared with the placebo (WMD = 0.82 Hedges’ g; 95% CI 0.33 to 1.30; p ˂ 0.001) in five publications [30,31,36,38,41]. They found that RCTs for less than 10 weeks of the follow-up period showed greatly increased adiponectin levels (WMD = 1.05 Hedges’ g; 95% CI 0.64 to 1.45; p ˂ 0.001).
Dehzad et al. 2023 [28] showed that curcumin intake of 50–1500 mg/day for 4–42 weeks significantly decreased serum leptin levels in health subjects or subjects with metabolic syndrome, NAFLD, impaired glucose tolerance test (IGTT), prediabetes, T2DM, and major depressive disorder in nine publications [29,30,31,32,33,34,35,36,37] (WMD = −4.46 ng/mL; 95% CI −6.70 to −2.21; p < 0.001; I2 = 96.1%, p < 0.001). Consistent with Dehzad et al. 2023 [28], Atkin et al. 2017 [132] also observed a significant decrease in plasma leptin levels following a curcuminoid intake of 250–1000 mg/day for 4–24 weeks [standardized mean difference (SMD) = 0.69; 95% CI −1.16 to −0.23; p = 0.003; I2 = 76.53%)] in subjects with T2DM, metabolic syndrome, and major depressive disorder.

3.3. Antioxidant Effects

The influence of curcumin on antioxidant activity in six meta-analyses of interventions is shown in Table 2.
To summarize Table 2, curcumin appeared to have antioxidant effects. In five of six meta-analyses, curcumin intake significantly lowered malondialdehyde (MDA) levels. In two of three meta-analyses, curcumin intake significantly increased total antioxidant capacity (TAC) levels. In three of four meta-analyses, curcumin intake significantly increased superoxide dismutase (SOD) levels. One meta-analysis showed no effects on SOD levels. In two meta-analyses, one meta-analysis showed curcumin intake significantly increased glutathione peroxidase (GPx) levels, while the other meta-analysis showed neutral effects on GPx levels. One meta-analysis showed significantly increased catalase (CAT) levels. One meta-analysis showed no effects on glutathione reductase (GR) levels.
A very recent meta-analysis of RCTs by Dehzad et al. 2023 [42] showed the antioxidant effect of curcumin (80–3000 mg/day) or curcuminoids (180–1500 mg/day) or turmeric (1500–3000 mg/day) with a decrease in MDA [end-product of lipid peroxidation induced by reactive oxygen species (ROS)] (WMD = −0.33 µmol/L; 95% CI −0.53 to −0.12; I2 = 99.6%; p < 0.001) and increases in TAC (WMD = 0.21 mmol/L; 95% CI 0.08 to 0.33; I2 = 99.6%; p < 0.001) and SOD activity (WMD = 20.51 u/L; 95% CI 7.35 to 33.67; I2 = 95.4%; p < 0.001) in eighteen publications [23,43,53,57,60,68,76,77,78,79,80,81,82,92,98,143,144,146] for MDA, sixteen publications [23,30,43,49,57,68,76,77,78,79,80,82,88,143,144,145] for TAC, and seven publications [60,63,64,79,95,145,147] for SOD.
For the MDA levels, Tabrizi et al. 2019 [125] showed a significant reduction in MDA levels from the meta-analysis of five publications (SMD = −3.14; 95% CI −4.76 to −1.53; p < 0.001). Qin et al. 2018 [159] observed a significant reduction in MDA levels (SMD = −0.769; 95% CI −1.059 to −0.478) in seven publications [27,57,98,114,124,153,156]. Alizadeh et al. 2019 [150] showed a significant reduction in MDA (SMD = −0.46; 95% CI −0.68 to −0.25) in 12 publications [27,43,98,124,143,151,152,153,154,155,156,157].
For the TAC levels, Jakubczyk et al. 2020 [148] found that curcumin (mean 645 mg/day for 67 days) significantly elevated TAC in a meta-analysis of three publications [43,109,143] (SMD = 2.696; Z = 2.003; 95% CI = 0.058 to 5.335; p = 0.045).
For the SOD levels, Qin et al. 2018 [159] observed a significant increase in SOD activity (SMD = 1.084; 95% CI 0.487 to 1.680) in four publications [27,124,141,156]. Alizadeh et al. 2019 [150] also found a significant increase in SOD (an additional antioxidant enzyme) (SMD = 0.82; 95% CI 0.27 to 1.38) in seven publications [62,124,141,145,155,156,158]. Moreover, they found increased levels of CAT (SMD = 10.26; 95% CI 0.92 to 19.61) in five publications [62,141,143,145,155] and GPx (an antioxidant enzyme) in five publications [62,141,145,151,158] (SMD = 8.90; 95% CI 6.62 to 11.19) following curcumin intake compared with the control group [150].
On the other hand, several meta-analyses found no effects of curcumin on certain antioxidant biomarkers in MDA (80–1000 mg/day of curcumin intake for 10–12 weeks) [148], TAC (80–1500 mg/day of curcumin or 90–3000 mg/day of curcuminoid intake for 1–12 weeks) [150], GPx activity in red blood cells (RBCs) (46–66.3 mg/day of curcumin intake for 4–8 weeks) [159], SOD (1000 mg/day of curcuminoid intake for 4–8 weeks) [125], and GR (320 mg/day of curcumin intake for 8 weeks) [150].

3.4. Glucose Control

The influence of curcumin on glucose control in 18 meta-analyses of interventions is shown in Table 3.
To summarize Table 3, curcumin intake appeared to be effective in glucose control. In 14 of 15 meta-analyses, curcumin intake significantly reduced fasting blood glucose (FBG) levels. In 12 of 12 meta-analyses, curcumin intake significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR). In seven of eight meta-analyses, curcumin intake significantly reduced glycated hemoglobin (HbA1c) levels. In eight of ten meta-analyses, curcumin intake significantly reduced insulin levels.
Sun et al. 2022 [100] extensively assessed RCTs for glucose control effects of curcumin in subjects with metabolic syndrome, obesity, prediabetes, T2DM, hyperlipidemia, hemodialysis, and diabetic foot ulcers (DFUs). They observed significant reductions in FBG (twenty-three publications [23,25,27,39,45,49,60,61,70,76,80,87,101,126,169,170,182,183,184,185,186,187,188]), Hb1Ac (sixteen publications [27,29,39,49,60,70,76,80,101,126,182,183,185,186,187,188]), HOMA-IR (eleven publications [39,45,49,60,70,76,80,101,183,188,189]), and insulin (five publications [45,76,80,187,188]) levels after curcumin intake of 80–2400 mg/day for 4–36 weeks.
Tian et al. 2022 [190] examined the effects of curcumin on glycemic control in a meta-analysis of RCTs with subjects with T2DM. The estimated pooled mean changes with curcumin −8.85 mg/dL (95% CI −14.4 to −3.29; p = 0.002) for FBG [38,49,57,87,101,114,182,183,191] and −0.54 (95% CI −0.81 to −0.27; p ≤ 0.001) for HbA1c (%) [38,49,57,87,101,114,182,183,191] were observed and compared with the controls. Zhang et al. 2021 [200] and Altobelli et al. 2021 [201] also conducted meta-analyses of RCTs in subjects with T2DM. Zhang et al. 2021 [200] found that curcumin intake of 80–1500 mg/day or curcuminoid intake of 300–1500 mg/day for 8–24 weeks significantly decreased HbA1c levels (WMD = −0.70; 95% CI −0.87 to −0.54; p < 0.0001) in 524 subjects with T2DM in five publications [31,60,70,183,185]. Interestingly, they found that HOMA-IR in the curcumin group was lower than that in the control group in the Middle East subgroup in one publication [60] (WMD = −0.60; 95% CI −0.74 to −0.46; p < 0.00001) and in the Asia subgroup in two publications [31,183] (WMD = −2.41; 95% CI −4.44 to −0.39; p = 0.02). The FBG in the curcumin group was lower than that in the control group in the Asia subgroup (SMD = −0.57; 95% CI −0.79 to −0.36; p < 0.00001), with no statistical significance in the Middle East subgroup in six publications [31,60,70,87,183,185]. Altobelli et al. 2021 [201] showed a significant reduction in HbA1c [effect size (ES) = −0.42; 95% CI −0.77 to −0.11; p = 0.008] in subjects with uncomplicated T2DM treated with curcumin in five publications [49,114,144,182,183]. In addition, HOMA-IR showed a statistically significant reduction in the curcumin-treated group (ES = −0.41; 95% CI −0.60 to −0.22; p < 0.001) [31,49,144,183].
Huang et al. 2019 [205] conducted a meta-analysis of subjects at risk for CVD. They found significant effects of curcumin treatment on FBG (SMD = −0.382; 95% CI −0.654 to −0.111 mg/dL, p = 0.006), HbA1c (SMD = −0.370; 95% CI −0.631% to −0.110%; p = 0.005) and HOMA-IR (SMD = −0.351; 95% CI −0.615 to −0.087; p = 0.009). Even though a meta-analysis by Tabrizi et al. 2018 [207] showed that curcumin intake (70–2000 mg/day of curcumin, 300–1000 mg/day of curcuminoids, 112–2400 mg/day of turmeric) for 4–24 weeks significantly reduced FBG levels (SMD = −0.78; 95% CI −1.20 to −0.37; p < 0.001) in nineteen publications [25,32,39,45,46,51,57,87,101,114,126,129,161,178,182,183,206,208,209], curcumin intake (294 mg/day of curcumin, 500–1000 mg/day of curcuminoids, 2000–2100 mg/day of turmeric) for 4–36 weeks was significantly associated increased insulin levels (SMD = 0.92; 95% CI 0.06 to 1.78; p = 0.036) in subjects with T2DM, obesity, hyperlipidemia, and NAFLD in seven publications [32,39,45,57,129,178,208]. Interestingly, Ashtary-Larky et al. 2021 [111] found that nano-curcumin intake of 40–120 mg/day for 6–12 weeks was associated with an improvement in FBG (WMD = −18.14 mg/dL; 95% CI −29.31 to −6.97; p = 0.001), insulin (WMD = −1.21 mg/dL; 95% CI −1.43 to −1.00; p < 0.001), and HOMA-IR (WMD = −0.28 mg/dL; 95% CI −0.33 to −0.23; p < 0.001).

3.5. Lipid Profiles

The influence of curcumin on lipid profiles in 21 meta-analyses of interventions is shown in Table 4.
To summarize Table 4, curcumin intake appeared to exert a total cholesterol (TC)-lowering effect, while curcumin intake has neutral effects on other lipids, including TG, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). In 14 of 19 meta-analyses, curcumin intake significantly reduced TC levels, while five meta-analyses showed no effects on TC levels. In nine of twenty meta-analyses, curcumin intake significantly reduced triglyceride (TG) levels, while eleven meta-analyses showed no effects on TG levels. In four of eighteen meta-analyses, curcumin intake significantly decreased LDL-C levels, while fourteen meta-analyses showed no effects on LDL-C levels. Only three of twenty meta-analyses showed significantly increased HDL-C levels.
Tabrizi et al. 2018 [207] extensively included RCTs (19 publications [25,31,45,51,52,57,87,101,114,126,138,161,178,183,206,208,214,219,220] for TG, 20 publications [25,45,51,52,57,87,101,114,126,138,161,178,182,183,206,208,209,214,219,220] for TC and HDL-C, and 21 publications [25,45,46,51,52,57,87,101,114,126,138,161,178,182,183,206,208,209,214,219,220] for LDL-C) in the meta-analysis. Curcumin intake (70–2000 mg/day of curcumin, 300–1000 mg/day of curcuminoids, 112–2100 mg/day of turmeric) for 4–24 weeks significantly decreased levels of TG (SMD = −1.21; 95% CI −1.78 to −0.65; p < 0.001) and TC (SMD = −0.73; 95% CI −1.32 to −0.13; p = 0.01) in subjects with obesity, metabolic syndrome, hyperlipidemia, NAFLD, T2DM, acute coronary syndrome, coronary artery disease (CAD), and diabetic nephropathy. However, they found no significant effect of curcumin on LDL-C and HDL-C.
Three meta-analyses [190,200,201] of RCTs were performed to examine the effects of curcumin on lipids in subjects with T2DM. A meta-analysis of nine publications (n = 604) [38,49,57,87,101,114,182,183,191] by Tian et al. 2022 [190] showed significant reductions in TG (WMD = −18.97 mg/dL; 95% CI −36.47 to −1.47; p = 0.03) and TC (WMD = −8.91 mg/dL; 95% CI −14.18 to −3.63, p = 0.001), while no differences in LDL-C and HDL-C were found compared with the controls after the intake of curcumin (80–1500 mg/day), curcuminoids (300–1000 mg/day), or turmeric (1500–2100 mg/day) for 4–12 weeks. Zhang et al. 2021 [200] reported that TC and TG levels of the curcumin group with T2DM, who consumed a curcumin dose of 1500 mg/day or a curcuminoid dose of 300 mg/day for 12–24 weeks decreased in the Asia subgroup [31,183] (TC: WMD = −23.45; 95% CI −40.04 to −6.84; p = 0.006; TG: WMD = −54.14; 95% CI −95.71 to −12.57; p = 0.01), while there was no statistical significance in the Middle East subgroup [87,101] after the intake of 1500 mg/day of curcumin or 300 mg/day of curcuminoids for 8–12 weeks. Curcumin supplementation (1500 mg/day of curcumin or, 300 mg/day of curcuminoids) for 12–24 weeks also reduced LDL-C in subjects with T2DM in the Asia subgroup [31,183] (WMD = −20.85; 95% CI −28.78 to −12.92; p < 0.00001). The difference in HDL-C was not significant between groups by curcumin supplementation (1500 mg/day of curcumin, 300–1000 mg/day of curcuminoids, 1500 mg/day of turmeric) for 8–24 weeks. Altobelli et al. 2021 [201] showed significant reductions in TG (ES = −0.57; 95% CI −0.83 to −0.31; p < 0.001), TC (ES = −0.30; 95% CI −0.53 to −0.07; p < 0.001), and LDL-C (ES = −0.28; 95% CI −0.52 to −0.04; p = 0.021), but there was no effect on HDL-C in subjects with uncomplicated T2DM treated with curcumin (80–1500 mg/day of curcumin, 300 mg/day of curcuminoids, 2100 mg/day of turmeric) for 8–12 weeks compared with the placebo in a meta-analysis of five publications [31,38,49,114,183].
The effects of curcumin on lipid profiles in subjects with chronic kidney diseases were meta-analyzed by Futuhi et al. 2022 [102]. Curcumin intake (80–500 mg/day of curcumin, 2500 mg/day of turmeric) for 8–12 weeks significantly reduced TC (WMD = −13.77 mg/dL; 95% CI −26.77 to −0.77; p = 0.04) in five publications [71,72,76,151,212] compared with the controls. However, the significant effect of curcumin intake (80–500 mg/day of curcumin, 2500 mg/day of turmeric) for 8–12 weeks was not confirmed on TG, LDL-C, and HDL-C.
Qin et al. 2017 [221] performed a meta-analysis to investigate the effects of curcumin on lipids in subjects with cardiovascular risk. In seven publications [25,31,57,114,126,161,182], curcumin intake (80 mg/day of curcumin, 70–1890 mg/day of curcuminoids, 2000–2400 mg/day of turmeric) for 4–12 weeks significantly reduced LDL-C (SMD = −0.340; 95% CI −0.530 to −0.150; p < 0.0001) and TG (SMD = −0.214; 95% CI −0.369 to −0.059; p = 0.007) compared with the controls. However, HDL-C and TC levels were not significantly improved after curcumin intake (80 mg/day of curcumin, 70–1890 mg/day of curcuminoids, 2000–2400 mg/day of turmeric) for 4–12 weeks. Interestingly, Ashtary-Larky et al. 2021 [111] observed that nano-curcumin intake of 40–120 mg/day for 6–12 weeks elevated HDL-C (WMD = 5.77 mg/dL; 95% CI 2.90 to 8.64; p < 0.001) in six publications [23,50,71,76,171,182] in 337 subjects with metabolic syndrome, hemodialysis, NAFLD, and T2DM.
On the other hand, several meta-analyses showed no effect on lipids. Saeedi et al. 2022 [211] updated the protective effects of curcumin on blood lipid levels, including 10 publications [25,51,101,126,164,165,177,184,191,209] after curcumin intake (50–2000 mg/day of curcumin, 1000 mg/day of curcuminoids, 2100 mg/day of turmeric) for 4–12 weeks. However, they did not find significant effects on TG, TC, LDL-C, and HDL-C. Sahebkar et al. 2014 [222] also found no effect of curcumin (45–6000 mg/day of curcuminoids) for 1–24 weeks on TC, LDL-C, TG, and HDL-C in five publications [52,114,214,215,218].

3.6. Body Weight, Body Mass Index, and Waist Circumference

The influence of curcumin on BW, body mass index (BMI), and waist circumference (WC) in meta-analyses of interventions is shown in Table 5.
To summarize Table 5, curcumin intake appeared to have neutral effects on BW, BMI, and WC. In four of ten meta-analyses, curcumin intake significantly reduced BW levels, while six meta-analyses showed no effect on BW levels. In five of twelve meta-analyses, curcumin intake significantly reduced WC levels, while seven meta-analyses showed no effect on WC levels. In seven of fourteen meta-analyses, curcumin intake significantly reduced BMI levels, while seven meta-analyses showed no effect on BMI levels.
Sun et al. 2022 [100] found decreased BW (WMD = −0.94 kg; 95% CI −1.40 to −0.47) and BMI (WMD = −0.40 kg/m2; 95% CI −0.60 to −0.19) after 80–2400 mg/day of curcumin for 4–24 weeks in subjects with metabolic syndrome, obesity, hyperlipidemia, prediabetes, T2DM, diabetic sensorimotor polyneuropathy (DSPN), and hemodialysis in 15 publications [23,25,38,49,60,61,70,101,126,170,182,183,185,209,223] for BW and 16 publications [23,25,29,49,60,61,76,101,126,170,182,183,185,188,209,223] for BMI. However, no effect on WC was observed after a curcumin intake of 80–2400 mg/day for 4–17 weeks. Similar findings were observed in a meta-analysis by Mousavi et al. 2020 [225] in overweight and obese subjects with metabolic syndrome, obesity, prediabetes, NAFLD, and T2DM who consumed curcumin (200–1000 mg/day of curcumin, 1000–1500 mg/day of curcuminoids) for 4–39 weeks. Azhdari et al. 2019 [204] also showed no significant WC change in subjects with metabolic syndrome who consumed curcumin at a dose of 800–2400 mg/day for 4–8 weeks in four publications [25,61,172,223].

3.7. Blood Pressure and Endothelial Function

The influence of curcumin on BP and endothelial function in meta-analyses of interventions is shown in Table 6.
To summarize Table 6, curcumin intake appeared to have neutral effects on BP. In two of two meta-analyses, curcumin intake significantly increased FMD levels. Even though both meta-analyses showed a positive effect of curcumin intake on FMD, meta-analyses with more RCTs will be needed to determine the effect of curcumin on FMD. In two of five meta-analyses, curcumin intake significantly lowered diastolic blood pressure (DBP) levels. In one of five meta-analyses, curcumin intake significantly lowered systolic blood pressure (SBP) levels.
In a meta-analysis of three publications [25,27,61] by Azhdari et al. 2019 [204], a significant change in DBP (WMD = −2.96 mmHg; 95% CI −5.09 to −0.83; p = 0.007) in subjects with metabolic syndrome who consumed curcumin (1000 mg/day of curcumin, 1000 mg/day of curcuminoids, 2400 mg/day of turmeric) for 8 weeks was noted, while no change in SBP was observed.
Ashtary-Larky et al. 2021 [111] observed that a nano-curcumin dose of 40–80 mg/day for 6–12 weeks significantly reduced SBP (WMD = −7.09 mmHg; 95% CI −12.98 to −1.20; p < 0.001) in four publications [23,50,76,171]. However, a nano-curcumin dose of 40–80 mg/day for 12 weeks showed no effect on DBP in three publications [50,76,171].
On the other hand, Hadi et al. 2019 [242] extensively included 11 publications [25,50,61,65,66,89,151,178,219,243,244] on subjects with metabolic syndrome, obesity, T2DM, healthy elderly, NAFLD, COPD, diabetic proteinuria, chronic kidney disease (CKD), and lupus nephritis. They failed to find significant reductions in SBP and DBP after curcumin intake (80–1000 mg/day of curcumin, 320–2400 mg/day of turmeric) for 8–24 weeks.

3.8. Depression and Cognitive Function

The influence of curcumin on depression and cognitive function in meta-analyses of interventions is shown in Table 7.
To summarize Table 7, curcumin intake appeared to have positive effects on depression. In four of four meta-analyses, curcumin intake significantly improved depression. In one of two meta-analyses, curcumin intake significantly improved cognitive function. In one of one meta-analysis, curcumin intake significantly improved response rates. In one of one meta-analysis, curcumin intake significantly lowered anxiety symptoms. In one of one meta-analysis, curcumin intake significantly improved working memory. In one of one meta-analysis, curcumin intake significantly improved working memory.
Four meta-analyses [245,255,257,258] of RCTs showed significantly improved depression. Wang et al. 2021 [245] found that curcumin intake of 80–3000 mg/day for 4–24 weeks improved depressive symptoms (SMD = −0.32; 95% CI −0.50 to −0.13; I2 = 15%, p = 0.30) in four publications [251,252,253,254] and response rates [odds ratio (OR) = 3.20; 95% CI 1.28 to 7.99; I2 = 35%, p = 0.21] in three publications [139,248,250]. Fusar-Poli et al. 2020 [255] showed an improvement in depression after curcumin intake of 150–1500 mg/day for 4–12 weeks in nine publications [139,246,247,248,249,250,252,254,256] (Hedge’s g = −0.75; 95% CI −1.11 to −0.39; p < 0.001; I2 = 26.28%) and anxiety symptoms after curcumin intake of 500–1000 mg/day for 4–12 weeks in four publications [248,249,252,256] (Hedge’s g = −2.62; 95% CI −4.06 to −1.17; p < 0.001) with large ES. A meta-analysis of six publications [139,246,249,250,252,256] by Ng et al. 2017 [257] showed an improved effect of curcumin intake of 500–1000 mg/day for 4–8 weeks on depressive symptoms compared with a placebo or control (pooled SMD = −0.344; 95% CI −0.558 to −0.129; p = 0.002). This improved effect was based on the Hamilton Rating Scale for Depression (HAM-D) score from the baseline after curcumin intake. A meta-analysis of six RCTs [139,246,249,250,252,256] by Al-Karawi et al. 2017 [258] showed decreased major depression (SMD = −0.34; 95% CI −0.56 to −0.13; p = 0.002) after curcumin intake of 500–1000 mg/day for 4–8 weeks. A bigger effect was seen when a longer and higher dose of curcumin intake in middle-aged subjects was supplemented.
With regard to the effect of curcumin on cognitive function, Tsai et al. 2021 [259] examined the effect of curcumin on cognition in a meta-analysis of RCTs. Working memory in three publications [261,266,267] was enhanced after curcumin intake of 80–180 mg/day for 8–16 weeks compared with the placebo (Hedges’ g = 0.396; 95% CI 0.078 to 0.714; p = 0.015; I2 = 0.0%). Zhu et al. 2019 [268] suggested that curcumin intake of 80–1320 mg/day for 4–72 weeks appeared to improve cognitive function in older subjects rather than in subjects with AD or schizophrenia. Curcumin was more effective in improving cognitive function in the elderly (SMD = 0.33; 95% CI 0.05 to 0.62; p = 0.02) in three publications [118,263,269]. Cognitive state measures calculated using the Mini-Mental State Examination (MMSE) were worse in subjects with AD taking curcumin than in placebo subjects (SMD = −0.90; 95% CI −1.48 to −0.32; p = 0.002) in two publications [264,265]. In a meta-analysis of four RCTs [172,262,271,272] by Sarraf et al. 2019 [270], curcumin intake (200–1820 mg/day during 8–12 weeks) was associated with higher serum brain-derived neurotrophic factor (BDNF) concentrations (WMD = 1789.38 pg/mL; 95% CI 722.04 to 2856.71; p < 0.01; I2 = 83.5%; p < 0.001).

4. Discussion

The present study aimed to examine the effects of curcumin on chronic inflammatory metabolic disease by extensively evaluating meta-analyses of RCTs. Fifty-four meta-analyses were included in this review, which investigated the effects of curcumin supplementation on inflammation, antioxidants, glucose control, lipids, anthropometric parameters, BP, endothelial function, depression, and cognitive function.
This review clearly observed that curcumin intake could significantly reduce major inflammatory markers of CRP (seven of ten meta-analyses of RCTs), IL-6 (five of eight meta-analyses of RCTs), and TNF-α (six of nine meta-analyses of RCTs). In light of this review finding that curcumin intake significantly lowered MDA levels in five of six meta-analyses, curcumin intake appeared to have antioxidant activity.
Consistent with our findings, Naghsh et al. 2023 [273] found the effects of curcumin on inflammatory biomarkers in an umbrella meta-analysis of 10 RCTs [111,113,115,116,122,125,133,137,140,274], in which curcumin doses ranging from 100 to 1900 mg/day were supplemented for 4.5 to 10.5 weeks. Curcumin supplementation decreased levels in CRP (corresponding ES = −0.74; 95% CI −1.11 to −0.37; p < 0.001; I2 = 62.1%, p = 0.015) in seven meta-analyses [111,115,116,122,125,140,274], IL-6 (ES = −1.07; 95% CI −1.71 to −0.44; p < 0.001; I2 = 75.6%, p < 0.001) in six meta-analyses [111,113,116,122,125,133], and TNF-α (ES = −1.92; 95% CI −2.64 to −1.19; p < 0.01; I2 = 18.1%; p = 0.296) in six meta-analyses [111,113,116,122,125,137]. In particular, greater reductions in CRP and TNF-α were observed in subjects aged over 45 years compared with younger subjects [273].
Several studies have elucidated the mechanisms responsible for the beneficial effects of curcumin on inflammation. Curcumin inhibited inflammatory eicosanoid-generating enzymes, such as cyclooxygenase and lipoxygenase [275]. Curcumin suppressed the nitric oxide (NO) production and expression of inducible nitric oxide synthase (iNOS) protein and messenger ribonucleic acid (mRNA) [276,277]. Curcumin decreased the activation of nuclear factor-κB (NF-κB), a transcription factor that regulates the expression of inflammatory response-related genes resulting in the down-regulation of pro-inflammatory cytokines, such as IL-6 and TNF-α [278]. Furthermore, curcumin has an antioxidant effect through free-radical scavenging activity and antioxidant enzyme regulatory activity [279,280]. Curcumin treatment resulted in significant increases in glutathione (GSH) concentration and GPx and SOD activity and a significant decrease in lipid peroxidation in mouse skin exposed to fractionated γ-radiation [281]. Due to the relationship between oxidative stress and inflammation through activating transcription factors associated with inflammation, the antioxidant effect of curcumin may contribute to the anti-inflammatory activity of curcumin.
In the present review, curcumin intake showed a glucose-lowering effect in most meta-analyses of RCTs. Curcumin intake significantly reduced FBG levels in 14 of 15 meta-analyses and significantly reduced HOMA-IR in 12 of 12 meta-analyses. In addition, curcumin intake significantly reduced HbA1c levels in seven of eight meta-analyses and significantly reduced insulin levels in eight of ten meta-analyses. In bisphenol A (BPA)-induced insulin resistant HepG2 cells, curcumin treatment improved glucose consumption and insulin signaling through the suppression of JNK/p38 pathways [282]. Moreover, significant reductions in the TNF-α, IL-6, MDA, and COX-2 levels confirmed that inflammation and oxidative stress have been associated with insulin resistance [282].
In the present review, we observed the TC-lowering effect of curcumin intake in 14 of 19 meta-analyses of RCTs, but we could not find the other lipids, such as TG, LDL-C, and HDL-C. Similarly, an umbrella meta-analysis by Musazadeh et al. 2022 [283] found the lipid-lowering effect of curcumin intake in adults, with significant improvement in TC (ES = −0.81 mg/dL; 95% CI −1.39 to −0.24; p = 0.006), TG (ES = −0.84 mg/dL; 95% CI −1.42 to −0.27; p = 0.004), LDL-C (ES = −0.49 mg/dL; 95% CI −0.85 to −0.13; p = 0.007), and HDL-C levels (ES = 1.34 mg/dL; 95% CI 0.37 to 2.31; p = 0.007).
This review could not find significant effects of curcumin intake on BW, BMI, and WC. Unlike our findings, curcumin intake significantly reduced WC (MD = −1.32 cm; 95% CI −1.95 to −0.69 cm), BMI (MD = −0.24 kg/m2; 95% CI −0.32 to −0.16 kg/m2), and BW (MD = −0.59 kg; 95% CI −0.81 to −0.36 kg) in an umbrella review and updated meta-analysis of 50 RCTs conducted by Unhapipatpong et al. 2023 [284] with the purpose of finding the effects of curcumin on weight loss. This conflicting result could be explained by factors affecting the efficacy of curcumin, which have been described in several studies. The beneficial effects of curcumin on BMI reduction were only shown in subjects with BMI ≥ 25 kg/m2 in Unhapipatpong et al. 2023 [284]. A dose–response meta-analysis concluded that curcumin can significantly reduce BW (WMD: −1.14 kg, 95% CI: −2.16, −0.12, p = 0.02) and BMI (WMD: −0.48 kg/m2, 95% CI: −0.78, −0.17, p = 0.002), but WC can only be reduced in subgroup of a dose of ≥1000 mg/day of curcumin for ≥8 weeks of duration in overweight subjects [225]. Additionally, the effects of curcumin on anthropometric indices differed, depending on the forms of curcumin, and they showed more efficacy in the bioavailable form [284,285].
The strength of this study is that it includes a meta-analysis of as many RCTs as possible to extensively investigate the effects of curcumin intake on chronic inflammatory metabolic diseases, including inflammatory markers, antioxidant effects, glucose control, lipid profiles, BW, BMI, WC, BP, endothelial function, depression, and cognitive function. This present study comprehensively reviewed and compared the results of individual meta-analyses of RCTs. This study provides evidence on the question of whether curcumin intake is really effective for chronic inflammatory metabolic disease by examining the meta-analyses of the contributors to risks for chronic inflammatory disease. The present study has limitations. We included articles in the English language in PubMed®/MEDLINE to identify and select relevant meta-analyses of RCTs. Several RCTs used in the meta-analyses included in this study were of low quality, which might result in limitations in generalizing the findings of this review. In order to generalize the findings, RCTs with robust designs should be implemented, and a meta-analysis should be performed based on these RCTs.

5. Conclusions

In conclusion, we evaluated the effects of curcumin intake on chronic inflammatory metabolic disease by reviewing meta-analyses of RCTs. Curcumin intake (40–6000 mg/day of curcumin, 150–1500 mg/day of curcuminoids, 900–3000 mg/day of turmeric) for 12 days–24 weeks significantly reduced CRP in seven of ten meta-analyses of RCTs. Curcumin intake (40–6000 mg/day of curcumin, 100–1500 mg/day of curcuminoids, 112–3000 mg/day of turmeric) for 12 days–32 weeks significantly reduced IL-6 in five of eight meta-analyses of RCTs. Curcumin intake (80–1500 mg/day of curcumin, 150–1500 mg/day of curcuminoids, 112–3000 mg/day of turmeric) for 4–12 weeks significantly reduced TNF-α in six of nine meta-analyses of RCTs. Curcumin intake (50–1500 mg/day of curcumin, 1500 mg/day of curcuminoids) for 4–42 weeks significantly increased adiponectin levels in four of five meta-analyses. Curcumin intake (46–1500 mg/day of curcumin, 90–4000 mg/day of curcuminoids, 1500–3000 mg/day of turmeric) for 3 days–16 weeks significantly decreased MDA levels in five of six meta-analyses. Curcumin intake (50–2400 mg/day of curcumin, 294–2000 mg/day of curcuminoids, 112–3000 mg/day of turmeric) for 4–36 weeks significantly reduced FBG levels in 14 of 15 meta-analyses. Curcumin intake (40–2100 mg/day of curcumin, 70–1500 mg/day of curcuminoids, 300–3000 mg/day of turmeric) for 4–36 weeks significantly reduced HOMA-IR in 12 of 12 meta-analyses. Curcumin intake significantly reduced TC levels in 14 of 19 meta-analyses. Our results reveal that curcumin intake effectively and protectively exerts chronic inflammatory metabolic diseases through improved levels of glucose homeostasis, MDA, TC, and inflammation (CRP, IL-6, TNF-α, and adiponectin). The safety and efficacy of curcumin indicate that it is possible to prevent and treat chronic inflammatory metabolic diseases.

Author Contributions

Y.K. and Y.-M.L. conceived and designed the research. Y.K. and Y.-M.L. wrote the manuscript. Y.K. and Y.-M.L. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors have no conflicts of interest related to this manuscript.

References

  1. Bernell, S.; Howard, S.W. Use Your Words Carefully: What Is a Chronic Disease? Front. Public Health 2016, 4, 159. [Google Scholar] [CrossRef]
  2. Vos, T.; Barber, R.M.; Bell, B.; Bertozzi Villa, A.; Biryukov, S.; Bolliger, I.; Charlson, F.; Davis, A.; Degenhardt, L.; Dicker, D. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386, 743–800. [Google Scholar] [CrossRef]
  3. Kimokoti, R.W.; Millen, B.E. Nutrition for the prevention of chronic diseases. Med. Clin. 2016, 100, 1185–1198. [Google Scholar] [CrossRef]
  4. Reynolds, L.M.; Zamora, C.; Lee, U.J.; Stokes, A.C.; Benjamin, E.J.; Bhatnagar, A.; Payne, T.J.; Rodriguez, C.J. Tobacco use prevalence and transitions from 2013 to 2018 among adults with a history of cardiovascular disease. J. Am. Heart Assoc. 2021, 10, e021118. [Google Scholar] [CrossRef] [PubMed]
  5. Lavie, C.J.; Ozemek, C.; Carbone, S.; Katzmarzyk, P.T.; Blair, S.N. Sedentary behavior, exercise, and cardiovascular health. Circ. Res. 2019, 124, 799–815. [Google Scholar] [CrossRef]
  6. Nugent, R. Preventing and managing chronic diseases. BMJ 2019, 364, l459. [Google Scholar] [CrossRef]
  7. Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 2019, 25, 1822–1832. [Google Scholar] [CrossRef] [PubMed]
  8. Allison, D.J.; Ditor, D.S. The common inflammatory etiology of depression and cognitive impairment: A therapeutic target. J. Neuroinflammation 2014, 11, 151. [Google Scholar] [CrossRef] [PubMed]
  9. Guo, Q.; Jin, Y.; Chen, X.; Ye, X.; Shen, X.; Lin, M.; Zeng, C.; Zhou, T.; Zhang, J. NF-κB in biology and targeted therapy: New insights and translational implications. Signal Transduct. Target. Ther. 2024, 9, 53. [Google Scholar] [CrossRef]
  10. Lestari, M.L.; Indrayanto, G. Curcumin. Profiles DrugSubst. Excip. Relat. Methodol. 2014, 39, 113–204. [Google Scholar]
  11. Vogel, H.; Pelletier, J. Curcumin-biological and medicinal properties. J. Pharma 1815, 2, 24–29. [Google Scholar]
  12. Prasad, S.; Gupta, S.C.; Tyagi, A.K.; Aggarwal, B.B. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol. Adv. 2014, 32, 1053–1064. [Google Scholar] [CrossRef]
  13. Anamika, B. Extraction of curcumin. J. Environ. Sci. Toxicol. Food Technol. 2012, 1, 1–16. [Google Scholar]
  14. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as “Curecumin”: From kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787–809. [Google Scholar] [CrossRef]
  15. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807–818. [Google Scholar] [CrossRef]
  16. Priyadarsini, K.I.; Maity, D.K.; Naik, G.; Kumar, M.S.; Unnikrishnan, M.; Satav, J.; Mohan, H. Role of phenolic OH and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free. Radic. Biol. Med. 2003, 35, 475–484. [Google Scholar] [CrossRef]
  17. Jayaraj, R.L.; Tamilselvam, K.; Manivasagam, T.; Elangovan, N. Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson’s disease. J. Mol. Neurosci. 2013, 51, 863–870. [Google Scholar] [CrossRef] [PubMed]
  18. Meng, B.; Li, J.; Cao, H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr. Pharm. Des. 2013, 19, 2101–2113. [Google Scholar] [PubMed]
  19. Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41, 40–59. [Google Scholar] [CrossRef]
  20. He, Y.; Yue, Y.; Zheng, X.; Zhang, K.; Chen, S.; Du, Z. Curcumin, inflammation, and chronic diseases: How are they linked? Molecules 2015, 20, 9183–9213. [Google Scholar] [CrossRef]
  21. Blagov, A.V.; Summerhill, V.I.; Sukhorukov, V.N.; Zhigmitova, E.B.; Postnov, A.Y.; Orekhov, A.N. Potential use of antioxidants for the treatment of chronic inflammatory diseases. Front. Pharmacol. 2024, 15, 1378335. [Google Scholar] [CrossRef]
  22. Qiu, L.; Gao, C.; Li, J. Effects of dietary polyphenol curcumin supplementation on metabolic, inflammatory, and oxidative stress indices in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Front. Endocrinol. 2023, 14, 1216708. [Google Scholar] [CrossRef] [PubMed]
  23. Osali, A. Aerobic exercise and nano-curcumin supplementation improve inflammation in elderly females with metabolic syndrome. Diabetol. Metab. Syndr. 2020, 12, 26. [Google Scholar] [CrossRef] [PubMed]
  24. Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Simental-Mendía, L.E.; Majeed, M.; Sahebkar, A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed. Pharmacother. 2016, 82, 578–582. [Google Scholar] [CrossRef] [PubMed]
  25. Amin, F.; Islam, N.; Anila, N.; Gilani, A. Clinical efficacy of the co-administration of Turmeric and Black seeds (Kalongi) in metabolic syndrome–A double blind randomized controlled trial–TAK-MetS trial. Complement. Ther. Med. 2015, 23, 165–174. [Google Scholar] [CrossRef]
  26. Bateni, Z.; Behrouz, V.; Rahimi, H.R.; Hedayati, M.; Afsharian, S.; Sohrab, G. Effects of nano-curcumin supplementation on oxidative stress, systemic inflammation, adiponectin, and NF-κB in patients with metabolic syndrome: A randomized, double-blind clinical trial. J. Herb. Med. 2022, 31, 100531. [Google Scholar] [CrossRef]
  27. Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Majeed, M.; Sahebkar, A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin. Nutr. 2015, 34, 1101–1108. [Google Scholar] [CrossRef] [PubMed]
  28. Dehzad, M.J.; Ghalandari, H.; Nouri, M.; Askarpour, M. Effects of curcumin/turmeric supplementation on obesity indices and adipokines in adults: A grade-assessed systematic review and dose–response meta-analysis of randomized controlled trials. Phytother. Res. 2023, 37, 1703–1728. [Google Scholar] [CrossRef] [PubMed]
  29. Funamoto, M.; Shimizu, K.; Sunagawa, Y.; Katanasaka, Y.; Miyazaki, Y.; Kakeya, H.; Yamakage, H.; Satoh-Asahara, N.; Wada, H.; Hasegawa, K. Effects of highly absorbable curcumin in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. J. Diabetes Res. 2019, 2019, 8208237. [Google Scholar] [CrossRef]
  30. Campbell, M.S.; Ouyang, A.; Krishnakumar, I.; Charnigo, R.J.; Westgate, P.M.; Fleenor, B.S. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition 2019, 62, 135–139. [Google Scholar] [CrossRef]
  31. Chuengsamarn, S.; Rattanamongkolgul, S.; Phonrat, B.; Tungtrongchitr, R.; Jirawatnotai, S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J. Nutr. Biochem. 2014, 25, 144–150. [Google Scholar] [CrossRef] [PubMed]
  32. Ismail, N.A.; Ragab, S.; El-Baky, A.; Hamed, M.; Ibrahim, A. Effect of oral curcumin administration on insulin resistance, serum resistin and fetuin-A in obese children: Randomized placebo-controlled study. Res. J. Pharm. Biol. Chem. Sci. 2014, 5, 887–896. [Google Scholar]
  33. Lopresti, A.L.; Maes, M.; Meddens, M.J.; Maker, G.L.; Arnoldussen, E.; Drummond, P.D. Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur. Neuropsychopharmacol. 2015, 25, 38–50. [Google Scholar] [CrossRef] [PubMed]
  34. Mirhafez, S.R.; Farimani, A.R.; Dehhabe, M.; Bidkhori, M.; Hariri, M.; Ghouchani, B.F.N.M.; Abdollahi, F. Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. J. Gastrointest. Liver Dis. 2019, 28, 183–189. [Google Scholar] [CrossRef] [PubMed]
  35. Navekar, R.; Rafraf, M.; Ghaffari, A.; Asghari-Jafarabadi, M.; Khoshbaten, M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J. Am. Coll. Nutr. 2017, 36, 261–267. [Google Scholar] [CrossRef] [PubMed]
  36. Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Soflaei, S.S.; Majeed, M.; Sahebkar, A. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition 2016, 32, 1116–1122. [Google Scholar] [CrossRef] [PubMed]
  37. Srinivasan, A.; Selvarajan, S.; Kamalanathan, S.; Kadhiravan, T.; Prasanna Lakshmi, N.C.; Adithan, S. Effect of Curcuma longa on vascular function in native Tamilians with type 2 diabetes mellitus: A randomized, double-blind, parallel arm, placebo-controlled trial. Phytother. Res. 2019, 33, 1898–1911. [Google Scholar] [CrossRef] [PubMed]
  38. Adibian, M.; Hodaei, H.; Nikpayam, O.; Sohrab, G.; Hekmatdoost, A.; Hedayati, M. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Phytother. Res. 2019, 33, 1374–1383. [Google Scholar] [CrossRef]
  39. Chuengsamarn, S.; Rattanamongkolgul, S.; Luechapudiporn, R.; Phisalaphong, C.; Jirawatnotai, S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35, 2121–2127. [Google Scholar] [CrossRef]
  40. Kalhori, A.; Rafraf, M.; Navekar, R.; Ghaffari, A.; Jafarabadi, M.A. Effect of turmeric supplementation on blood pressure and serum levels of sirtuin 1 and adiponectin in patients with nonalcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial. Prev. Nutr. Food Sci. 2022, 27, 37. [Google Scholar] [CrossRef]
  41. Salahshooh, M.M.; Parizadeh, S.M.R.; Pasdar, A.; Saberi Karimian, M.; Safarian, H.; Javandoost, A.; Ferns, G.A.; Ghayour-Mobarhan, M.; Sahebkar, A. The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome. Comp. Clin. Pathol. 2017, 26, 17–23. [Google Scholar] [CrossRef]
  42. Dehzad, M.J.; Ghalandari, H.; Nouri, M.; Askarpour, M. Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: A GRADE-assessed systematic review and dose–response meta-analysis of randomized controlled trials. Cytokine 2023, 164, 156144. [Google Scholar] [CrossRef] [PubMed]
  43. Alizadeh, F.; Javadi, M.; Karami, A.A.; Gholaminejad, F.; Kavianpour, M.; Haghighian, H.K. Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial. Phytother. Res. 2018, 32, 514–521. [Google Scholar] [CrossRef] [PubMed]
  44. Jacob, J.; Amalraj, A.; Raj, K.J.; Divya, C.; Kunnumakkara, A.B.; Gopi, S. A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite™) improves symptoms and diagnostic indicators in rheumatoid arthritis patients-A randomized, double blind and placebo controlled study. J. Tradit. Complement. Med. 2019, 9, 346–352. [Google Scholar] [CrossRef] [PubMed]
  45. Kocher, A.; Bohnert, L.; Schiborr, C.; Frank, J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol. Nutr. Food Res. 2016, 60, 1555–1563. [Google Scholar] [CrossRef] [PubMed]
  46. Nieman, D.C.; Cialdella-Kam, L.; Knab, A.M.; Shanely, R.A. Influence of red pepper spice and turmeric on inflammation and oxidative stress biomarkers in overweight females: A metabolomics approach. Plant Foods Hum. Nutr. 2012, 67, 415–421. [Google Scholar] [CrossRef] [PubMed]
  47. Uchio, R.; Muroyama, K.; Okuda-Hanafusa, C.; Kawasaki, K.; Yamamoto, Y.; Murosaki, S. Hot water extract of Curcuma longa L. improves serum inflammatory markers and general health in subjects with overweight or prehypertension/mild hypertension: A randomized, double-blind, placebo-controlled trial. Nutrients 2019, 11, 1822. [Google Scholar] [CrossRef] [PubMed]
  48. Abdolahi, M.; Sarraf, P.; Javanbakht, M.H.; Honarvar, N.M.; Hatami, M.; Soveyd, N.; Tafakhori, A.; Sedighiyan, M.; Djalali, M.; Jafarieh, A. A novel combination of ω-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity C-reactive protein serum levels in patients with migraine: A randomized clinical trial study. CNS Neurol. Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol.Disord.) 2018, 17, 430–438. [Google Scholar] [CrossRef] [PubMed]
  49. Adab, Z.; Eghtesadi, S.; Vafa, M.R.; Heydari, I.; Shojaii, A.; Haqqani, H.; Arablou, T.; Eghtesadi, M. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother. Res. 2019, 33, 1173–1181. [Google Scholar] [CrossRef]
  50. Jazayeri-Tehrani, S.A.; Rezayat, S.M.; Mansouri, S.; Qorbani, M.; Alavian, S.M.; Daneshi-Maskooni, M.; Hosseinzadeh-Attar, M.-J. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): A double-blind randomized placebo-controlled clinical trial. Nutr. Metab. 2019, 16, 8. [Google Scholar] [CrossRef]
  51. Mirzabeigi, P.; Mohammadpour, A.H.; Salarifar, M.; Gholami, K.; Mojtahedzadeh, M.; Javadi, M.R. The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: A pilot randomized, double-blind, placebo-controlled trial. Iran. J. Pharm.Res. IJPR 2015, 14, 479. [Google Scholar]
  52. Mohammadi, A.; Sahebkar, A.; Iranshahi, M.; Amini, M.; Khojasteh, R.; Ghayour-Mobarhan, M.; Ferns, G.A. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother. Res. 2013, 27, 374–379. [Google Scholar] [CrossRef]
  53. Pakfetrat, M.; Basiri, F.; Malekmakan, L.; Roozbeh, J. Effects of turmeric on uremic pruritus in end stage renal disease patients: A double-blind randomized clinical trial. J. Nephrol. 2014, 27, 203–207. [Google Scholar] [CrossRef]
  54. Rahimnia, A.-R.; Panahi, Y.; Alishiri, G.; Sharafi, M.; Sahebkar, A. Impact of supplementation with curcuminoids on systemic inflammation in patients with knee osteoarthritis: Findings from a randomized double-blind placebo-controlled trial. Drug Res. 2014, 65, 521–525. [Google Scholar] [CrossRef] [PubMed]
  55. Saadati, S.; Sadeghi, A.; Mansour, A.; Yari, Z.; Poustchi, H.; Hedayati, M.; Hatami, B.; Hekmatdoost, A. Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019, 19, 133. [Google Scholar] [CrossRef]
  56. Sadeghi, N.; Mansoori, A.; Shayesteh, A.; Hashemi, S.J. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytother. Res. 2020, 34, 1123–1133. [Google Scholar] [CrossRef] [PubMed]
  57. Maithili Karpaga Selvi, N.; Sridhar, M.; Swaminathan, R.; Sripradha, R. Efficacy of turmeric as adjuvant therapy in type 2 diabetic patients. Indian J. Clin. Biochem. 2015, 30, 180–186. [Google Scholar] [CrossRef]
  58. Sohaei, S.; Amani, R.; Tarrahi, M.J.; Ghasemi-Tehrani, H. The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. Complement. Ther. Med. 2019, 47, 102201. [Google Scholar] [CrossRef] [PubMed]
  59. Tamaddoni, A.; Nasseri, E.; Mohammadi, E.; Qujeq, D.; Zayeri, F.; Zand, H.; Mir, S.M.; Gholami, M. A double-blind randomized controlled trial of curcumin for improvement in glycemic status, lipid profile and systemic inflammation in β-thalassemia major. J. Herb. Med. 2020, 21, 100324. [Google Scholar] [CrossRef]
  60. Panahi, Y.; Khalili, N.; Sahebi, E.; Namazi, S.; Simental-Mendía, L.E.; Majeed, M.; Sahebkar, A. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Res. 2018, 68, 403–409. [Google Scholar] [CrossRef]
  61. Saberi-Karimian, M.; Parizadeh, S.M.R.; Ghayour-Mobarhan, M.; Salahshooh, M.M.; Dizaji, B.F.; Safarian, H.; Javandoost, A.; Ferns, G.A.; Sahebkar, A.; Ahmadinejad, M. Evaluation of the effects of curcumin in patients with metabolic syndrome. Comp. Clin. Pathol. 2018, 27, 555–563. [Google Scholar] [CrossRef]
  62. DiSilvestro, R.A.; Joseph, E.; Zhao, S.; Bomser, J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr. J. 2012, 11, 79. [Google Scholar] [CrossRef] [PubMed]
  63. Panahi, Y.; Ghanei, M.; Bashiri, S.; Hajihashemi, A.; Sahebkar, A. Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: Positive results of a randomized double-blind placebo-controlled trial. Drug Res. 2014, 65, 567–573. [Google Scholar] [CrossRef] [PubMed]
  64. Panahi, Y.; Saadat, A.; Beiraghdar, F.; Sahebkar, A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytother. Res. 2014, 28, 1461–1467. [Google Scholar] [CrossRef] [PubMed]
  65. Funamoto, M.; Sunagawa, Y.; Katanasaka, Y.; Miyazaki, Y.; Imaizumi, A.; Kakeya, H.; Yamakage, H.; Satoh-Asahara, N.; Komiyama, M.; Wada, H. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. Int. J. Chronic Obstr. Pulm. Dis. 2016, 11, 2029–2034. [Google Scholar]
  66. Santos-Parker, J.R.; Strahler, T.R.; Bassett, C.J.; Bispham, N.Z.; Chonchol, M.B.; Seals, D.R. Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. Aging 2017, 9, 187. [Google Scholar] [CrossRef] [PubMed]
  67. Shao, N.; Jia, H.; Li, Y.; Li, J. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: A randomized placebo-controlled double-blind clinical trial. Immunol. Res. 2017, 65, 969–974. [Google Scholar] [CrossRef] [PubMed]
  68. Ghaffari, A.; Rafraf, M.; Navekar, R.; Asghari-Jafarabadi, M. Effects of turmeric and chicory seed supplementation on antioxidant and inflammatory biomarkers in patients with non-alcoholic fatty liver disease (NAFLD). Adv. Integr. Med. 2018, 5, 89–95. [Google Scholar] [CrossRef]
  69. Haroyan, A.; Mukuchyan, V.; Mkrtchyan, N.; Minasyan, N.; Gasparyan, S.; Sargsyan, A.; Narimanyan, M.; Hovhannisyan, A. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: A comparative, randomized, double-blind, placebo-controlled study. BMC Complement. Altern. Med. 2018, 18, 7. [Google Scholar] [CrossRef]
  70. Thota, R.N.; Acharya, S.H.; Garg, M.L. Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: A randomised controlled trial. Lipids Health Dis. 2019, 18, 31. [Google Scholar] [CrossRef]
  71. Vafadar_afshar, G.; Khadem-Ansari, M.-H.; Makhdomii, K.; Rasooli, J. The effects of nano-curcumin supplementation on serum level of hs-CRP, adhesion molecules, and lipid profiles in hemodialysis patients, a randomized controlled clinical trial. Iran. J. Kidney Dis. 2020, 14, 52. [Google Scholar] [PubMed]
  72. Alvarenga, L.; Salarolli, R.; Cardozo, L.F.; Santos, R.S.; de Brito, J.S.; Kemp, J.A.; Reis, D.; de Paiva, B.R.; Stenvinkel, P.; Lindholm, B. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clin. Nutr. 2020, 39, 3594–3600. [Google Scholar] [CrossRef] [PubMed]
  73. Asan, S.A.; Baş, M.; Eren, B.; Karaca, E. The effects of curcumin supplementation added to diet on anthropometric and biochemical status in women with polycystic ovary syndrome: A randomized, placebo-controlled trial. Prog. Nutr. 2020, 22, e2020089. [Google Scholar]
  74. Atabaki, M.; Shariati-Sarabi, Z.; Tavakkol-Afshari, J.; Mohammadi, M. Significant immunomodulatory properties of curcumin in patients with osteoarthritis; a successful clinical trial in Iran. Int. Immunopharmacol. 2020, 85, 106607. [Google Scholar] [CrossRef] [PubMed]
  75. Kuszewski, J.C.; Wong, R.H.; Wood, L.G.; Howe, P.R. Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial. Nutr. Metab. Cardiovasc. Dis. 2020, 30, 625–633. [Google Scholar] [CrossRef] [PubMed]
  76. Shafabakhsh, R.; Asemi, Z.; Reiner, Ž.; Soleimani, A.; Aghadavod, E.; Bahmani, F. The effects of nano-curcumin on metabolic status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial. Iran. J. Kidney Dis. 2020, 14, 290–299. [Google Scholar] [PubMed]
  77. Shafabakhsh, R.; Mobini, M.; Raygan, F.; Aghadavod, E.; Ostadmohammadi, V.; Amirani, E.; Mansournia, M.A.; Asemi, Z. Curcumin administration and the effects on psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease. Clin. Nutr. ESPEN 2020, 40, 77–82. [Google Scholar] [CrossRef] [PubMed]
  78. Darmian, M.A.; Hoseini, R.; Amiri, E.; Golshani, S. How combined and separate aerobic training and turmeric supplementation alter lipid profile and glycemic status? A clinical trial in middle-aged females with type 2 diabetes and hyperlipidemia. Int. Cardiovasc. Res. J. 2021, 15, e118791. [Google Scholar]
  79. Helli, B.; Gerami, H.; Kavianpour, M.; Heybar, H.; Hosseini, S.K.; Haghighian, H.K. Curcumin nanomicelle improves lipid profile, stress oxidative factors and inflammatory markers in patients undergoing coronary elective angioplasty; a randomized clinical trial. Endocr. Metab. Immune Disord.-Drug Targets (Former. Curr. Drug Targets-Immune Endocr. Metab.Disord.) 2021, 21, 2090–2098. [Google Scholar]
  80. Mokhtari, M.; Razzaghi, R.; Momen-Heravi, M. The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. Phytother. Res. 2021, 35, 2099–2107. [Google Scholar] [CrossRef]
  81. Rodrigues, H.C.N.; Martins, T.F.P.; Braga, C.C.; Silva, M.A.C.; da Cunha, L.C.; de Araújo Sugizaki, C.S.; de Souza Freitas, A.T.V.; Costa, N.A.; Peixoto, M.d.R.G. Antioxidant and anti-inflammatory response to curcumin supplementation in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial. Clin. Nutr. ESPEN 2021, 44, 136–142. [Google Scholar] [CrossRef] [PubMed]
  82. Salehi, M.; Mashhadi, N.S.; Esfahani, P.S.; Feizi, A.; Hadi, A.; Askari, G. The effects of curcumin supplementation on muscle damage, oxidative stress, and inflammatory markers in healthy females with moderate physical activity: A randomized, double-blind, placebo-controlled clinical trial. Int. J. Prev. Med. 2021, 12, 94. [Google Scholar] [PubMed]
  83. Thanawala, S.; Shah, R.; Somepalli, V.; Alluri, K.V.; Desomayanandam, P.; Bhuvanendran, A. A multicenter, randomized, double-blind, placebo-controlled trial assessing efficacy and safety of a novel low-dose turmeric extract formulation in healthy adults with chronic knee pain. Clin. Pharmacol. Adv. Appl. 2021, 13, 91–100. [Google Scholar] [CrossRef] [PubMed]
  84. Uchio, R.; Kawasaki, K.; Okuda-Hanafusa, C.; Saji, R.; Muroyama, K.; Murosaki, S.; Yamamoto, Y.; Hirose, Y. Curcuma longa extract improves serum inflammatory markers and mental health in healthy participants who are overweight: A randomized, double-blind, placebo-controlled trial. Nutr. J. 2021, 20, 91. [Google Scholar] [CrossRef] [PubMed]
  85. Varma, K.; Amalraj, A.; Divya, C.; Gopi, S. The efficacy of the novel bioavailable curcumin (cureit) in the management of sarcopenia in healthy elderly subjects: A randomized, placebo-controlled, double-blind clinical study. J. Med. Food 2021, 24, 40–49. [Google Scholar] [CrossRef] [PubMed]
  86. Ganjali, S.; Sahebkar, A.; Mahdipour, E.; Jamialahmadi, K.; Torabi, S.; Akhlaghi, S.; Ferns, G.; Parizadeh, S.M.R.; Ghayour-Mobarhan, M. Investigation of the effects of curcumin on serum cytokines in obese individuals: A randomized controlled trial. Sci. World J. 2014, 2014, 898361. [Google Scholar] [CrossRef] [PubMed]
  87. Khajehdehi, P.; Pakfetrat, M.; Javidnia, K.; Azad, F.; Malekmakan, L.; Nasab, M.H.; Dehghanzadeh, G. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study. Scand. J. Urol. Nephrol. 2011, 45, 365–370. [Google Scholar] [CrossRef] [PubMed]
  88. Abbas, S.H.; Abdulridha, M.K.; Najeb, A.A. Potential benefit of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease. Asian J. Pharm. Clin. Res. 2017, 10, 313–317. [Google Scholar]
  89. Campbell, M.S.; Berrones, A.J.; Krishnakumar, I.; Charnigo, R.J.; Westgate, P.M.; Fleenor, B.S. Responsiveness to curcumin intervention is associated with reduced aortic stiffness in young, obese men with higher initial stiffness. J. Funct. Foods 2017, 29, 154–160. [Google Scholar] [CrossRef]
  90. Setiawati, M.C.N.; Ikawati, Z.; Nyoman, K. Effect of Curcuma Xanthorrhiza Roxb. Extract on TNF α concentration and depression’s score in patient with systemic lupus erythematosus. Indones J. Pharm. 2017, 28, 185–190. [Google Scholar] [CrossRef]
  91. Gupte, P.A.; Giramkar, S.A.; Harke, S.M.; Kulkarni, S.K.; Deshmukh, A.P.; Hingorani, L.L.; Mahajan, M.P.; Bhalerao, S.S. Evaluation of the efficacy and safety of Capsule Longvida® Optimized Curcumin (solid lipid curcumin particles) in knee osteoarthritis: A pilot clinical study. J. Inflamm. Res. 2019, 12, 145–152. [Google Scholar] [CrossRef] [PubMed]
  92. da Silva, T.A.; de Medeiros, D.C.; da Silva Cunha de Medeiros, R.C.; Medeiros, R.M.; de Souza, L.B.; de Medeiros, J.A.; dos Santos, R.V.; de Alcântara Varela, P.W.; Leite-Lais, L.; Dantas, P.M. Influence of curcumin on glycemic profile, inflammatory markers, and oxidative stress in HIV-infected individuals: A randomized controlled trial. Phytother. Res. 2020, 34, 2323–2330. [Google Scholar] [CrossRef] [PubMed]
  93. Singgih Wahono, C.; Diah Setyorini, C.; Kalim, H.; Nurdiana, N.; Handono, K. Effect of Curcuma xanthorrhiza supplementation on systemic lupus erythematosus patients with hypovitamin D which were given vitamin D 3 towards disease activity (SLEDAI), IL-6, and TGF-β1 serum. Int. J. Rheumatol. 2017, 2017, 7687053. [Google Scholar] [CrossRef] [PubMed]
  94. Ahmadi, M.; Hajialilo, M.; Dolati, S.; Eghbal-Fard, S.; Heydarlou, H.; Ghaebi, M.; Ghassembaglou, A.; Aghebati-Maleki, L.; Samadi Kafil, H.; Kamrani, A. The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial. J. Cell. Biochem. 2020, 121, 103–110. [Google Scholar] [CrossRef]
  95. Khdair, S.A.; Abdulridha, M.K.; Shafek, M.A. The effect of curcumin adjuvant therapy on pulmonary function and levels of interleukin-6 (IL-6) and superoxide dismutase-3 (EC-SOD3) in patients with chronic bronchial asthma. Indones. J. Pharm. 2021, 32, 232–240. [Google Scholar]
  96. Rezaie, S.; Askari, G.; Khorvash, F.; Tarrahi, M.J.; Amani, R. Effects of curcumin supplementation on clinical features and inflammation, in migraine patients: A double-blind controlled, placebo randomized clinical trial. Int. J. Prev. Med. 2021, 12, 161. [Google Scholar]
  97. Vafadar-Afshar, G.; Rasmi, Y.; Yaghmaei, P.; Khadem-Ansari, M.H.; Makhdoomi, K.; Rasouli, J. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: A randomized controlled trial. Hemodial. Int. 2021, 25, 232–239. [Google Scholar] [CrossRef]
  98. Srivastava, S.; Saksena, A.K.; Khattri, S.; Kumar, S.; Dagur, R.S. Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of knee: A four-month, double-blind, randomized, placebo-controlled trial. Inflammopharmacology 2016, 24, 377–388. [Google Scholar] [CrossRef]
  99. Shen, W.; Qu, Y.; Jiang, H.; Wang, H.; Pan, Y.; Zhang, Y.; Wu, X.; Zhang, Y. Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis. Front. Endocrinol. 2022, 13, 1051111. [Google Scholar] [CrossRef]
  100. Sun, Z.; Wei, X.; Bai, J.; Li, W.; Yang, J.; Deng, Z.; Wu, M.; Ying, T.; He, G. The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: A systematic review and dose-effect meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2022, 63, 9282–9298. [Google Scholar] [CrossRef]
  101. Panahi, Y.; Khalili, N.; Sahebi, E.; Namazi, S.; Reiner, Ž.; Majeed, M.; Sahebkar, A. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement. Ther. Med. 2017, 33, 1–5. [Google Scholar] [CrossRef]
  102. Futuhi, F.; Naghibzadeh Tahami, A.; Azmandian, J.; Saber, A. The effects of curcumin-containing supplementations on inflammatory markers and lipid profiles in patients with chronic kidney diseases: A systematic review and meta-analysis of randomized controlled trials. J. Complement. Integr. Med. 2022, 19, 531–541. [Google Scholar] [CrossRef] [PubMed]
  103. Samadian, F.; Dalili, N.; Gholi, F.P.-R.; Fattah, M.; Malih, N.; Nafar, M.; Firoozan, A.; Ahmadpoor, P.; Samavat, S.; Ziaie, S. Evaluation of Curcumin’s effect on inflammation in hemodialysis patients. Clin. Nutr. ESPEN 2017, 22, 19–23. [Google Scholar] [CrossRef] [PubMed]
  104. Moreillon, J.J.; Bowden, R.G.; Deike, E.; Griggs, J.; Wilson, R.; Shelmadine, B.; Cooke, M.; Beaujean, A. The use of an anti-inflammatory supplement in patients with chronic kidney disease. J. Complement. Integr. Med. 2013, 10, 143–152. [Google Scholar] [CrossRef]
  105. Gorabi, A.M.; Abbasifard, M.; Imani, D.; Aslani, S.; Razi, B.; Alizadeh, S.; Bagheri-Hosseinabadi, Z.; Sathyapalan, T.; Sahebkar, A. Effect of curcumin on C-reactive protein as a biomarker of systemic inflammation: An updated meta-analysis of randomized controlled trials. Phytother. Res. 2022, 36, 85–97. [Google Scholar] [CrossRef] [PubMed]
  106. Amalraj, A.; Varma, K.; Jacob, J.; Divya, C.; Kunnumakkara, A.B.; Stohs, S.J.; Gopi, S. A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: A randomized, double-blind, placebo-controlled, two-dose, three-arm, and parallel-group study. J. Med. Food 2017, 20, 1022–1030. [Google Scholar] [CrossRef]
  107. Panahi, Y.; Sahebkar, A.; Parvin, S.; Saadat, A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 2012, 49, 580–588. [Google Scholar] [CrossRef]
  108. Phrommintikul, A.; Chanchai, R.; Wongcharoen, W. Effects of curcuminoids on myocardial injury after percutaneous coronary intervention. J. Med. Food 2019, 22, 680–684. [Google Scholar] [CrossRef]
  109. Saraf-Bank, S.; Ahmadi, A.; Paknahad, Z.; Maracy, M.; Nourian, M. Effects of curcumin supplementation on markers of inflammation and oxidative stress among healthy overweight and obese girl adolescents: A randomized placebo-controlled clinical trial. Phytother. Res. 2019, 33, 2015–2022. [Google Scholar] [CrossRef]
  110. Wongcharoen, W.; Jai-Aue, S.; Phrommintikul, A.; Nawarawong, W.; Woragidpoonpol, S.; Tepsuwan, T.; Sukonthasarn, A.; Apaijai, N.; Chattipakorn, N. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am. J. Cardiol. 2012, 110, 40–44. [Google Scholar] [CrossRef]
  111. Ashtary-Larky, D.; Rezaei Kelishadi, M.; Bagheri, R.; Moosavian, S.P.; Wong, A.; Davoodi, S.H.; Khalili, P.; Dutheil, F.; Suzuki, K.; Asbaghi, O. The effects of nano-curcumin supplementation on risk factors for cardiovascular disease: A GRADE-assessed systematic review and meta-analysis of clinical trials. Antioxidants 2021, 10, 1015. [Google Scholar] [CrossRef] [PubMed]
  112. Abdolahi, M.; Tafakhori, A.; Togha, M.; Okhovat, A.A.; Siassi, F.; Eshraghian, M.R.; Sedighiyan, M.; Djalali, M.; Mohammadzadeh Honarvar, N.; Djalali, M. The synergistic effects of ω-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-α gene expression and serum level in migraine patients. Immunogenetics 2017, 69, 371–378. [Google Scholar] [CrossRef] [PubMed]
  113. Gorabi, A.M.; Razi, B.; Aslani, S.; Abbasifard, M.; Imani, D.; Sathyapalan, T.; Sahebkar, A. Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials. Cytokine 2021, 143, 155541. [Google Scholar] [CrossRef] [PubMed]
  114. Usharani, P.; Mateen, A.; Naidu, M.; Raju, Y.; Chandra, N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: A randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 2008, 9, 243–250. [Google Scholar] [CrossRef] [PubMed]
  115. Abdelazeem, B.; Abbas, K.S.; Shehata, J.; Baral, N.; Banour, S.; Hassan, M. The effects of curcumin as dietary supplement for patients with polycystic ovary syndrome: An updated systematic review and meta-analysis of randomized clinical trials. Phytother. Res. 2022, 36, 22–32. [Google Scholar] [CrossRef] [PubMed]
  116. Ferguson, J.J.; Abbott, K.A.; Garg, M.L. Anti-inflammatory effects of oral supplementation with curcumin: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2021, 79, 1043–1066. [Google Scholar] [CrossRef] [PubMed]
  117. Chainani-Wu, N.; Silverman, S., Jr.; Reingold, A.; Bostrom, A.; Mc Culloch, C.; Lozada-Nur, F.; Weintraub, J. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 2007, 14, 437–446. [Google Scholar] [CrossRef] [PubMed]
  118. Cox, K.H.; Pipingas, A.; Scholey, A.B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J. Psychopharmacol. 2015, 29, 642–651. [Google Scholar] [CrossRef] [PubMed]
  119. Panahi, Y.; Khalili, N.; Sahebi, E.; Namazi, S.; Atkin, S.L.; Majeed, M.; Sahebkar, A. Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus. Curr. Clin. Pharmacol. 2017, 12, 253–258. [Google Scholar] [CrossRef]
  120. Wu, S.; Xiao, D. Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2016, 117, 697–702.e691. [Google Scholar] [CrossRef]
  121. Soveyd, N.; Abdolahi, M.; Djalali, M.; Hatami, M.; Tafakhori, A.; Sarraf, P.; Honarvar, N.M. The combined effects of ω-3 fatty acids and nano-curcumin supplementation on intercellular adhesion molecule-1 (ICAM-1) gene expression and serum levels in migraine patients. CNS Neurol. Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol.Disord.) 2017, 16, 1120–1126. [Google Scholar] [CrossRef] [PubMed]
  122. White, C.M.; Pasupuleti, V.; Roman, Y.M.; Li, Y.; Hernandez, A.V. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2019, 146, 104280. [Google Scholar] [CrossRef] [PubMed]
  123. Panahi, Y.; Rahimnia, A.R.; Sharafi, M.; Alishiri, G.; Saburi, A.; Sahebkar, A. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Phytother. Res. 2014, 28, 1625–1631. [Google Scholar] [CrossRef] [PubMed]
  124. Panahi, Y.; Khalili, N.; Sahebi, E.; Namazi, S.; Karimian, M.S.; Majeed, M.; Sahebkar, A. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: A randomized controlled trial. Inflammopharmacology 2017, 25, 25–31. [Google Scholar] [CrossRef]
  125. Tabrizi, R.; Vakili, S.; Akbari, M.; Mirhosseini, N.; Lankarani, K.B.; Rahimi, M.; Mobini, M.; Jafarnejad, S.; Vahedpoor, Z.; Asemi, Z. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 253–262. [Google Scholar] [CrossRef] [PubMed]
  126. Yang, Y.S.; Su, Y.F.; Yang, H.W.; Lee, Y.H.; Chou, J.I.; Ueng, K.C. Lipid-lowering effects of curcumin in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Phytother. Res. 2014, 28, 1770–1777. [Google Scholar] [CrossRef] [PubMed]
  127. Clark, C.C.; Ghaedi, E.; Arab, A.; Pourmasoumi, M.; Hadi, A. The effect of curcumin supplementation on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab.Syndr. Clin. Res. Rev. 2019, 13, 2819–2825. [Google Scholar] [CrossRef] [PubMed]
  128. Simental-Mendia, L.E.; Cicero, A.F.; Atkin, S.L.; Majeed, M.; Sahebkar, A. A systematic review and meta-analysis of the effect of curcuminoids on adiponectin levels. Obes. Res. Clin. Pract. 2019, 13, 340–344. [Google Scholar] [CrossRef] [PubMed]
  129. Ismail, N.A.; Abd El Dayem, S.M.; Salama, E.; Ragab, S.; Abd El Baky, A.N.; Ezzat, W.M. Impact of curcumin intake on gluco-insulin homeostasis, leptin and adiponectin in obese subjects. Res. J. Pharm. Biol. Chem. Sci. 2016, 7, 1891–1897. [Google Scholar]
  130. Ohara, K.; Uchida, A.; Nagasaka, R.; Ushio, H.; Ohshima, T. The effects of hydroxycinnamic acid derivatives on adiponectin secretion. Phytomedicine 2009, 16, 130–137. [Google Scholar] [CrossRef]
  131. Akbari, M.; Lankarani, K.B.; Tabrizi, R.; Ghayour-Mobarhan, M.; Peymani, P.; Ferns, G.; Ghaderi, A.; Asemi, Z. The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2019, 10, 649. [Google Scholar] [CrossRef] [PubMed]
  132. Atkin, S.L.; Katsiki, N.; Derosa, G.; Maffioli, P.; Sahebkar, A. Curcuminoids lower plasma leptin concentrations: A meta-analysis. Phytother. Res. 2017, 31, 1836–1841. [Google Scholar] [CrossRef] [PubMed]
  133. Derosa, G.; Maffioli, P.; Simental-Mendía, L.E.; Bo, S.; Sahebkar, A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2016, 111, 394–404. [Google Scholar] [CrossRef] [PubMed]
  134. Na, L.X.; Yan, B.L.; Jiang, S.; Cui, H.L.; Li, Y.; Sun, C.H. Curcuminoids target decreasing serum adipocyte-fatty acid binding protein levels in their glucose-lowering effect in patients with type 2 diabetes. Biomed. Environ. Sci. 2014, 27, 902–906. [Google Scholar] [PubMed]
  135. Chainani-Wu, N.; Madden, E.; Lozada-Nur, F.; Silverman, S., Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J. Am. Acad. Dermatol. 2012, 66, 752–760. [Google Scholar] [CrossRef] [PubMed]
  136. Gupta, S.C.; Tyagi, A.K.; Deshmukh-Taskar, P.; Hinojosa, M.; Prasad, S.; Aggarwal, B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch. Biochem. Biophys. 2014, 559, 91–99. [Google Scholar] [CrossRef] [PubMed]
  137. Sahebkar, A.; Cicero, A.F.; Simental-Mendía, L.E.; Aggarwal, B.B.; Gupta, S.C. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 2016, 107, 234–242. [Google Scholar] [CrossRef] [PubMed]
  138. Panahi, Y.; Khalili, N.; Hosseini, M.S.; Abbasinazari, M.; Sahebkar, A. Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complement. Ther. Med. 2014, 22, 851–857. [Google Scholar] [CrossRef] [PubMed]
  139. Yu, J.-J.; Pei, L.-B.; Zhang, Y.; Wen, Z.-Y.; Yang, J.-L. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychopharmacol. 2015, 35, 406–410. [Google Scholar] [CrossRef]
  140. Sahebkar, A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 2014, 28, 633–642. [Google Scholar] [CrossRef]
  141. Panahi, Y.; Sahebkar, A.; Amiri, M.; Davoudi, S.M.; Beiraghdar, F.; Hoseininejad, S.L.; Kolivand, M. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: Results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 2012, 108, 1272–1279. [Google Scholar] [CrossRef] [PubMed]
  142. Belcaro, G.; Cesarone, M.; Dugall, M.; Pellegrini, L.; Ledda, A.; Grossi, M.; Togni, S.; Appendino, G. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010, 52, 55–62. [Google Scholar] [PubMed]
  143. Nasseri, E.; Mohammadi, E.; Tamaddoni, A.; Qujeq, D.; Zayeri, F.; Zand, H. Benefits of curcumin supplementation on antioxidant status in β-Thalassemia major patients: A double-blind randomized controlled clinical trial. Ann. Nutr. Metab. 2018, 71, 136–144. [Google Scholar] [CrossRef] [PubMed]
  144. Hodaei, H.; Adibian, M.; Nikpayam, O.; Hedayati, M.; Sohrab, G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: A randomized, double-blind clinical trial. Diabetol. Metab. Syndr. 2019, 11, 41. [Google Scholar] [CrossRef] [PubMed]
  145. Hejazi, J.; Rastmanesh, R.; Taleban, F.-A.; Molana, S.-H.; Hejazi, E.; Ehtejab, G.; Hara, N. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: A double blinded, randomized, placebo-controlled study. Nutr. Cancer 2016, 68, 77–85. [Google Scholar] [CrossRef] [PubMed]
  146. Jarhahzadeh, M.; Alavinejad, P.; Farsi, F.; Husain, D.; Rezazadeh, A. The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: A randomized double blind clinical trial. Diabetol. Metab. Syndr. 2021, 13, 112. [Google Scholar] [CrossRef] [PubMed]
  147. Heshmati, J.; Golab, F.; Morvaridzadeh, M.; Potter, E.; Akbari-Fakhrabadi, M.; Farsi, F.; Tanbakooei, S.; Shidfar, F. The effects of curcumin supplementation on oxidative stress, Sirtuin-1 and peroxisome proliferator activated receptor γ coactivator 1α gene expression in polycystic ovarian syndrome (PCOS) patients: A randomized placebo-controlled clinical trial. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 77–82. [Google Scholar] [CrossRef] [PubMed]
  148. Jakubczyk, K.; Drużga, A.; Katarzyna, J.; Skonieczna-Żydecka, K. Antioxidant potential of curcumin—A meta-analysis of randomized clinical trials. Antioxidants 2020, 9, 1092. [Google Scholar] [CrossRef] [PubMed]
  149. Mohajer, A.; Ghayour-Mobarhan, M.; Parizadeh, S.M.R.; Tavallaie, S.; Rajabian, M.; Sahebkar, A. Effects of supplementation with curcuminoids on serum copper and zinc concentrations and superoxide dismutase enzyme activity in obese subjects. Trace Elem. Electrolytes 2014, 32, 16–21. [Google Scholar] [CrossRef]
  150. Alizadeh, M.; Kheirouri, S. Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: A comprehensive meta-analysis of randomized controlled trials. BioMedicine 2019, 9, 23. [Google Scholar] [CrossRef]
  151. Jiménez-Osorio, A.S.; García-Niño, W.R.; González-Reyes, S.; Álvarez-Mejía, A.E.; Guerra-León, S.; Salazar-Segovia, J.; Falcón, I.; de Oca-Solano, H.M.; Madero, M.; Pedraza-Chaverri, J. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: A pilot study. J. Ren. Nutr. 2016, 26, 237–244. [Google Scholar] [CrossRef] [PubMed]
  152. Judaki, A.; Rahmani, A.; Feizi, J.; Asadollahi, K.; Ahmadi, M.R.H. Curcumin in combination with triple therapy regimes ameliorates oxidative stress and histopathologic changes in chronic gastritis-associated Helicobacter pylori infection. Arq. Gastroenterol. 2017, 54, 177–182. [Google Scholar] [CrossRef] [PubMed]
  153. Pakfetrat, M.; Akmali, M.; Malekmakan, L.; Dabaghimanesh, M.; Khorsand, M. Role of turmeric in oxidative modulation in end-stage renal disease patients. Hemodial. Int. 2015, 19, 124–131. [Google Scholar] [CrossRef] [PubMed]
  154. Panahi, Y.; Ghanei, M.; Hajhashemi, A.; Sahebkar, A. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: A randomized controlled trial. J. Diet. Suppl. 2016, 13, 93–105. [Google Scholar] [CrossRef] [PubMed]
  155. Panahi, Y.; Saadat, A.; Beiraghdar, F.; Nouzari, S.M.H.; Jalalian, H.R.; Sahebkar, A. Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: A randomized double-blind placebo-controlled trial. J. Funct. Foods 2014, 6, 615–622. [Google Scholar] [CrossRef]
  156. Panahi, Y.; Alishiri, G.H.; Parvin, S.; Sahebkar, A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: Results of a randomized controlled trial. J. Diet. Suppl. 2016, 13, 209–220. [Google Scholar] [CrossRef] [PubMed]
  157. Roohi, B.N.; Moradlou, A.N.; Bolboli, L. Influence of curcumin supplementation on exercise-induced oxidative stress. Asian J. Sports Med. 2017, 8, e35776. [Google Scholar]
  158. Sudheeran, S.P.; Jacob, D.; Mulakal, J.N.; Nair, G.G.; Maliakel, A.; Maliakel, B.; Kuttan, R.; Krishnakumar, I. Safety, tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress: A randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychopharmacol. 2016, 36, 236–243. [Google Scholar] [CrossRef] [PubMed]
  159. Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Tang, Y.; Ren, H.; Hu, H. Meta-analysis of randomized controlled trials of 4 weeks or longer suggest that curcumin may afford some protection against oxidative stress. Nutr. Res. 2018, 60, 1–12. [Google Scholar] [CrossRef]
  160. Lukkunaprasit, T.; Tansawet, A.; Boonmanunt, S.; Sobhonslidsuk, A.; McKay, G.J.; Attia, J.; Thakkinstian, A. An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand. Sci. Rep. 2023, 13, 5824. [Google Scholar] [CrossRef]
  161. Rahmani, S.; Asgary, S.; Askari, G.; Keshvari, M.; Hatamipour, M.; Feizi, A.; Sahebkar, A. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother. Res. 2016, 30, 1540–1548. [Google Scholar] [CrossRef] [PubMed]
  162. Panahi, Y.; Valizadegan, G.; Ahamdi, N.; Ganjali, S.; Majeed, M.; Sahebkar, A. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. J. Cell. Biochem. 2019, 120, 15989–15996. [Google Scholar] [CrossRef] [PubMed]
  163. Chirapongsathorn, S.; Jearjesdakul, J.; Sanpajit, T.; Juthaputthi, A. Curcumin trend to improve alanine transaminase (ALT) in non-alcoholic fatty liver disease (NAFLD) with abnormal ALT. J. Gastroenterol. Hepatol. 2012, 27, 231–232. [Google Scholar]
  164. Chashmniam, S.; Mirhafez, S.R.; Dehabeh, M.; Hariri, M.; Azimi Nezhad, M.; Nobakht, M.; Gh, B.F. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2019, 73, 1224–1235. [Google Scholar] [CrossRef] [PubMed]
  165. Saadati, S.; Hatami, B.; Yari, Z.; Shahrbaf, M.A.; Eghtesad, S.; Mansour, A.; Poustchi, H.; Hedayati, M.; Aghajanpoor-Pasha, M.; Sadeghi, A. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur. J. Clin. Nutr. 2019, 73, 441–449. [Google Scholar] [CrossRef]
  166. Saberi-Karimian, M.; Keshvari, M.; Ghayour-Mobarhan, M.; Salehizadeh, L.; Rahmani, S.; Behnam, B.; Jamialahmadi, T.; Asgary, S.; Sahebkar, A. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complement. Ther. Med. 2020, 49, 102322. [Google Scholar] [CrossRef]
  167. Mirhafez, S.R.; Azimi-Nezhad, M.; Dehabeh, M.; Hariri, M.; Naderan, R.D.; Movahedi, A.; Abdalla, M.; Sathyapalan, T.; Sahebkar, A. The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial. Adv. Exp. Med. Biol. 2021, 1308, 25–35. [Google Scholar]
  168. Mirhafez, S.R.; Dehabeh, M.; Hariri, M.; Farimani, A.R.; Movahedi, A.; Naderan, R.D.; Jamialahmadi, T.; Simental-Mendía, L.E.; Sahebkar, A. Curcumin and piperine combination for the treatment of patients with non-alcoholic fatty liver disease: A double-blind randomized placebo-controlled trial. Adv. Exp. Med. Biol. 2021, 1328, 11–19. [Google Scholar]
  169. Zhang, H. Study on the effect of curcumin on glucose and lipid metabolism in patients with metabolic syndrome. Mod. J. Integr. Tradit. Chin. West. Med. 2019, 28, 1103–1105. [Google Scholar]
  170. Alidadi, M.; Sahebkar, A.; Eslami, S.; Vakilian, F.; Jarahi, L.; Alinezhad-Namaghi, M.; Arabi, S.M.; Vakili, S.; Tohidinezhad, F.; Nikooiyan, Y.; et al. The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv. Exp. Med. Biol. 2021, 1308, 1–11. [Google Scholar] [CrossRef]
  171. Bateni, Z.; Rahimi, H.R.; Hedayati, M.; Afsharian, S.; Goudarzi, R.; Sohrab, G. The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: A randomized, double-blind clinical trial. Phytother. Res. 2021, 35, 3945–3953. [Google Scholar] [CrossRef] [PubMed]
  172. Salimi Avansar, M. The effects of eight weeks interval training and curcumin consumption on TNF-α and BDNF levels in men with metabolic syndrome. J. Ardabil Univ. Med. Sci. 2017, 17, 299–310. [Google Scholar]
  173. Różański, G.; Tabisz, H.; Zalewska, M.; Niemiro, W.; Kujawski, S.; Newton, J.; Zalewski, P.; Słomko, J. Meta-analysis of exploring the effect of curcumin supplementation with or without other advice on biochemical and anthropometric parameters in patients with metabolic-associated fatty liver disease (MAFLD). Int. J. Environ. Res. Public Health 2023, 20, 4266. [Google Scholar] [CrossRef] [PubMed]
  174. Moradi Kelardeh, B.; Keshavarz, S.; Karimi, M. Effects of nonlinear resistance training with curcumin supplement on liver enzymes in men with non-alcoholic fatty liver disease. Rep. Health Care 2017, 3, 1–9. [Google Scholar]
  175. Hariri, M.; Gholami, A.; Mirhafez, S.R.; Bidkhori, M.; Sahebkar, A. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement. Ther. Med. 2020, 51, 102447. [Google Scholar] [CrossRef] [PubMed]
  176. Kelardeh, B.M.; Rahmati-Ahmadabad, S.; Farzanegi, P.; Helalizadeh, M.; Azarbayjani, M.-A. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. J. Bodyw. Mov. Ther. 2020, 24, 154–160. [Google Scholar] [CrossRef] [PubMed]
  177. Panahi, Y.; Kianpour, P.; Mohtashami, R.; Jafari, R.; Simental-Mendía, L.E.; Sahebkar, A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J. Cardiovasc. Pharmacol. 2016, 68, 223–229. [Google Scholar] [CrossRef] [PubMed]
  178. Panahi, Y.; Kianpour, P.; Mohtashami, R.; Jafari, R.; Simental-Mendía, L.E.; Sahebkar, A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial. Drug Res. 2017, 67, 244–251. [Google Scholar] [CrossRef] [PubMed]
  179. Cicero, A.F.; Sahebkar, A.; Fogacci, F.; Bove, M.; Giovannini, M.; Borghi, C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur. J. Nutr. 2020, 59, 477–483. [Google Scholar] [CrossRef]
  180. Ngu, M.; Norhayati, M.; Rosnani, Z.; Zulkifli, M. Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: A systematic review and meta-analysis. Complement. Ther. Med. 2022, 68, 102843. [Google Scholar] [CrossRef]
  181. Saadati, S.; Hekmatdoost, A.; Hatami, B.; Mansour, A.; Zahra, Z.; Hedayati, M.; Sadeghi, A. Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterol. Hepatol. Bed Bench 2018, 11, S8. [Google Scholar] [PubMed]
  182. Rahimi, H.R.; Mohammadpour, A.H.; Dastani, M.; Jaafari, M.R.; Abnous, K.; Mobarhan, M.G.; Oskuee, R.K. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial. Avicenna J. Phytomedicine 2016, 6, 567. [Google Scholar]
  183. Na, L.X.; Li, Y.; Pan, H.Z.; Zhou, X.L.; Sun, D.J.; Meng, M.; Li, X.X.; Sun, C.H. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: A double-blind, placebo-controlled trial. Mol. Nutr. Food Res. 2013, 57, 1569–1577. [Google Scholar] [CrossRef]
  184. Javandoost, A.; Afshari, A.; Saberi-Karimian, M.; Sahebkar, A.; Safarian, H.; Moammeri, M.; Dizaji, B.F.; Tavalaei, S.; Ferns, G.A.; Pasdar, A. The effects of curcumin and a modified curcumin formulation on serum Cholesteryl Ester Transfer Protein concentrations in patients with metabolic syndrome: A randomized, placebo-controlled clinical trial. Avicenna J. Phytomed. 2018, 8, 330. [Google Scholar]
  185. Asadi, S.; Gholami, M.S.; Siassi, F.; Qorbani, M.; Khamoshian, K.; Sotoudeh, G. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled clinical trial. Complement. Ther. Med. 2019, 43, 253–260. [Google Scholar] [CrossRef] [PubMed]
  186. Vanaie, A.; Shahidi, S.; Iraj, B.; Siadat, Z.D.; Kabirzade, M.; Shakiba, F.; Mohammadi, M.; Parvizian, H. Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 2019, 24, 77. [Google Scholar]
  187. Karandish, M.; Mozaffari-khosravi, H.; Mohammadi, S.M.; Cheraghian, B.; Azhdari, M. The effect of curcumin and zinc co-supplementation on glycemic parameters in overweight or obese prediabetic subjects: A phase 2 randomized, placebo-controlled trial with a multi-arm, parallel-group design. Phytother. Res. 2021, 35, 4377–4387. [Google Scholar] [CrossRef] [PubMed]
  188. Neta, J.F.d.F.; Veras, V.S.; Sousa, D.F.d.; Cunha, M.d.C.d.S.O.; Queiroz, M.V.O.; Neto, J.C.G.L.; Damasceno, M.M.C.; Araújo, M.F.M.d.; Freitas, R.W.J.F.d. Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic control of patients with type 2 diabetes: A randomised double-blind placebo-controlled clinical trial. Int. J. Food Sci. Nutr. 2021, 72, 968–977. [Google Scholar] [CrossRef]
  189. Thota, R.N.; Rosato, J.I.; Dias, C.B.; Burrows, T.L.; Martins, R.N.; Garg, M.L. Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3β and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer’s Disease. Nutrients 2020, 12, 1032. [Google Scholar] [CrossRef]
  190. Tian, J.; Feng, B.; Tian, Z. The effect of curcumin on lipid profile and glycemic status of patients with type 2 Diabetes Mellitus: A systematic review and meta-analysis. Evid.-Based Complement. Altern. Med. 2022, 2022, 8278744. [Google Scholar] [CrossRef]
  191. Abbood, M.S. Hypolipidaemic and anti-inflammatory effects of curcumin versus atorvastatin in type 2 diabetic patients. Int. J. Pharm. Sci. Rev. Res 2018, 49, 1–7. [Google Scholar]
  192. Nouri, M.; Sohaei, S.; Shalaby, M.N.; Mehrabani, S.; Ramezani, A.; Faghih, S. Effect of curcumin on body mass index and glycemic indices in females with PCOS: A systematic review and meta-analysis of randomized controlled trial. Nutr. Food Sci. 2022, 52, 1129–1141. [Google Scholar] [CrossRef]
  193. Jamilian, M.; Foroozanfard, F.; Kavossian, E.; Aghadavod, E.; Shafabakhsh, R.; Hoseini, A.; Asemi, Z. Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. ESPEN 2020, 36, 128–133. [Google Scholar] [CrossRef] [PubMed]
  194. Heshmati, J.; Moini, A.; Sepidarkish, M.; Morvaridzadeh, M.; Salehi, M.; Palmowski, A.; Mojtahedi, M.F.; Shidfar, F. Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Phytomedicine 2021, 80, 153395. [Google Scholar] [CrossRef] [PubMed]
  195. Khalili, L.; Nammi, S. The effects of curcumin supplementation on metabolic biomarkers and body mass index in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Curr. Pharm. Des. 2022, 28, 1911–1925. [Google Scholar] [CrossRef] [PubMed]
  196. Husain, D.; Jarahzadeh, M.; Alavinejad, P.; Rezazadeh, A.; Haghighizadeh, M. Turmeric supplementation in nonalcoholic fatty liver disease. Plant Arch 2020, 20, 3640–3647. [Google Scholar]
  197. Sohrevardi, S.M.; Heydari, B.; Azarpazhooh, M.R.; Teymourzadeh, M.; Simental-Mendía, L.E.; Atkin, S.L.; Sahebkar, A.; Karimi-Zarchi, M. Therapeutic effect of curcumin in women with polycystic ovary syndrome receiving metformin: A randomized controlled trial. Pharmacol. Prop. Plant-Deriv. Nat. Prod. Implic. Hum. Health 2021, 1308, 109–117. [Google Scholar]
  198. Wu, J.-L.; Liu, J.-C.; Liu, F.; Deng, X.; Fang, F.; Hu, R.-J.; Zhu, D.-P. Randomized controlled trial of Curcuma longa on improving insulin sensitivity in patients with polycystic ovary syndrome. Chin. J. Integr. Tradit. West. Med. 2022, 42, 444–448. [Google Scholar]
  199. Wu, J.; Mei, X.; Tang, S.; Fang, F.; Li, S.; Zhang, H. Clinical study of Curcuma longa combined with metformin on improving insulin resistance in patients with polycystic ovary syndrom. Chin. J. Integr. Med. 2020, 40, 406–412. [Google Scholar]
  200. Zhang, T.; He, Q.; Liu, Y.; Chen, Z.; Hu, H. Efficacy and safety of curcumin supplement on improvement of insulin resistance in people with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Evid.-Based Complement. Altern. Med. 2021, 2021, 4471944. [Google Scholar] [CrossRef]
  201. Altobelli, E.; Angeletti, P.M.; Marziliano, C.; Mastrodomenico, M.; Giuliani, A.R.; Petrocelli, R. Potential therapeutic effects of curcumin on glycemic and lipid profile in uncomplicated type 2 diabetes—A meta-analysis of randomized controlled trial. Nutrients 2021, 13, 404. [Google Scholar] [CrossRef] [PubMed]
  202. Chien, Y.-J.; Chang, C.-Y.; Wu, M.-Y.; Chen, C.-H.; Horng, Y.-S.; Wu, H.-C. Effects of curcumin on glycemic control and lipid profile in polycystic ovary syndrome: Systematic review with meta-analysis and trial sequential analysis. Nutrients 2021, 13, 684. [Google Scholar] [CrossRef] [PubMed]
  203. Jalali, M.; Mahmoodi, M.; Mosallanezhad, Z.; Jalali, R.; Imanieh, M.H.; Moosavian, S.P. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med. 2020, 48, 102283. [Google Scholar] [CrossRef] [PubMed]
  204. Azhdari, M.; Karandish, M.; Mansoori, A. Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 1289–1301. [Google Scholar] [CrossRef] [PubMed]
  205. Huang, J.; Qin, S.; Huang, L.; Tang, Y.; Ren, H.; Hu, H. Efficacy and safety of Rhizoma curcumea longae with respect to improving the glucose metabolism of patients at risk for cardiovascular disease: A meta-analysis of randomised controlled trials. J. Hum. Nutr. Diet. 2019, 32, 591–606. [Google Scholar] [CrossRef] [PubMed]
  206. Kim, S.-W.; Ha, K.-C.; Choi, E.-K.; Jung, S.-Y.; Kim, M.-G.; Kwon, D.-Y.; Yang, H.-J.; Kim, M.-J.; Kang, H.-J.; Back, H.-I. The effectiveness of fermented turmeric powder in subjects with elevated alanine transaminase levels: A randomised controlled study. BMC Complement. Altern. Med. 2013, 13, 58. [Google Scholar] [CrossRef] [PubMed]
  207. Tabrizi, R.; Vakili, S.; Lankarani, K.B.; Akbari, M.; Mirhosseini, N.; Ghayour-Mobarhan, M.; Ferns, G.; Karamali, F.; Karamali, M.; Taghizadeh, M. The effects of curcumin on glycemic control and lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Curr. Pharm. Des. 2018, 24, 3184–3199. [Google Scholar] [CrossRef] [PubMed]
  208. Adab, Z.; Eghtesadi, S.; Vafa, M.; Heydari, I.; Shojaei, A.; Haqqani, H.; Khorraminia, N. Effect of turmeric on body measurement indices, glycemic condition, and lipid profile in hyperlipidemic patients with type 2 diabetes. Iran. J. Nutr. Sci. Food Technol. 2013, 8, 217–227. [Google Scholar]
  209. Ferguson, J.J.; Stojanovski, E.; MacDonald-Wicks, L.; Garg, M.L. Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial. Metabolism 2018, 82, 22–35. [Google Scholar] [CrossRef]
  210. Wen, W.; Zou, Y. Effect of β-cyclodextrin curcumin on lowering blood lipid in human body. Strait Pharm J. 2020, 32, 135–138. [Google Scholar]
  211. Saeedi, F.; Farkhondeh, T.; Roshanravan, B.; Amirabadizadeh, A.; Ashrafizadeh, M.; Samarghandian, S. Curcumin and blood lipid levels: An updated systematic review and meta-analysis of randomised clinical trials. Arch. Physiol. Biochem. 2022, 128, 1493–1502. [Google Scholar] [CrossRef] [PubMed]
  212. Murillo Ortiz, B.O.; Fuentes Preciado, A.R.; Ramírez Emiliano, J.; Martínez Garza, S.; Ramos Rodríguez, E.; de Alba Macías, L.A. Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol. Clin. Interv. Aging 2019, 14, 2055–2062. [Google Scholar] [CrossRef] [PubMed]
  213. Simental-Mendía, L.E.; Pirro, M.; Gotto, A.M., Jr.; Banach, M.; Atkin, S.L.; Majeed, M.; Sahebkar, A. Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2019, 59, 1178–1187. [Google Scholar] [CrossRef] [PubMed]
  214. Alwi, I.; Santoso, T.; Suyono, S.; Sutrisna, B.; Suyatna, F.D.; Kresno, S.B.; Ernie, S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med. Indones. 2008, 40, 201–210. [Google Scholar] [PubMed]
  215. Baum, L.; Cheung, S.K.; Mok, V.C.; Lam, L.C.; Leung, V.P.; Hui, E.; Ng, C.C.; Chow, M.; Ho, P.C.; Lam, S. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 2007, 56, 509–514. [Google Scholar] [CrossRef] [PubMed]
  216. Pashine, L.; Singh, J.; Vaish, A.; Ojha, S.; Mahdi, A. Effect of turmeric (Curcuma longa) on overweight hyperlipidemic subjects: Double blind study. Indian J. Community Health 2012, 24, 113–117. [Google Scholar]
  217. Sukandar, E.Y.; Sudjana, P.; Sigit, J.I.; Leliqia, N.P.E.; Lestari, F. Safety of garlic (Allium sativum) and turmeric (Curcuma domestica) extract in comparison with simvastatin on improving lipid profile in dyslipidemia patients. J. Med. Sci. 2013, 13, 10–18. [Google Scholar] [CrossRef]
  218. Pungcharoenkul, K.; Thongnopnua, P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother. Res. 2011, 25, 1721–1726. [Google Scholar] [CrossRef]
  219. Adibian, M.; Hodaie, H.; Hedayati, M.; Sohrab, G. Effect of curcumin supplementation on risk factors of cardiovascular disease in patient with type 2 diabetes. Res. Med. 2017, 41, 86–96. [Google Scholar]
  220. Amirkhani, Z.; Azarbayjani, M.A.; Peeri, M.; Matin Homaei, H. Effect of combining resistance training and curcumin supplementation on lipid profile in obese women. Iran. J. Obstet. Gynecol. Infertil. 2017, 20, 24–32. [Google Scholar]
  221. Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: A meta-analysis of randomized controlled trials. Nutr. J. 2017, 16, 68. [Google Scholar] [CrossRef] [PubMed]
  222. Sahebkar, A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin. Nutr. 2014, 33, 406–414. [Google Scholar] [CrossRef] [PubMed]
  223. Di Pierro, F.; Bressan, A.; Ranaldi, D.; Rapacioli, G.; Giacomelli, L.; Bertuccioli, A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: Preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 4195–4202. [Google Scholar] [PubMed]
  224. Mirhafez, S.R.; Rezai, A.; Dehabeh, M.; Gh, B.F.N.M.; Bidkhori, M.; Sahebkar, A.; Hariri, M. Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease. Int. J. Vitam. Nutr. Res. 2019, 91, 278–286. [Google Scholar] [CrossRef] [PubMed]
  225. Mousavi, S.M.; Milajerdi, A.; Varkaneh, H.K.; Gorjipour, M.M.; Esmaillzadeh, A. The effects of curcumin supplementation on body weight, body mass index and waist circumference: A systematic review and dose-response meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2020, 60, 171–180. [Google Scholar] [CrossRef] [PubMed]
  226. Mohammadi, A.; Sadeghnia, H.R.; Saberi-Karimian, M.; Safarian, H.; Ferns, G.A.; Ghayour-Mobarhan, M.; Sahebkar, A. Effects of curcumin on serum vitamin E concentrations in individuals with metabolic syndrome. Phytother. Res. 2017, 31, 657–662. [Google Scholar] [CrossRef] [PubMed]
  227. Jazayeri-Tehrani, S.A.; Rezayat, S.M.; Mansouri, S.; Qorbani, M.; Alavian, S.M.; Daneshi-Maskooni, M.; Hosseinzadeh-Attar, M.-J. The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): A double-blind randomized placebo-controlled clinical trial. Nanomed. J. 2018, 5, 67–76. [Google Scholar]
  228. Baziar, N.; Parohan, M. The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose–response meta-analysis of randomized controlled trials. Phytother. Res. 2020, 34, 464–474. [Google Scholar] [CrossRef] [PubMed]
  229. Sahebkar, A.; Mohammadi, A.; Atabati, A.; Rahiman, S.; Tavallaie, S.; Iranshahi, M.; Akhlaghi, S.; Ferns, G.A.; Ghayour-Mobarhan, M. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res. 2013, 27, 1883–1888. [Google Scholar] [CrossRef]
  230. Wei, Z.; Liu, N.; Tantai, X.; Xing, X.; Xiao, C.; Chen, L.; Wang, J. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Hepatol. Int. 2019, 13, 302–313. [Google Scholar] [CrossRef]
  231. Guyatt, G.; Oxman, A.D.; Sultan, S.; Brozek, J.; Glasziou, P.; Alonso-Coello, P.; Atkins, D.; Kunz, R.; Montori, V.; Jaeschke, R. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J. Clin. Epidemiol. 2013, 66, 151–157. [Google Scholar] [CrossRef] [PubMed]
  232. Jafarirad, S.; Mansoori, A.; Adineh, A.; Panahi, Y.; Hadi, A.; Goodarzi, R. Does turmeric/curcumin supplementation change anthropometric indices in patients with non-alcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. Res. 2019, 8, 196–208. [Google Scholar] [CrossRef] [PubMed]
  233. Kelardeh, B.M.; Azarbayjani, M.A.; Peeri, M.; Homaee, H. Effect of curcumin supplementation and resistance training in patients with nonalcoholic fatty liver disease. J. Med. Plants 2016, 15, 161–172. [Google Scholar]
  234. Changal, K.H.; Khan, M.S.; Bashir, R.; Sheikh, M.A. Curcumin preparations can improve flow-mediated dilation and endothelial function: A meta-analysis. Complement. Med. Res. 2020, 27, 272–281. [Google Scholar] [CrossRef] [PubMed]
  235. Akazawa, N.; Choi, Y.; Miyaki, A.; Tanabe, Y.; Sugawara, J.; Ajisaka, R.; Maeda, S. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr. Res. 2012, 32, 795–799. [Google Scholar] [CrossRef] [PubMed]
  236. Nakayama, H.; Tsuge, N.; Sawada, H.; Masamura, N.; Yamada, S.; Satomi, S.; Higashi, Y. A single consumption of curry improved postprandial endothelial function in healthy male subjects: A randomized, controlled crossover trial. Nutr. J. 2014, 13, 67. [Google Scholar] [CrossRef]
  237. Oliver, J.M.; Stoner, L.; Rowlands, D.S.; Caldwell, A.R.; Sanders, E.; Kreutzer, A.; Mitchell, J.B.; Purpura, M.; Jäger, R. Novel form of curcumin improves endothelial function in young, healthy individuals: A double-blind placebo controlled study. J. Nutr. Metab. 2016, 2016, 1089653. [Google Scholar] [CrossRef]
  238. Barber-Chamoux, N.; Milenkovic, D.; Verny, M.A.; Habauzit, V.; Pereira, B.; Lambert, C.; Richard, D.; Boby, C.; Mazur, A.; Lusson, J.R. Substantial variability across individuals in the vascular and nutrigenomic response to an acute intake of curcumin: A randomized controlled trial. Mol. Nutr. Food Res. 2018, 62, 1700418. [Google Scholar] [CrossRef] [PubMed]
  239. Hallajzadeh, J.; Milajerdi, A.; Kolahdooz, F.; Amirani, E.; Mirzaei, H.; Asemi, Z. The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 2989–2995. [Google Scholar] [CrossRef]
  240. Sugawara, J.; Akazawa, N.; Miyaki, A.; Choi, Y.; Tanabe, Y.; Imai, T.; Maeda, S. Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: Pilot study. Am. J. Hypertens. 2012, 25, 651–656. [Google Scholar] [CrossRef]
  241. Derosa, G.; Catena, G.; Raddino, R.; Gaudio, G.; Maggi, A.; D’Angelo, A.; Maffioli, P. Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. Phytomedicine 2018, 42, 75–82. [Google Scholar] [CrossRef]
  242. Hadi, A.; Pourmasoumi, M.; Ghaedi, E.; Sahebkar, A. The effect of Curcumin/Turmeric on blood pressure modulation: A systematic review and meta-analysis. Pharmacol. Res. 2019, 150, 104505. [Google Scholar] [CrossRef]
  243. Khajehdehi, P.; Zanjaninejad, B.; Aflaki, E.; Nazarinia, M.; Azad, F.; Malekmakan, L.; Dehghanzadeh, G.-R. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: A randomized and placebo-controlled study. J. Ren. Nutr. 2012, 22, 50–57. [Google Scholar] [CrossRef]
  244. Akazawa, N.; Choi, Y.; Miyaki, A.; Tanabe, Y.; Sugawara, J.; Ajisaka, R.; Maeda, S. Effects of curcumin intake and aerobic exercise training on arterial compliance in postmenopausal women. Artery Res. 2013, 7, 67–72. [Google Scholar] [CrossRef]
  245. Wang, Z.; Zhang, Q.; Huang, H.; Liu, Z. The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis. J. Affect. Disord. 2021, 282, 242–251. [Google Scholar] [CrossRef]
  246. Bergman, J.; Miodownik, C.; Bersudsky, Y.; Sokolik, S.; Lerner, P.P.; Kreinin, A.; Polakiewicz, J.; Lerner, V. Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol. 2013, 36, 73–77. [Google Scholar] [CrossRef] [PubMed]
  247. Kanchanatawan, B.; Tangwongchai, S.; Sughondhabhirom, A.; Suppapitiporn, S.; Hemrunrojn, S.; Carvalho, A.F.; Maes, M. Add-on treatment with curcumin has antidepressive effects in Thai patients with major depression: Results of a randomized double-blind placebo-controlled study. Neurotox. Res. 2018, 33, 621–633. [Google Scholar] [CrossRef] [PubMed]
  248. Lopresti, A.L.; Drummond, P.D. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J. Affect. Disord. 2017, 207, 188–196. [Google Scholar] [CrossRef] [PubMed]
  249. Lopresti, A.L.; Maes, M.; Maker, G.L.; Hood, S.D.; Drummond, P.D. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J. Affect. Disord. 2014, 167, 368–375. [Google Scholar] [CrossRef]
  250. Sanmukhani, J.; Satodia, V.; Trivedi, J.; Patel, T.; Tiwari, D.; Panchal, B.; Goel, A.; Tripathi, C.B. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytother. Res. 2014, 28, 579–585. [Google Scholar] [CrossRef]
  251. Asadi, S.; Gholami, M.S.; Siassi, F.; Qorbani, M.; Sotoudeh, G. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. Phytother. Res. 2020, 34, 896–903. [Google Scholar] [CrossRef] [PubMed]
  252. Esmaily, H.; Sahebkar, A.; Iranshahi, M.; Ganjali, S.; Mohammadi, A.; Ferns, G.; Ghayour-Mobarhan, M. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin. J. Integr. Med. 2015, 21, 332–338. [Google Scholar] [CrossRef] [PubMed]
  253. Miodownik, C.; Lerner, V.; Kudkaeva, N.; Lerner, P.P.; Pashinian, A.; Bersudsky, Y.; Eliyahu, R.; Kreinin, A.; Bergman, J. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 2019, 42, 117–122. [Google Scholar] [CrossRef] [PubMed]
  254. Setiawati, M.C.; Ikawati, Z.; Kertia, I.N. Antiinflamatory and antidepressive activities of extract Curcuma xanthorrhiza roxb in systemic lupus Erythematosus. Indones. J. Pharm. 2017, 28, 185. [Google Scholar] [CrossRef]
  255. Fusar-Poli, L.; Vozza, L.; Gabbiadini, A.; Vanella, A.; Concas, I.; Tinacci, S.; Petralia, A.; Signorelli, M.S.; Aguglia, E. Curcumin for depression: A meta-analysis. Crit. Rev. Food Sci. Nutr. 2020, 60, 2643–2653. [Google Scholar] [CrossRef] [PubMed]
  256. Panahi, Y.; Badeli, R.; Karami, G.R.; Sahebkar, A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. 2015, 29, 17–21. [Google Scholar] [CrossRef] [PubMed]
  257. Ng, Q.X.; Koh, S.S.H.; Chan, H.W.; Ho, C.Y.X. Clinical use of curcumin in depression: A meta-analysis. J. Am. Med. Dir. Assoc. 2017, 18, 503–508. [Google Scholar] [CrossRef]
  258. Al-Karawi, D.; Al Mamoori, D.A.; Tayyar, Y. The role of curcumin administration in patients with major depressive disorder: Mini meta-analysis of clinical trials. Phytother. Res. 2016, 30, 175–183. [Google Scholar] [CrossRef] [PubMed]
  259. Tsai, I.-C.; Hsu, C.-W.; Chang, C.-H.; Tseng, P.-T.; Chang, K.-V. The effect of curcumin differs on individual cognitive domains across different patient populations: A systematic review and meta-analysis. Pharmaceuticals 2021, 14, 1235. [Google Scholar] [CrossRef]
  260. Kuszewski, J.C.; Wong, R.H.X.; Howe, P.R.C. Can curcumin counteract cognitive decline? Clinical trial evidence and rationale for combining ω-3 fatty acids with curcumin. Adv. Nutr. 2018, 9, 105–113. [Google Scholar] [CrossRef]
  261. Kucukgoncu, S.; Guloksuz, S.; Tek, C. Effects of curcumin on cognitive functioning and inflammatory state in schizophrenia: A double-blind, placebo-controlled pilot trial. J. Clin. Psychopharmacol. 2019, 39, 182–184. [Google Scholar] [CrossRef] [PubMed]
  262. Wynn, J.K.; Green, M.F.; Hellemann, G.; Karunaratne, K.; Davis, M.C.; Marder, S.R. The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr. Res. 2018, 195, 572–573. [Google Scholar] [CrossRef]
  263. Rainey-Smith, S.R.; Brown, B.M.; Sohrabi, H.R.; Shah, T.; Goozee, K.G.; Gupta, V.B.; Martins, R.N. Curcumin and cognition: A randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br. J. Nutr. 2016, 115, 2106–2113. [Google Scholar] [CrossRef]
  264. Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.; Heath, D.D.; Apostolova, L.G. Oral curcumin for Alzheimer’s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res. Ther. 2012, 4, 43. [Google Scholar] [CrossRef]
  265. Baum, L.; Lam, C.W.K.; Cheung, S.K.-K.; Kwok, T.; Lui, V.; Tsoh, J.; Lam, L.; Leung, V.; Hui, E.; Ng, C. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 2008, 28, 110–113. [Google Scholar] [CrossRef]
  266. Cox, K.H.; White, D.J.; Pipingas, A.; Poorun, K.; Scholey, A. Further evidence of benefits to mood and working memory from lipidated curcumin in healthy older people: A 12-week, double-blind, placebo-controlled, partial replication study. Nutrients 2020, 12, 1678. [Google Scholar] [CrossRef] [PubMed]
  267. Kuszewski, J.C.; Howe, P.R.; Wong, R.H. Evaluation of cognitive performance following fish-oil and curcumin supplementation in middle-aged and older adults with overweight or obesity. J. Nutr. 2020, 150, 3190–3199. [Google Scholar] [CrossRef]
  268. Zhu, L.N.; Mei, X.; Zhang, Z.G.; Xie, Y.p.; Lang, F. Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis. Phytother. Res. 2019, 33, 524–533. [Google Scholar] [CrossRef] [PubMed]
  269. Small, G.W.; Siddarth, P.; Li, Z.; Miller, K.J.; Ercoli, L.; Emerson, N.D.; Martinez, J.; Wong, K.-P.; Liu, J.; Merrill, D.A. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. Am. J. Geriatr. Psychiatry 2018, 26, 266–277. [Google Scholar] [CrossRef]
  270. Sarraf, P.; Parohan, M.; Javanbakht, M.H.; Ranji-Burachaloo, S.; Djalali, M. Short-term curcumin supplementation enhances serum brain-derived neurotrophic factor in adult men and women: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutr. Res. 2019, 69, 1–8. [Google Scholar] [CrossRef]
  271. Osali, A. The effect of eight-week aerobic exercise and consumption of curcumin on il-6, il-10 and BDNF in 60-65 years women with metabolic syndrome. Med. J. Tabriz Univ. Med. Sci. 2018, 40, 7–14. [Google Scholar]
  272. Fanaei, H.; Khayat, S.; Kasaeian, A.; Javadimehr, M. Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: A randomized, double-blind, placebo-controlled trial. Neuropeptides 2016, 56, 25–31. [Google Scholar] [CrossRef] [PubMed]
  273. Naghsh, N.; Musazadeh, V.; Nikpayam, O.; Kavyani, Z.; Moridpour, A.H.; Golandam, F.; Faghfouri, A.H.; Ostadrahimi, A. Profiling Inflammatory Biomarkers following Curcumin Supplementation: An Umbrella Meta-Analysis of Randomized Clinical Trials. Evid.-Based Complement. Altern. Med. 2023, 2023, 4875636. [Google Scholar] [CrossRef] [PubMed]
  274. Ebrahimzadeh, A.; Abbasi, F.; Ebrahimzadeh, A.; Jibril, A.T.; Milajerdi, A. Effects of curcumin supplementation on inflammatory biomarkers in patients with rheumatoid arthritis and ulcerative colitis: A systematic review and meta-analysis. Complement. Ther. Med. 2021, 61, 102773. [Google Scholar] [CrossRef] [PubMed]
  275. Rao, C.V. Regulation of COX and LOX by curcumin. Mol. Targets Ther. Uses Curcumin Health Dis. 2007, 595, 213–226. [Google Scholar]
  276. Mahattanadul, S.; Kongpuckdee, S.; Wiwattanapatapee, R.; Tansakul, P.; Nitiruangjaras, A.; Hansakul, P. Comparative Inhibitory Efficacy on the iNOS/NO System of Curcuminand Tetrahydrocurcumin-Self-Microemulsifying Liquid Formulation in Chronic Gastric Ulcer Model. Curr. Pharm. Biotechnol. 2021, 22, 1005–1012. [Google Scholar] [CrossRef] [PubMed]
  277. Onoda, M.; Inano, H. Effect of curcumin on the production of nitric oxide by cultured rat mammary gland. Nitric Oxide 2000, 4, 505–515. [Google Scholar] [CrossRef] [PubMed]
  278. Wang, Y.; Tang, Q.; Duan, P.; Yang, L. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacol. Immunotoxicol. 2018, 40, 476–482. [Google Scholar] [CrossRef] [PubMed]
  279. Ak, T.; Gülçin, I. Antioxidant and radical scavenging properties of curcumin. Chem.-Biol. Interact. 2008, 174, 27–37. [Google Scholar] [CrossRef]
  280. Lin, X.; Bai, D.; Wei, Z.; Zhang, Y.; Huang, Y.; Deng, H.; Huang, X. Curcumin attenuates oxidative stress in RAW264. 7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway. PLoS ONE 2019, 14, e0216711. [Google Scholar]
  281. Jagetia, G.C.; Rajanikant, G.K. Curcumin stimulates the antioxidant mechanisms in mouse skin exposed to fractionated γ-irradiation. Antioxidants 2015, 4, 25–41. [Google Scholar] [CrossRef] [PubMed]
  282. Geng, S.; Wang, S.; Zhu, W.; Xie, C.; Li, X.; Wu, J.; Zhu, J.; Jiang, Y.; Yang, X.; Li, Y. Curcumin attenuates BPA-induced insulin resistance in HepG2 cells through suppression of JNK/p38 pathways. Toxicol. Lett. 2017, 272, 75–83. [Google Scholar] [CrossRef] [PubMed]
  283. Musazadeh, V.; Roshanravan, N.; Mohammadizadeh, M.; Kavyani, Z.; Dehghan, P.; Mosharkesh, E. Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis. Nutr. Metab. Cardiovasc. Dis. 2022, 32, 2493–2504. [Google Scholar] [CrossRef] [PubMed]
  284. Unhapipatpong, C.; Polruang, N.; Shantavasinkul, P.C.; Julanon, N.; Numthavaj, P.; Thakkinstian, A. The effect of curcumin supplementation on weight loss and anthropometric indices: An umbrella review and updated meta-analyses of randomized controlled trials. Am. J. Clin. Nutr. 2023, 117, 1005–1016. [Google Scholar] [CrossRef]
  285. Hariri, M.; Haghighatdoost, F. Effect of curcumin on anthropometric measures: A systematic review on randomized clinical trials. J. Am. Coll. Nutr. 2018, 37, 215–222. [Google Scholar] [CrossRef]
Nutrients 16 01728 g001
Figure 1. Flow diagram of the literature review.
Figure 1. Flow diagram of the literature review.
Nutrients 16 01728 g001
Table 1. Meta-analyses of RCTs investigating the effect of curcumin intake on inflammation.
Table 1. Meta-analyses of RCTs investigating the effect of curcumin intake on inflammation.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Qiu et al. 2023 [22]2 publications [23,24]Mets12234–64P6–880 mg/day of curcumin,
1000 mg/day of curcuminoids		↔ IL-6
(MD = −1.5 pg/mL; 95% CI −3.97 to 0.97; p = 0.23)
↓ TNF-α
(MD = −12.97; 95% CI −18.37 to −7.57; p < 0.00001)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
2 publications [23,25]Mets13054–64P6–880 mg/day of nano-curcumin,
2400 mg/day of turmeric		↓ CRP
(MD = −1.24 mg/L; 95% CI −1.71 to −0.77; p < 0.00001)
2 publications [26,27]Mets14334–61P8–1280 mg/day of nano-curcumin,
1000 mg/day of curcuminoids		↔ hs-CRP
(MD = −1.10 mg/L; 95% CI −4.35 to 2.16; p = 0.51)
Dehzad et al. 2023 [28]9 publications [29,30,31,32,33,34,35,36,37]Healthy, Mets, NAFLD, IGTT, prediabetes, T2DM, major depressive disorder117218–70P4–4250–1500 mg/day of curcumin↓ leptin
(WMD = −4.46 ng/mL; 95% CI −6.70 to −2.21; p < 0.001; I2 = 96.1%; p < 0.001)		Cochrane risk of bias tool (61.0%)PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar
11 publications [29,30,31,32,34,36,37,38,39,40,41]Healthy, Mets, IGTT, T2DM, prediabetic, NAFLD78318–70P4–4250–1500 mg/day of curcumin↑ adiponectin
(WMD = 2.48 μg/mL; 95% CI 1.34 to 3.62; p < 0.001; I2 = 96.3%; p < 0.001)
Dehzad et al. 2023 [42]46 publications [23,29,38,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]Mets, healthy, obese, hemodialysis, chronic pulmonary complications, solid tumor, OA, T2DM, CAD, COPD, hyperlipidemia, migraine, infertile men, NAFLD, coronary elective angioplasty, RA, PCOS, Takayasu arteritis, pre-HTN, UC, diabetic foot ulcer287318–70P,
CO		4–2480–2000 mg/day of curcumin,
150–1500 mg/day of curcuminoids,
900–3000 mg/day of turmeric		↓ CRP
(WMD = −0.58 mg/L; 95% CI −0.74 to −0.41; p < 0.05)		Cochrane risk of bias tool (84.2%)PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar
23 publications [24,43,47,48,50,54,55,56,60,63,64,67,68,71,79,83,86,87,88,89,90,91,92]Mets, T2DM, OA, PUD, UC, obese, hemodialysis, NAFLD, HIV, solid tumor, migraine, lupus erythematosus, Takayasu arteritis, infertile coronary elective angioplasty148818–70P,
CO		4–1280–1500 mg/day of curcumin,
150–1000 mg/day of curcuminoids,
1500–3000 mg/day of turmeric		↓ TNF-α
(WMD = −3.48 pg/mL; 95% CI −4.38 to −2.58; p < 0.05)
20 publications [23,24,45,46,47,48,50,54,63,64,68,83,86,89,91,93,94,95,96,97]Mets, obese, chronic pulmonary complications, solid tumor, OA, hemodialysis, hyperlipidemia, lupus erythematosus, migraine, pre-HTN, ankylosing spondylitis, chronic branchial asthma, chronic knee pain116618–70P,
CO		4–1260–1500 mg/day of curcumin,
100–1500 mg/day of curcuminoids,
2800–3000 mg/day of turmeric		↓ IL-6
(WMD = −1.31 pg/mL; 95% CI −1.58 to −0.67; p < 0.05)
6 publications [47,79,86,88,91,98]Obese, knee OA, PUD, pre-HTN, coronary elective angioplasty48218–70P,
CO		4–1680–1500 mg/day of curcumin↔ IL-1β
(WMD = −0.46 pg/mL; 95% CI −1.18 to 0.27; p > 0.05)
Shen et al. 2022 [99]2 publications [58,73]PCOS8124–35P6–893.34–1000 mg/day of curcumin↓ CRP
(WMD = −0.785; 95% CI −1.553 to −0.017; p = 0.045)		Cochrane risk of bias tool (73.5%)PubMed, Embase, Cochrane Library, Web of Science, Scopus, Clinical Trials, Chinese Clinical Trial
Registry, Chinese Biomedical Literature Database, Chinese National knowledge Infrastructure, VIP database, and Wanfang Database
Sun et al. 2022 [100]9 publications [27,29,38,49,60,61,76,80,101]Mets, T2DM, DFU, CHD, hyperlipidemia, IGT69738–70P,
CO		6–2480–2100 mg/day of curcumin↓ hs-CRP
(WMD = −1.11; 95% CI −2.16 to −0.05; p = 0.039)		Cochrane risk of bias tool (69.3%) Jadad scale
(77.0%)		PubMed, Embase, Web of Science, CNKI, Wanfang, and CBM
4 publications [29,31,38,39] T2DM, IGT52557–70P,
CO		10–36180–1500 mg/day of curcumin↔ adiponectin
(WMD = 6.43 ng/mL; 95% CI −1.19 to 14.05; p = 0.98)
Futuhi et al. 2022 [102]5 publications [71,72,81,103,104]ESRD hemodialysis, CKD21232–73P8–12120 mg/day of curcumin,
1000 mg/day of curcuminoids,
2500 mg/day of turmeric		↔ CRP
(WMD = −0.13 mg/L; 95% CI −3.25 to 3.30; p = 0.93)		Cochrane risk of bias tool (73.0%)PubMed, Scopus,
Cochrane
Library, and Web of Science
3 publications [71,103,104]ESRD, hemodialysis, CKD14132–73P8–12120 mg/day of curcumin,
1500 mg/day of turmeric		↓ TNF-α
(WMD = −18.87 pg/mL; 95% CI −28.36 to −9.38; p < 0.001)
Gorabi et al. 2022 [105]7 publications [25,43,44,45,46,47,106]Mets, RA, overweight, infertility49318–65P4–1280–1000 mg/day of curcumin, 250–500 mg/day of curcuminoids
900–2400 mg/day of turmeric.		↓ CRP
(WMD = 3.67 mg/L; 95% CI −6.96 to −0.38; p = 0.02; I2 = 99.5%; p < 0.001)
↓ CRP
(WMD = −2.77 mg/L; 95% CI −4.34 to −1.19; p < 0.001) at ≤1000 mg/day of curcumin compared with dose > 1000 mg/day of curcumin
↓ CRP
(WMD = −3.48 mg/L; 95% CI −5.64 to −1.33; p < 0.001) with intervention duration of >10 weeks		Jadad scale
(81.3%)		MEDLINE/
PubMed, Cochrane Library, Web of Science, and Scopus
22 publications [27,29,38,48,49,50,51,52,53,54,55,56,57,58,59,60,61,103,107,108,109,110]Mets, CAD, chronic cutaneous, ESRD, knee OA, T2DM, migraine114218–73P3 days–8 weeks1000–4000 mg/day of curcuminoids,
1500 mg/day of turmeric		↓ hs-CRP in RCTs with ≤1000 mg/day and those with ≤10-week intervention period
Ashtary-Larky et al. 2021 [111]5 publications [23,48,50,71,76]NAFLD, Mets, migraine, T2DM, hemodialysis27928–68P6–1240–120 mg/day of nano-curcumin↓ CRP
(WMD = −1.29 mg/L; 95% CI −2.15 to −0.44; p = 0.003)		Cochrane risk of bias tool (55.6%)PubMed, Scopus, Embase, and Web of Science
3 publications [23,48,50]NAFLD, Mets, migraine17228–63P6–1240–80 mg/day of nano-curcumin↓ IL-6
(WMD = −2.78 mg/dL; 95% CI −3.76 to −1.79; p <0.001)
2 publications [50,112]NAFLD, migraine12228–49P8–1240–80 mg/day of nano-curcumin↔ TNF-α
(WMD = −3.09 mg/dL; 95% CI −8.75 to 2.57; p = 0.284)
Gorabi et al. 2021 [113]3 publications [47,86,98]Knee OA, overweight30718–65P4–161000 mg/day of curcuminoids,
500–900 mg/day of turmeric		↓ IL-1
(WMD = −2.33 pg/mL; 95% CI −3.33 to −1.34; p < 0.001)		Jadad scale (not indicated)PubMed/MEDLINE, Web of Science, Scopus, and Cochrane Library
12 publications [24,43,46,47,50,54,55,56,86,87,103,114]Mets, T2DM,
overweight, knee OA, NAFLD, ESRD, diabetic nephropathy, infertility, UC		76018–65P4–1280–1500 mg/day of curcumin,
300–1500 mg/day of curcuminoids,
112–1500 mg/day of turmeric		↓ TNF-α
(WMD = −1.61 pg/mL; 95% CI −2.72 to −0.51; p < 0.001)
12 publications [24,45,46,47,48,50,54,86,103,107,109,114]Mets, T2DM, overweight, knee OA, hyperlipidemia, ESRD, NAFLD, migraine80818–65P4–1280–1000 mg/day of curcumin,
300–1500 mg/day of curcuminoids,
112–1500 mg/day of turmeric		↔ IL-6
(WMD = −0.33 pg/mL; 95% CI −0.99 to −0.34; p = 0.33)
4 publications [46,86,87,107]Diabetic nephropathy, chronic cutaneous, overweight24018–65P4–81000 mg/day of curcuminoids,
112–1500 mg/day of turmeric		↔ IL-8
(WMD = 0.52 pg/mL; 95% CI −1.13 to −2.17; p = 0.53)
Abdelazeem et al. 2021 [115]2 publications [58,73]PCOS8124–35P6–893.34–1000 mg/day of curcumin↔ CRP
(MD = −0.55; 95% CI −1.64 to 0.54; p = 0.33)		Cochrane risk of bias tool (73.3%)PubMed, EMBASE, Scopus, Web of Science, and Cochrane Central and Google Scholar
Ferguson et al. 2020 [116]22 publications [27,38,43,45,46,48,50,51,52,53,57,60,63,65,66,67,70,103,106,107,117,118]Episodic migraine, T2DM, RA, oral lichen planus, healthy, CAD, hemodialysis patients with pruritus, history of sulfur mustard intoxication, Mets, sulfur mustard-induced cutaneous complications, infertile men, NAFLD, high cholesterol or/and high CRP, overweight/obese, COPD, acute Takayasu arteritis, prediabetes126630–70P,
CO		12 days–24 weeks46–4560 mg/day of curcumin↓ CRP
(WMD = −1.55 mg/L; 95% CI −1.81 to −1.30; p < 0.05)		American Dietetic Association’s Quality Criteria Checklist (65.6%)EMBASE, MEDLINE, CINAHL, Scopus, and Cochrane Library
11 publications [24,45,46,50,63,86,103,107,114,117,118]Episodic migraine, oral lichen planus, dyslipidemia, obese, healthy, history of sulfur mustard intoxication, Mets, sulfur mustard-induced cutaneous complications, T2DM77836–70P,
CO		12 days–12 weeks80–4560 mg/day of curcumin↓ IL-6
(WMD = −1.69 pg/mL; 95% CI −2.56 to −0.82; p < 0.05)
12 publications [24,43,46,50,63,67,86,112,114,118,119,120]Episodic migraine, infertile men, healthy, dyslipidemia, NAFLD, overweight/obese, history of sulfur mustard intoxication, Mets, T2DM, acute Takayasu arteritis90030–70P,
CO		4–1280–1140 mg/day of curcumin↓ TNF-α
(WMD = −3.13 pg/mL; 95% CI −4.62 to −1.64; p < 0.05)
4 publications [46,63,86,107]Dyslipidemia, obese, Mets, sulfur mustard-induced cutaneous complications53938–56P,
CO		4112–1140 mg/day of curcumin↓ IL-8
(WMD = −0.54 pg/mL; 95% CI −0.82 to −0.28; p < 0.05)
3 publications [24,63,86]Dyslipidemia, obese, Mets, history of sulfur mustard intoxication23838–54P,
CO		4–8665–1140 mg/day of curcumin↓ MCP-1
(WMD = −2.48 pg/mL; 95% CI −3.96 to −1.00; p < 0.05)
2 publications [120,121]Healthy, episodic migraine31336–48P4–880–400 mg/day of curcumin↔ ICAM-1
(WMD = −86.24 ng/mL; 95% CI −206.80 to 34.32; p > 0.05)
White et al. 2019 [122]5 publications [25,45,46,53,106]RA, Mets, hyperlipidemia, overweight/obese with CRP ≥ 2 mg/L, ESRD37629–69P,
CO		4–1320.1–500 mg/day of curcumin↔ CRP
(MD = −2.71 mg/L; 95%CI −5.73 to 0.31; p = 0.08)		Cochrane risk of bias tool (Supple)PubMed, Scopus, EMBASE, Web of Science, and Cochrane Library
6 publications [27,51,52,54,57,103]Mets, obese hyperlipidemia, CAD, knee OA, T2DM, Hemodialysis38128–72P,
CO		4–1222.1–2000 mg/day of curcumin↔ hs-CRP
(MD = −1.44 mg/L; 95%CI −2.94 to 0.06; p = 0.06)
2 publications [86,98]Obesity, knee OA20542–58.6P,
CO		8–12500–1000 mg/day of curcumin↔ IL-1β
(MD = −4.25 pg/mL; 95%CI −13.32 to 4.82; p = 0.36)
7 publications [24,45,86,93,103,114,123]T2DM, obese, Mets, hyperlipidemia, hemodialysis, knee OA, SLE47820–69P,
CO		6–1220.1–1000 mg/day of curcumin↔ IL-6
(MD = −0.71 pg/mL; 95%CI −1.68 to 0.25; p = 0.15)
7 publications [46,86,87,103,114,123,124]Mets, T2DM, obese, knee OA, hemodialysis, nephropathy40834–66P,
CO		4–1266.3–1000 mg/day of curcumin↔ TNF-α
(MD = −1.23 pg/mL; 95%CI −3.01 to 0.55; p = 0.18)
Tabrizi et al. 2019 [125]5 publications [36,45,46,86,114]Mets, obese, T2DM, hyperlipidemia29318–75P4–8294 mg/day of curcumin,
300–1000 mg/day of curcuminoids, 112 mg/day of turmeric		↓ IL-6
(SMD = −2.08; 95% CI −3.90 to −0.25; p = 0.02)		Cochrane risk of bias tool (82.9%)Cochrane Library, Embase, PubMed, and Web of Science
9 publications [25,27,39,45,46,52,57,110,126]T2DM, Mets, hyperlipidemia, overweight, obese, coronary vascular artery83218–75P3 days–36 weeks112–2400 mg/day of turmeric,
4000 mg/day of curcuminoids,
294–1890 mg/day of curcumin		↓ hs-CRP
(SMD = −0.65; 95% CI −1.20 to −0.10; p = 0.02)
5 publications [24,46,86,87,114]Mets, overweight, obese, T2DM, diabetic nephropathy29118–75P4–8112–1500 mg/day of turmeric,
300–1000 mg/day of curcuminoids		↔ TNF-α
(SMD = −1.62; 95% CI −3.60 to 0.36; p = 0.10)
Clark et al. 2019 [127]5 publications [30,31,36,38,41]Mets, prediabetes, obese, T2DM65227.1–59.37 P6–39200–1500 mg/day of curcumin↑ adiponectin
(WMD = 0.82 Hedges’ g; 95% CI 0.33 to 1.30; p ˂ 0.001)
↑ adiponectin
(WMD = 1.05 Hedges’ g; 95% CI 0.64 to 1.45; p ˂ 0.001) for ≤ 10 weeks of follow-up period		Jadad scale (100%)PubMed/Medline, Scopus, Web of Science, Cochrane Library, and Google scholar
Simental-Mendía et al. 2019 [128] 5 publications [31,39,41,129,130]Mets, prediabetes, obese, T2DM68618–71P4–36500–1500 mg/day of curcumin↑ adiponectin
(WMD = 6.47 ng/mL; 95% CI 1.85 to 11.10; p = 0.010)		Cochrane risk of bias tool (60.0%)PubMed–Medline, Scopus, ISI Web of Science, and Google Scholar
Akbari et al. 2019 [131]3 publications [24,31,32]Mets, obese, T2DM3388–71P4–24500–1000 mg/day of curcumin,
1500 mg/day of curcuminoids		↓ leptin
(SMD = −0.97; 95% CI −1.18 to −0.75; p < 0.001)		Cochrane risk of bias tool (77.8%)Cochrane Library, EMBASE, PubMed, and Web of Science
4 publications [24,31,32,39]Mets, obese, T2DM5728–71P4–36500–1000 mg/day of curcumin,
1500 mg/day of curcuminoids		↑ adiponectin
(SMD = 1.05; 95% CI 0.23 to 1.87; p = 0.01)
Atkin et al. 2017 [132]4 publications [31,33,36,129]T2DM, Mets, depression4658–61P4–24250–1000 mg/day of curcuminoids↓ leptin
(SMD = −0.69; 95% CI −1.16 to −0.23; p = 0.003; I2 = 76.53%)		Jadad scale (40%)PubMed, Medline, Scopus, Web of Science, and Google Scholar
Derosa et al. 2016 [133]9 publications [24,54,63,86,107,114,134,135,136]Mets osteoarthritis, knee OA, oral lichen planus, obesity, T2DM, sulfur mustard intoxication, chronic pruritic skin lesions60933–69P,
CO		2–32200–6000 mg/day of curcumin↓ IL-6
(WMD = −0.60 pg/mL; 95% CI −1.06 to −0.14; p = 0.011)		Cochrane risk of bias tool (44.4%)Medline, SCOPUS, Web of Science, and Google Scholar
Sahebkar et al. 2016 [137]9 publications [24,63,86,87,114,123,134,138,139]Mets, obese, T2DM, type 2 diabetic nephropathy, major depressive disorder, knee OA, sulfur mustard-exposed veterans54936–59P,
CO		4–12300–1500 mg/day of curcumin↓ TNF-α
(WMD = −4.69 pg/mL; 95% CI −7.10 to −2.28; p < 0.001)		Cochrane risk of bias tool (42.9%)Medline, SCOPUS, Web of Science, and Google Scholar
Sahebkar et al. 2014 [140]7 publications [52,62,107,110,135,141,142]Healthy, obese, dyslipidemia, chronic complications due to sulfur mustard, oral lichen planus, coronary artery bypass grafting, OA34225–70P4–1280–6000 mg/day of curcumin↓ CRP
(MD = 6.44 mg/L; 95% CI −10.77 to −2.11; p = 0.004)		Jadad scale (66.7%)Medline and SCOPUS
CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; CO, crossover; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DFU, diabetic foot ulcer; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity C-reactive protein; HTN, hypertension; ICAM-1, intercellular adhesion molecule-1; IGT, impaired glucose tolerance; IGTT, impaired glucose tolerance test; IL-1, interleukin 1; IL-1β, interleukin 1β; IL-6, interleukin 6; IL-8, interleukin 8; MD, mean difference; Mets, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; OA, osteoarthritis; P, parallel; PCOS, polycystic ovary syndrome; pre-HTN, pre-hypertension; PUD, peptic ulcer disease; RA, rheumatoid arthritis; RCTs, randomized controlled trials; SLE, systemic lupus erythematosus; SMD, standardized mean difference; TNF-α, tumor necrosis factor α; T2DM, type 2 diabetes mellitus; UC, ulcerative colitis; WMD, weighted mean difference. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale) or positive quality (American Dietetic Association’s Quality Criteria Checklist). ↑, increase; ↓, decrease; ↔ no effect.
Table 2. Meta-analyses of RCTs investigating the effect of curcumin intake on antioxidant activity.
Table 2. Meta-analyses of RCTs investigating the effect of curcumin intake on antioxidant activity.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Qiu et al. 2023 [22]2 publications [26,27]Mets16534–64P6–1280 mg/day of nano-curcumin,
1000 mg/day of curcuminoids		↓ MDA
(MD = −2.35 µmol/L; 95% CI −4.47 to −0.24; p = 0.03)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
Dehzad et al. 2023 [42]16 publications [23,30,43,49,57,68,76,77,78,79,80,82,88,143,144,145]Mets, obese, T2DM, prostate cancer, PUD, NAFLD, hemodialysis, infertile men, β-thalassemia, hyperlipidemia, coronary elective angioplasty, DFU, healthy85718–70P4–1280–3000 mg/day of curcumin,
2000–3000 mg/day of turmeric		↑ TAC
(WMD = 0.21 mmol/L; 95% CI 0.08 to 0.33; I2 = 99.6%; p < 0.001)		Cochrane risk of bias tool (84.2%)PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar
18 publications [23,43,53,57,60,68,76,77,78,79,80,81,82,92,98,143,144,146]Mets, hemodialysis, chronic pulmonary complications, T2DM, knee OA, beta-thalassemia, healthy, Takayasu arteritis, infertile men, NAFLD, HIV, hyperlipidemia, coronary elective angioplasty, DFU147518–70P4–1680–1500 mg/day of curcumin,
1500 mg/day of curcuminoids,
1500–3000 mg/day of turmeric		↓ MDA
(WMD = −0.33 µmol/L; 95% CI −0.53 to −0.12; I2 = 99.6%; p < 0.001)
7 publications [60,63,64,79,95,145,147]T2DM, solid tumor, prostate cancer, chronic pulmonary complications, PCOS, coronary elective angioplasty, chronic bronchial asthma49718–70P4–1280–3000 mg/day of curcumin,
180–1500 mg/day of curcuminoids		↑ SOD
(WMD = 20.51 u/L; 95% CI 7.35 to 33.67; I2 = 95.4%; p < 0.001)
Jakubc-zyk et al. 2020 [148]3 publications [43,109,143]Overweight/obese, infertile, β-thalassemia major patients17713–45P10–1280–1000 mg/day of curcumin↑ TAC
(SMD = 2.696; Z = 2.003; 95% CI = 0.058 to 5.335; p = 0.045)		Cochrane risk of bias tool (57.1%)PubMed/MEDLINE and Embase
3 publications [43,109,143]Overweight/obese, infertile, β-thalassemia major patients17713–45P10–1280–1000 mg/day of curcumin↔ MDA
(SMD = −1.579, Z = −1.714, CI = 95%, p = 0.086)
Tabrizi et al. 2019 [125]5 publications [27,57,110,114,124]Mets, T2DM, coronary vascular artery42518–70P3 days–
8 weeks		300–4000 mg/day of curcuminoids,
2000 mg/day of turmeric		↓ MDA
(SMD = −3.14; 95% CI −4.76 to −1.53; p < 0.001)		Cochrane risk of bias tool (82.9%)Cochrane Library, Embase, PubMed, and Web of Science
3 publications
[27,124,149]		Mets, obese, T2DM,26018–65P4–8 1000 mg/day of curcuminoids↔ SOD
(SMD 0.34; 95% CI −1.06 to 1.74, p = 0.63)
Alizadeh et al. 2019 [150]12 publications [27,43,98,124,143,151,152,153,154,155,156,157]Mets, knee OA, T2DM, healthy, infertile oligoasthenospermia, non-diabetic or diabetic proteinuric CKD, chronic gastritis, β-thalassemia, hemodialysis, sulfur mustard Iraq–Iran war chronic pulmonary complications, solid cancer100520–75P1–1680–1000 mg/day of curcumin,
90–1500 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↓ MDA
(SMD = −0.46; 95% CI −0.68 to −0.25)		Cochrane risk of bias tool (59.0%)PubMed, Embase, Cochrane Central, Scopus, and Google Scholar
7 publications [62,124,141,145,155,156,158]Healthy, prostate cancer treated with radiotherapy, veterans of the Iraq–Iran war with chronic pruritus, sulfur mustard Iraq–Iran war chronic pulmonary complications, solid cancer, Mets, knee OA, T2DM61835–79P4–12900–3000 mg/day of curcuminoids↑ SOD
(SMD = 0.82; 95% CI 0.27 to 1.38)
5 publications [62,141,143,145,155]Healthy, prostate cancer treated with radiotherapy, β-thalassemia, veterans of the Iraq–Iran war with chronic pruritus, solid cancer32220–79P4–12900–3000 mg/day of curcuminoids↑ CAT
(SMD = 10.26; 95% CI 0.92 to 19.61)
5 publications [62,141,145,151,158]Non-diabetic or diabetic proteinuric CKD, prostate cancer treated with radiotherapy, veterans of the Iraq-Iran war with chronic pruritus, occupational stress-related anxiety and fatigue35726–79P4–12320–782 mg/day of curcumin,
1000–3000 mg/day of curcuminoids		↑ GPx
(SMD = 8.90; 95% CI 6.62 to 11.19)
6 publications
[43,88,143,145,152,157]		PUD, infertile oligoasthenospermia, prostate cancer treated with radiotherapy, β-thalassemia, chronic gastritis, healthy33022–79P1–1280–1500 mg/day of curcumin,
90–3000 mg/day of curcuminoids		↔ TAC
(SMD = 0.30; 95% CI −0.20 to 0.81)
1 publication [151]Non-diabetic or diabetic proteinuric CKD10137–57P8320 mg/day of curcumin↔ GR
(SMD = −0.01; 95% CI −0.03 to 0.02)
Qin et al. 2018 [159]7 publications [27,57,98,114,124,153,156]T2DM, OA, Mets, end-stage renal disease52534–67P4–846–1000 mg/day of curcumin↓ MDA
(SMD = −0.769; 95% CI −1.059 to −0.478)		Cochrane risk of bias tool (54.2%)PubMed, EMBASE, Web of Science, Medline Ovid, Books@Ovid, Journals@Ovid, and Cochrane Library
4 publications [27,124,141,156]T2DM, OA, Mets, chronic pruritic skin lesions34134–67P4–81000–1500 mg/day of curcumin↑ SOD
(SMD = 1.084; 95% CI 0.487 to 1.680)
2 publications [57,153]T2DM, end-stage renal disease10832–67P4–846–66.3 mg/day of curcumin↔ GPx
(SMD = 0.13; 95% CI −0.25 to 0.51)
CAT, chloramphenicol acetyltransferase; CKD, chronic kidney disease; DFU, diabetic foot ulcer; GPx, glutathione peroxidase; GR, glutathione reductase; HIV, human immunodeficiency virus; MD, mean difference; MDA, malondialdehyde; Mets, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; OA, osteoarthritis; P, parallel; PCOS, polycystic ovary syndrome; PUD, peptic ulcer disease; RCTs, randomized controlled trials; SMD, standard difference in means; SOD, superoxide dismutase; TAC, total antioxidant capacity; T2DM, type 2 diabetes mellitus; WMD, weighted mean differences. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool). ↑, increase; ↓, decrease; ↔ no effect.
Table 3. Meta-analyses of RCTs investigating the effect of curcumin intake on glucose control.
Table 3. Meta-analyses of RCTs investigating the effect of curcumin intake on glucose control.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Lukkunaprasit et al. 2023 [160]3 publications [50,161,162]MAFLD23126–38P8–1280–500 mg/day of curcumin↔ HbA1c
(MD = −0.24; 95% CI −0.66 to 0.18; p > 0.05)		Cochrane risk of bias tool (68.8%)Medline and SCOPUS
12 publications [34,35,50,146,161,162,163,164,165,166,167,168]MAFLD71018–72P8–2480–1500 mg/day of curcumin, 2000–3000 mg/day of turmeric↓ FBG
(MD = −2.05 mg/dL; 95% CI −3.08 to −1.01; p < 0.05)
Qiu et al. 2023 [22]9 publications [23,25,27,61,126,169,170,171,172]Mets57628–81P4–1280–1500 mg/day of curcumin,
1000 mg/day of curcuminoids,
2400 mg/day of turmeric		↓ FBG
(MD = −8.6 mg/dL; 95% CI −15.45 to −1.75; p = 0.01)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
Różański et al. 2023 [173]14 publications [34,35,50,55,161,164,165,166,174,175,176,177,178,179]MAFLD84718–70P8–1270–1500 mg/day of curcuminoids,
80–1000 mg/day of curcumin,
3000 mg/day of turmeric		↓ Insulin
(MD = −1.1430 μIU/mL; 95% CI −1.5439 to −0.7421; p < 0.0001)
↓ HOMA-IR
(MD = −0.2884; 95%CI −0.3950 to −0.1817; p < 0.0001)		Cochrane risk of bias tool (90.8%)PubMed, Web of Science, and Scopus
Ngu et al. 2022 [180]3 publications [50,177,181]NAFLD23818–70P8–1280–1500 mg/day of curcumin↔ QUICKI
(MD = 0.01; 95% CI −0.00 to 0.02; p = 0.30)		Cochrane risk of bias tool (79.5%)Cochrane Central Register of Controlled Trials, and PubMed
Sun et al. 2022 [100]23 publications [23,25,27,39,45,49,60,61,70,76,80,87,101,126,169,170,182,183,184,185,186,187,188] T2DM, obese, nephropathy, proteinuria, hemodialysis, DFU, IFG/IGT, Mets, hyperlipidemia184735–68P,
CO		4–3680–2400 mg/day of curcumin↓ FBG
(WMD = −0.50 mg/dL; 95% CI −0.72 to −0.28)		Cochrane risk of bias tool (69.3%)
Jadad scale (77.0%)		PubMed, Embase, Web of Science,
CNKI, Wanfang and CBM
16 publications
[27,29,39,49,60,70,76,80,101,126,182,183,185,186,187,188]		T2DM, obese, proteinuria, hemodialysis, DFU, IFG/IGT, Mets, hyperlipidemia122435–70P,
CO		8–3680–2100 mg/day of curcumin↓ Hb1Ac
(WMD = −0.42%; 95% CI −0.57 to −0.26)
5 publications [45,76,80,187,188]T2DM, IGT, hyperlipidemia, hemodialysis, DFU24735–63P,
CO		6–1780–500 mg/day of curcumin↓ Insulin
(WMD = −1.70 μIU/mL; 95% CI −2.03 to −1.38)
11 publications [39,45,49,60,70,76,80,101,183,188,189] T2DM, obese, hyperlipidemia, hemodialysis, IFG, IGT, DFU87442–63P,
CO		6–3680–2100 mg/day of curcumin↓ HOMA-IR
(WMD = −0.71; 95% CI −1.11 to −0.31)
Tian et al. 2022 [190]9 publications [38,49,57,87,101,114,182,183,191]T2DM60441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↓ FBG
(WMD = −8.85 mg/dL; 95% CI −14.4 to −3.29; p = 0.002)		Cochrane risk of bias tool (57.1%)PubMed, EMBASE, Web of Science, and Cochrane Library
8 publications
[38,49,57,101,114,182,183,191]		T2DM56441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ HbA1c
(WMD = −0.54; 95% CI −0.81 to −0.27; p ≤ 0.001)
Nouri et al. 2022 [192]4 publications [58,73,193,194]PCOS19828–31P6–1293.34–1500 mg/day of curcumin↓ FBG
(ES = −3.62 mg/dL; 95% CI −5.65 to −1.58; p < 0.001)
↓ Insulin
(ES = −1.67 mU/mL; 95% CI −3.06 to −0.28; p = 0.018)
↓ HOMA-IR
(ES = −0.42; 95% CI −0.76 to −0.09; p < 0.01)		Cochrane risk of bias tool (75.0%)PubMed, Scopus, and ISI Web of Science
Khalili et al. 2022 [195]9 publications [34,50,161,164,165,166,177,179,196]NAFLD68342–67P4–1250–2000 mg/day of curcumin↓ FBG
(SMD = −0.28; 95% CI −0.46 to −0.09; p = 0.003)		Cochrane risk of bias tool (65.5%)Web of Science, Science Direct, PubMed,
and Embase
Shen et al. 2022 [99]7 publications [58,73,193,194,197,198,199]PCOS44720–38P6–2480–1500 mg/day of curcumin↓ FBG
(WMD = −3.618; 95% CI −5.165 to −2.071; p < 0.001)
↓ Insulin
(WMD = −1.834; 95% CI −2.701 to −0.968; p < 0.001)
↓ HOMA-IR
(WMD = −0.565; 95% CI −0.779 to −0.351; p < 0.001)		Cochrane risk of bias tool (73.5%)PubMed, Embase, Cochrane Library, Web of Science, Scopus, Clinical Trials, Chinese Clinical Trial Registry, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, VIP database, and Wanfang Database
4 publications [58,193,194,197]PCOS26623–38P6–1280–1500 mg/day of curcumin↑ QUICKI
(WMD = 0.011; 95% CI 0.005 to 0.017; p = 0.001)
Ashtary-Larky et al. 2021 [111]7 publications [23,50,71,76,171,182,185]Mets, NAFLD, T2DM, hemodialysis41736–68P6–1240–120 mg/day of nano-curcumin↓ FBG
(WMD = −18.14 mg/dL; 95% CI −29.31 to −6.97; p = 0.001)		Cochrane risk of bias tool (55.6%)PubMed, Scopus, Embase, and Web of Science
3 publications [50,76,171]Mets, NAFLD, T2DM, hemodialysis18036–68P12 40–80 mg/day of nano-curcumin↓ Insulin
(WMD = −1.21 mg/dL; 95% CI −1.43 to −1.00; p < 0.001)
4 publications [50,171,182,185]Mets, NAFLD, T2DM27736–68P8–1240–80 mg/day of nano-curcumin↓ HbA1c
(WMD = −0.66 mg/dL; 95% CI −1.41 to −0.08; p < 0.001)
3 publications [50,76,171]Mets, NAFLD, T2DM, hemodialysis18036–68P1240–80 mg/day of nano-curcumin↓ HOMA-IR
(WMD = −0.28 mg/dL; 95% CI −0.33 to −0.23; p < 0.001)
Abdelazeem et al. 2021 [115]5 publications [58,73,193,194,197]PCOS29624–39P6–1280–1500 mg/day of curcumin↓ FBG
(MD = −3.67; 95% CI −5.25 to −2.08; p < 0.00001)
↓ Insulin
(MD = −1.91; 95% CI −2.97 to −0.84; p = 0.0005)
↓ HOMA-IR
(MD = −0.55; 95% CI −0.83 to −0.27; p = 0.0001)		Cochrane risk of bias tool (73.3%)PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar
4 publications [58,193,194,197]PCOS26624–36P6–1280–1500 mg/day of curcumin↓ QUICKI
(MD = 0.01; 95% CI 0.00 to 0.02; p = 0.0005)
Zhang et al. 2021 [200]5 publications [31,60,70,183,185]T2DM52434–70P8–2480–1500 mg/day of curcumin,
300–1500 mg/day of curcuminoids		↓ HbA1c
(WMD = −0.70; 95% CI −0.87 to −0.54; p < 0.0001)		Cochrane risk of bias tool (69.4%)Chinese database (CNKI, Wan Fang, VIP, CBM), PubMed, EMBASE, Cochrane Library, Web of Science, Medline Complete and, ClinicalTrials.gov
1 publication [60]T2DM10034–51P121000 mg/day of curcuminoids↓ HOMA-IR in the Middle East subgroup
(WMD = −0.60; 95% CI −0.74 to −0.46; p < 0.00001)
2 publications [31,183]T2DM31334–65P12–241500 mg/day of curcumin,
300 mg/day of curcuminoids		↓ HOMA-IR in the Asia subgroup
(WMD = −2.41; 95% CI −4.44 to −0.39; p = 0.02)
6 publications [31,60,70,87,183,185]T2DM56434–70P8–2480–1500 mg/day of curcumin,
300–1500 mg/day of curcuminoids,
1500 mg/day of turmeric		↓ FBG in the Asia subgroup
(SMD = −0.57; 95% CI −0.79 to −0.36; p < 0.00001)
↔ FBG in the Middle East subgroup
Altobelli et al. 2021 [201]5 publications [49,114,144,182,183]T2DM33318–80P8–1280–1500 mg/day of curcumin,
300 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ HbA1c
(ES = −0.42; 95% CI −0.77 to −0.11; p = 0.008)		Cochrane risk of bias tool (93.8%)Medline, EMBASE, Scopus, ClinicalTrials.gov, Web of Science, and Cochrane Library
4 publications [31,49,144,183]T2DM43218–70P8–241500 mg/day of curcumin,
250–300 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ HOMA-IR
(ES = −0.41; 95% CI −0.60 to −0.22; p < 0.001)
Chien et al. 2021 [202]3 publications [58,193,194]PCOS16824–39P6–12500–1500 mg/day of curcumin↓ FBG
(MD = −2.77; 95% CI −4.16 to −1.38; p < 0.001)
↓ Insulin
(MD = −1.33; 95% CI −2.18 to −0.49; p = 0.002)
↓ HOMA-IR
(MD = −0.32; 95% CI −0.52 to −0.12; p = 0.002)
↓ QUICKI
(MD = 0.010; 95% CI 0.003 to 0.018; p = 0.005)		Cochrane risk of bias tool (72.2%)PubMed, Embase, Scopus, Web of Science, and Cochrane Library
Jalali et al. 2020
[203]		6 publications [34,50,161,164,165,177]NAFLD40733–58P8–1250–1425 mg/day of curcumin↔ FBG
(MD = −0.22; 95% CI −0.42 to −0.02; p = 0.313)		Jadad scale (88.9%)PubMed, Embase, Scopus, Web of Science, and Cochrane Library
3 publications [50,165,177]NAFLD21136–58P8–1280–1425 mg/day of curcumin↓HOMA-IR
(MD = −0.37; 95% CI −0.70 to −0.03; p = 0.000)
↓ Insulin
(MD = −0.49; 95% CI −0.81 to −0.16; p = 0.000)
Azhda-ri et al. 2019 [204]5 publications [25,27,61,126,172]Mets35938–60P6–121000–1890 mg/day of curcumin,
1000 mg/day of curcuminoids,
2400 mg/day of turmeric		↓ FBG
(WMD = −9.18 mg/dL; 95% CI −16.70 to −1.66; p = 0.01)		Cochrane risk of bias tool (57.1%)Web of Science, Medline, Google Scholar, Scopus, Cochrane, and CINAHL
Huang et al. 2019 [205]13 publications [25,35,39,45,51,57,114,126,161,177,182,183,206]T2DM, NAFLD, Mets, hyperlipidemia, CAD, high ALT106430–72P,
CO		4–1270–1890 mg/day of curcumin,
294–2000 mg/day of curcuminoids,
2400–3000 mg/day of turmeric		↓ FBG
(SMD = −0.382; 95% CI −0.654 to −0.111 mg/dL; p = 0.006)		Cochrane risk of bias tool (83.7%)PubMed, Cochrane Library, Web of Science, and Embase
7 publications [31,35,39,45,57,177,183]T2DM, NAFLD, Mets, hyperlipidemia82130–72P,
CO		4–121000 mg/day of curcumin,
294–1500 mg/day of curcuminoids,
2000–3000 mg/day of turmeric		↓ HOMA-IR
(SMD = −0.351; 95% CI −0.615 to −0.087; p = 0.009)
8 publications
[39,57,114,126,161,177,182,183]		T2DM, NAFLD, Mets73140–74P4–1280–1890 mg/day of curcumin,
300–1500 mg/day of curcuminoids,
2000 mg/day of turmeric		↓ HbA1c
(SMD = −0.370; 95% CI −0.631% to −0.110%; p = 0.005)
5 publications [35,39,45,57,177]T2DM, NAFLD, Mets, hyperlipidemia50731–71P,
CO		4–121000 mg/day of curcumin,
294–1500 mg/day of curcuminoids,
2000–3000 mg/day of turmeric		↔ Insulin
(SMD = −0.058; 95% CI −0.352 to 0.235; p = 0.697)
Tabrizi et al. 2018 [207]19 publications [25,32,39,45,46,51,57,87,101,114,126,129,161,178,182,183,206,208,209]T2DM, hyperlipidemia, Mets, obese, diabetic nephropathy, NAFLD, CAD129910–73P4–2470–2000 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
112–2400 mg/day of turmeric		↓ FBG
(SMD = −0.78; 95% CI −1.20 to −0.37; p < 0.001)		Cochrane risk of bias tool (76.9%)Cochrane Library, EMBASE, MEDLINE, and Web of Science
7 publications [32,39,45,57,129,178,208]T2DM, obese, hyperlipidemia, NAFLD55218–68P4–36294 mg/day of curcumin,
500–1000 mg/day of curcuminoids,
2000–2100 mg/day of turmeric		↑ Insulin
(SMD = 0.92; 95% CI 0.06 to 1.78; p = 0.036)
8 publications [31,32,39,45,57,178,183,208]T2DM, obese, hyperlipidemia, NAFLD83610–65P4–36294 mg/day of curcumin,
500–1000 mg/day of curcuminoids,
300–2100 mg/day of turmeric		↓ HOMA-IR
(SMD = −0.91; 95% CI −1.52 to −0.31; p = 0.003)
10 publications [39,57,101,114,126,161,178,182,183,208]T2DM, Mets, obese,
hyperlipidemia, NAFLD		90618–73P4–3670–1890 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
300–2100 mg/day of turmeric		↓ HbA1c
(SMD = −0.92; 95% CI −1.37 to −0.47; p < 0.001)
ALT, alanine aminotransferase; CAD, coronary artery disease; CI, confidence interval; CO, crossover; DFU, diabetic foot ulcer; ES, effect size; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment for insulin resistance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; MD, mean difference; Mets, metabolic syndrome; MAFLD, metabolic (dysfunction)-associated fatty liver disease; NAFLD, non-alcoholic fatty liver disease; P, parallel, PCOS, polycystic ovary syndrome; QUICKI, quantitative insulin sensitivity check index; RCTs, randomized controlled trials; SMD, standardized mean difference; T2DM, type 2 diabetes mellitus; WMD, weighted mean difference. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale). ↑, increase; ↓, decrease; ↔ no effect.
Table 4. Meta-analyses of RCTs investigating the effect of curcumin intake on lipid profile changes.
Table 4. Meta-analyses of RCTs investigating the effect of curcumin intake on lipid profile changes.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Lukkunaprasit et al. 2023 [160]11 publications [34,50,146,161,162,163,164,165,166,167,168]MAFLD33521–72P8–2480–1500 mg/day of curcumin,
2000 mg/day of turmeric		↓ TC
(MD = −8.18 mg/dL; 95% CI −14.07 to −2.29; p < 0.05)
↔ TG
(MD = −12.03 mg/dL; 95% CI −24.36 to 0.30; p = 0.27)
↔ LDL-C
(MD = −4.35 mg/dL; 95% CI −10.93 to 2.23; p = 0.73)		Cochrane risk of bias tool (68.8%)Medline and SCOPUS
10 publications [34,50,146,161,162,164,165,166,167,168]MAFLD32528–59P8–1280–1500 mg/day of curcumin,
2000 mg/day of turmeric		↔ HDL-C
(MD = 0.80 mg/dL; 95% CI −2.92 to 4.52; p = 0.41)
Qiu et al. 2023 [22]8 publications [23,25,61,126,169,170,171,172]Mets47628–81P4–1280–1890 mg/day of curcumin,
2400 mg/day of turmeric		↔ TG
(MD = 1.28 mg/dL; 95% CI −3.75 to 6.30; p = 0.62)
↓ HDL-C
(MD = 4.98 mg/dL; 95% CI 2.58 to 7.38; p < 0.0001)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
Rozanski et al. 2023 [173]14 publications [34,35,50,55,161,164,165,166,174,175,176,177,178,179]MAFLD84718–70P8–1270–1500 mg/day of curcuminoids,
80–1000 mg/day of curcumin,
3000 mg/day of turmeric		↓ TG
(MD = −12.6001 mg/dL; 95% CI −22.9311 to −2.2692; p = 0.0168)
↓ TC
(MD = −15.7896 mg/dL; 95% CI −28.2686 to −3.3106; p = 0.0131)
↓ LDL-C
(MD = −14.1699 mg/dL; 95% CI −25.9117 to −2.4281; p = 0.018)		Cochrane risk of bias tool (90.8%)PubMed, Web of Science, and Scopus
Ngu et al. 2022 [180]10 publications [34,50,161,162,163,164,165,166,177,196]NAFLD77118–70P8–2450–1500 mg/day of curcumin,
2000 mg/day of turmeric		↓ TC
(MD = −11.86; 95% CI −19.25 to −4.46; p = 0.002)
↔ LDL-C
(MD = −8.78; 95% CI −18.74 to 1.18; p = 0.08)
↓ TG
(MD = −13.00; 95% CI −27.94 to 1.94; p = 0.09)		Cochrane risk of bias tool (79.5%)Cochrane Central Register of
Controlled Trials and PubMed
9 publications [34,50,161,162,164,165,166,177,196]NAFLD63818–70P8–1250–1500 mg/day of curcumin,
2000 mg/day of turmeric		↔ HDL-C
(MD = 0.43; 95% CI −3.88 to 4.74; p = 0.85)
Shen et al. 2022 [99]5 publications [58,73,193,197,199]PCOS38020–38P6–1280–1500 mg/day of curcumin↓ TC
(WMD = −15.591; 95% CI −27.908 to −3.273; p = 0.013)
↔ TG
(WMD = −8.889; 95% CI −27.246 to 9.468; p = 0.343)
↔ LDL-C
(WMD = −6.427; 95% CI −17.343 to 4.489; p = 0.249)
↔ HDL-C
(WMD = 3.713; 95% CI −0.786 to 8.211; p = 0.106)		Cochrane risk of bias tool (73.5%)PubMed, Embase, Cochrane Library, Web of Science, Scopus, Clinical Trials, Chinese Clinical Trial Registry, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, VIP database, and Wanfang Database
Tian et al. 2022 [190]9 publications [38,49,57,87,101,114,182,183,191]T2DM60441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↓ TG
(WMD = −18.97 mg/dL; 95% CI −36.47 to −1.47; p = 0.03)		Cochrane risk of bias tool (57.1%)PubMed, EMBASE, Web of Science, and Cochrane Library
9 publications [38,49,57,87,101,114,182,183,191]T2DM60441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↓ TC
(WMD = −8.91 mg/dL; 95% CI −14.18 to −3.63; p = 0.001)
9 publications [38,49,57,87,101,114,182,183,191]T2DM60441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↔ LDL-C
(WMD = −4.01 mg/dL; 95% CI −10.96 to 2.95; p = 0.259)
9 publications [38,49,57,87,101,114,182,183,191]T2DM60441–61P4–1280–1500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500–2100 mg/day of turmeric		↔ HDL-C
(WMD = 0.32 mg/dL; 95% CI −0.74 to 1.37; p = 0.557)
Sun et al. 2022 [100]16 publications [25,38,45,49,61,70,76,80,126,169,170,184,186,188,209,210]Mets, hyperlipidemia, hypercholesterolemia, T2DM, DFU, IGT, IFG, proteinuria, hemodialysis127438–68P,
CO		4–1680–2400 mg/day of curcumin↔ TC
(WMD = −2.45 mg/dL; 95% CI −9.00 to 4.09; p = 0.063)		Cochrane risk of bias tool (69.3%) Jadad scale
(77.0%)		PubMed, Embase, Web of Science, CNKI, Wanfang, and CBM
19 publications [23,25,29,38,45,49,61,70,76,126,169,170,182,183,184,186,188,209,210]Mets, obese, hyperlipidemia, hypercholesterolemia, T2DM, DFU, IGT, IFG, proteinuria, hemodialysis156138–70P,
CO		4–2480–2100 mg/day of curcumin↔ TG
(WMD = −10.50 mg/dL; 95% CI −23.18 to 2.18; p = 0.105)
19 publications [23,25,29,38,45,49,61,70,76,126,169,170,182,183,184,186,188,209,210]Mets, obese, hyperlipidemia, hypercholesterolemia, T2DM, DFU, IGT, IFG, proteinuria, hemodialysis156138–70P,
CO		4–2480–2100 mg/day of curcumin↑ HDL-C
(WMD = 1.73 mg/dL; 95% CI 0.78 to 2.68; p < 0.001)
17 publications [25,29,38,45,49,61,70,76,80,169,170,183,184,186,188,209,210]Mets, obese hyperlipidemia, hypercholesterolemia, T2DM, DFU, IGT, IFG, proteinuria, hemodialysis125639–70P,
CO		4–2480–2100 mg/day of curcumin↔ LDL-C
(WMD = −3.99 mg/dL; 95% CI −8.68 to 0.68; p = 0.094)
Saeedi et al. 2022 [211]10 publications [25,51,101,126,164,165,177,184,191,209]T2DM, CVD, Mets, dyslipidemia, NAFLD72618–65P4–1250–2000 mg/day of curcumin,
1000 mg/day of curcuminoids,
2100 mg/day of turmeric		↔ TG
(SMD = −0.05; 95% CI −0.20 to 0.11; p = 0.56)
↔ TC
(SMD = −0.21; 95% CI −0.55 to 0.13; p = 0.22)
↔ LDL-C
(SMD = −0.17; 95% CI −0.43 to 0.09; p = 0.82)
↔ HDL-C
(SMD = −0.04; 95% CI −0.36 to 0.29; p = 0.82)		Cochrane risk of bias tool (not indicate)Ovid-Medline, Web of Science, Scopus, Cochrane, Embase, and ProQuest
Futuhi et al. 2022 [102]5 publications [71,72,76,151,212]ESRD, diabetic proteinuric non-diabetic proteinuric CKD, hemodialysis27623–69P8–1280–500 mg/day of curcumin,
2500 mg/day of turmeric		↓ TC
(WMD = −13.77 mg/dL; 95% CI −26.77 to −0.77; p = 0.04)		Cochrane risk of bias tool (73.0%)PubMed, Scopus, Cochrane Library, and Web of Science
5 publications [71,72,76,151,212]ESRD, diabetic proteinuric non-diabetic proteinuric CKD, hemodialysis27623–69P8–1280–500 mg/day of curcumin,
2500 mg/day of turmeric		↔ TG
(WMD = −6.37 mg/dL; 95% CI −26.59 to 13.85; p = 0.54)
4 publications [71,72,76,212]ESRD, hemodialysis17523–69P1280–500 mg/day of curcumin,
2500 mg/day of turmeric		↔ LDL-C
(WMD = −5.65 mg/dL; 95% CI −20.81 to 9.50; p = 0.46)
4 publications [71,72,76,212]ESRD, hemodialysis17523–69P1280–500 mg/day of curcumin,
2500 mg/day of turmeric		↔ HDL-C
(WMD = 0.16 mg/dL; 95% CI −2.55 to 2.88; p = 0.91)
Khalili et al. 2022 [195]8 publications [34,50,161,165,166,177,179,196] NAFLD63842–67P4–1250–2000 mg/day of curcumin↓ TG
(SMD = −0.49; 95% CI −0.71 to −0.27; p = 0.000)		Cochrane risk of bias tool (65.5%)Web of Science, Science Direct, PubMed, and Embase
9 publications [34,50,161,164,165,166,177,179,196]NAFLD68342–67P4–1250–2000 mg/day of curcumin↔ LDL-C
(SMD = 0.48; 95% CI −0.97 to 0.01; p = 0.053)
9 publications [34,50,161,164,165,166,177,179,196]NAFLD68342–67P4–1250–2000 mg/day of curcumin↓ TC
(SMD = 0.81; 95% CI −1.34 to −0.27; p = 0.003)
8 publications [34,161,164,165,166,177,179,196]NAFLD59942–67P4–1250–2000 mg/day of curcumin↔ HDL-C
(SMD = 0.03; 95% CI −0.38 to 0.44; p = 0.886)
Zhang et al. 2021 [200]2 publications [31,183]T2DM31318–65P12–241500 mg/day of curcumin,
300 mg/day of curcuminoids		In the Asia subgroup,
↓ TC
(WMD = −23.45 mg/dL; 95% CI −40.04 to −6.84; p = 0.006)
↓ TG
(WMD = −54.14 mg/dL; 95% CI −95.71 to −12.57; p = 0.01)		Cochrane risk of bias tool (69.4%)Chinese database (CNKI, Wan Fang, VIP, CBM), PubMed, EMBASE, Cochrane Library, Web of Science, Medline Complete, and ClinicalTrials.gov
2 publications [87,101]T2DM14034–62P8–121000 mg/day of curcuminoids,
1500 mg/day of turmeric		In the Middle East subgroup,
↔ TC
(WMD = 22.91; 95% CI −16.94 to 62.75; p = 0.26)
↔ TG
(WMD = −4.56; 95% CI −19.28
to 10.16; p = 0.54)
2 publications
[31,183]		T2DM31318–65P12–241500 mg/day of curcumin,
300 mg/day of curcuminoids		↓ LDL-C in patients with T2DM in the Asia subgroup only
(WMD = −20.85 mg/dL; 95% CI −28.78 to −12.92; p < 0.00001)
5 publications [31,38,87,119,183]T2DM49734–70P8–241500 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
1500 mg/day of turmeric		↔ HDL-C
(WMD = 2.26 mg/dL; 95% CI −2.03 to 6.55; p = 0.30)
Altobelli et al. 2021 [201]5 publications [38,49,114,182,183]T2DM47618–80P8–1280–1500 mg/day of curcumin,
300 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ TG
(ES = −0.57; 95% CI −0.83 to −0.31; p < 0.001)		Cochrane risk of bias tool (93.8%)Medline, EMBASE, Scopus, ClinicalTrials.gov, Web of Science, and Cochrane Library
5 publications [38,49,114,182,183]T2DM31218–80P8–1280–1500 mg/day of curcumin,
300 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ TC
(ES = −0.30; 95% CI −0.53 to −0.07; p < 0.001)
5 publications [38,49,114,182,183]T2DM33318–80P8–1280–1500 mg/day of curcumin,
300 mg/day of curcuminoids,
2100 mg/day of turmeric		↔ HDL-C
(ES = 0.22; 95% CI −0.08 to 0.52; p = 0.143)
5 publications [31,38,49,114,183]T2DM30018–80P8–1280–1500 mg/day of curcumin,
300 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ LDL-C
(ES = −0.28; 95% CI −0.52 to −0.04; p = 0.021)
Abdelazeem et al. 2021 [115]4 publications [58,73,193,197]PCOS22924–35P6–1280–1000 mg/day of curcumin↔ TG
(MD = −10.18; 95% CI −31.20 to 10.83; p = 0.34)
↔ LDL-C
(MD = −8.53; 95% CI −22.97 to 5.91; p = 0.25)
↔ HDL-C
(MD = 4; 95% CI −1.74 to 9.75; p = 0.17)
↓ TC
(MD = −15.55; 95% CI −30.33 to −0.76; p < 0.04)		Cochrane risk of bias tool (73.3%)PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar
Chien et al. 2021 [202]2 publications [58,193]PCOS10124–35P6–121000–1500 mg/day of curcumin↓ HDL
(MD = 1.92; 95% CI 0.33 to 3.51; p = 0.018)
↓ TC
(MD = −12.45; 95% CI −22.05 to −2.85; p = 0.011)
↔ LDL
(MD = −6.02; 95% CI −26.66 to 14.62; p = 0.567)
↔ TG
(MD = 8.22; 95% CI −26.10 to 42.53; p = 0.639)		Cochrane risk of bias tool (72.2%)PubMed, Embase, Scopus, Web of Science, and Cochrane Library
Ashtary-Larky et al. 2021 [111]6 publications [23,50,71,76,171,182]NAFLD, T2DM, Mets, hemodialysis33736–68P6–1240–120 mg/day of nano-curcumin↔ TG
(WMD = −9.76 mg/dL; 95% CI −32.71 to 13.17; p = 0.404)		Cochrane risk of bias tool (55.6%)PubMed, Scopus, Embase, and Web of Science
5 publications [50,71,76,171,182]NAFLD, T2DM, Mets, hemodialysis30436–68P1240–120 mg/day of nano-curcumin↔ TC
(WMD = −3.34 mg/dL; 95% CI −14.43 to 7.73; p = 0.554)
5 publications [50,71,76,171,182]NAFLD, T2DM, Mets, hemodialysis30436–68P1240–120 mg/day of nano-curcumin↔ LDL-C
(WMD = −3.59 mg/dL; 95% CI −15.74 to 8.56; p = 0.562)
6 publications [23,50,71,76,171,182]NAFLD, T2DM, Mets, hemodialysis33736–68P6–1240–120 mg/day of nano-curcumin↑ HDL-C
(WMD = 5.77 mg/dL; 95% CI 2.90 to 8.64; p < 0.001)
Jalali et al. 2020
[203]		6 publications [34,50,161,164,165,177]NAFLD40733–58P8–1250–1425 mg/day of curcumin↔ TG
(MD = −0.608; 95% CI −1.253 to 0.038; p = 0.065)
↓ LDL-C
(MD = −1.028; 95% CI −1.942 to −0.113; p = 0.028)
↓ TC
(MD = −0.645; 95% CI −1.047 to −0.243; p = 0.002)
↔ HDL-C
(MD = 0.880; 95% CI −0.285 to 2.044; p = 0.139)		Jadad scale (88.9%)PubMed, Embase, Scopus, Web of Science, and Cochrane Library
Mendia et al. 2019 [213]17 publications [45,51,52,65,101,114,118,126,138,161,177,182,183,214,215,216,217]T2DM, Mets, NAFLD, COPD, dyslipidemia, CAD, acute coronary syndrome, healthy, elderly120530–83P,
CO		4–2445–4000 mg/day of curcumin,
294–1000 mg/day of curcuminoids, 1200 mg/day of turmeric		↔ LDL-C
(WMD = −5.82 mg/dL; 95% CI −15.80 to 4.16; p = 0.253)		Cochrane risk of bias tool (55.0%)PubMed–Medline, Scopus, and Web of Science
19 publications [31,45,51,52,62,65,101,114,126,138,161,177,182,183,214,215,216,217,218]T2DM, Mets, NAFLD, COPD, dyslipidemia, CAD, acute coronary syndrome, healthy, elderly143923–83P,
CO		1–2445–6000 mg/day of curcumin,
294–1000 mg/day of curcuminoids, 1200 mg/day of turmeric		↓ TG
(WMD = −21.36 mg/dL; 95% CI −32.18 to −10.53; p < 0.001)
18 publications [45,51,52,62,101,114,118,126,138,161,177,182,183,214,215,216,217,218]T2DM, Mets, NAFLD, COPD, dyslipidemia, CAD, acute coronary syndrome, healthy, elderly124723–83P,
CO		1–2445–6000 mg/day of curcumin,
294–1000 mg/day of curcuminoids, 1200 mg/day of turmeric		↔ TC
(WMD = −9.57 mg/dL; 95% CI −20.89 to 1.75; p = 0.098)
16 publications [45,51,52,65,101,114,126,138,161,177,182,183,214,215,216,217]T2DM, Mets, NAFLD, COPD, dyslipidemia, CAD, acute coronary syndrome, elderly114530–83P,
CO		4–2445–4000 mg/day of curcumin,
294–1000 mg/day of curcuminoids, 1200 mg/day of turmeric		↓ HDL-C levels
(WMD = 1.42 mg/dL; 95% CI 0.03 to 2.81; p = 0.046)
Azhdari et al. 2019 [204]5 publications [25,61,126,138,172]Mets25930–72P6–1220–1890 mg/day of curcumin,
1000 mg/day of curcuminoids,
2400 mg/day of turmeric		↓ TG
(WMD = −33.65 mg/dL; 95% CI −51.27 to −16.03; p < 0.001)
↑ HDL-C
(WMD = 4.31 mg/dL; 95% CI 1.50 to 7.11; p = 0.003)		Cochrane risk of bias tool (59.2%)Web of Science, MEDLINE, Google Scholar, Scopus, Cochrane, and CINAHL
Tabrizi et al. 2018 [207]19 publications [25,31,45,51,52,57,87,101,114,126,138,161,178,183,206,208,214,219,220]Mets, hyperlipidemia, T2DM, acute coronary syndrome, overweight/obese, diabetic nephropathy, NAFLD, CAD139618–73P4–2480–2000 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
112–2100 mg/day of turmeric		↓ TG
(SMD = −1.21; 95% CI −1.78 to −0.65; p < 0.001)		Cochrane risk of bias tool (76.9%)Cochrane Library, EMBASE, MEDLINE, and Web of Science
20 publications [25,45,51,52,57,87,101,114,126,138,161,178,182,183,206,208,209,214,219,220]Mets, hyperlipidemia, T2DM, acute coronary syndrome, overweight/obese, diabetic nephropathy, NAFLD, CAD122918–73P4–2470–2000 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
300–2100 mg/day of turmeric		↓ TC
(SMD = −0.73; 95% CI −1.32 to −0.13; p = 0.01)
21 publications [25,45,46,51,52,57,87,101,114,126,138,161,178,182,183,206,208,209,214,219,220]Mets, hyperlipidemia, T2DM, acute coronary syndrome, overweight/obese, diabetic nephropathy, NAFLD, CAD128918–73P4–2470–2000 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
112–2100 mg/day of turmeric		↔ LDL-C
(SMD = −0.52; 95% CI −1.14 to 0.11; p = 0.10)
20 publications [25,45,51,52,57,87,101,114,126,138,161,178,182,183,206,208,209,214,219,220]Mets, hyperlipidemia, T2DM, acute coronary syndrome, overweight/obese, diabetic nephropathy, NAFLD, CAD122918–73P4–2470–2000 mg/day of curcumin,
300–1000 mg/day of curcuminoids,
300–2100 mg/day of turmeric		↔ HDL-C
(SMD = 0.28; 95% CI −0.22 to 0.77; p = 0.27)
Qin et al. 2017 [221]7 publications [25,31,57,114,126,161,182]T2DM, Mets, NAFLD, dyslipidemia, prediabetes, prehypertension64928–72P4–1280 mg/day of curcumin,
70–1890 mg/day of curcuminoids,
2000–2400 mg/day of turmeric		↓ TG
(SMD = −0.214; 95% CI −0.369 to −0.059; p = 0.007)		Cochrane risk of bias tool (57.1%)PubMed, Embase, Ovid, Medlin, and Cochrane Library
6 publications [25,31,57,126,161,182]T2DM, Mets, NAFLD, dyslipidemia, prediabetes, prehypertension51228–72P4–1280 mg/day of curcumin,
70–1890 mg/day of curcuminoids,
2000–2400 mg/day of turmeric		↓ LDL-C
(SMD = −0.340; 95% CI −0.530 to −0.150; p < 0.0001)
↔ TC
(SMD = −0.38; 95% CI −0.78 to 0.01; p = 0.054)
↔ HDL-C
(SMD = 0.09; 95% CI −0.10 to 0.27; p = 0.370)
Sahebkar et al. 2014 [222]5 publications [52,114,214,215,218]T2DM, healthy obese, dyslipidemia, acute coronary syndrome, Alzheimer’s disease19723–83P,
CO		1–2445–6000 mg/day of curcuminoids↔ TG
(MD = −1.29 mg/dL; 95% CI −9.05 to 6.48; p = 0.75)
↔ TC
(MD = 8.97 mg/dL; 95% CI −4.56 to 22.51; p = 0.19)		Cochrane risk of bias tool (33.3%)PubMed–Medline, SCOPUS, Ovid-AMED, ClinicalTrials.gov, and Cochrane Library
4 publications [52,114,214,215]T2DM, obese, dyslipidemia, acute coronary syndrome, Alzheimer’s disease17327–83P,
CO		8–2445–4000 mg/day of curcuminoids↔ LDL-C
(MD = 16.15 mg/dL; 95% CI −4.43 to 36.74; p = 0.12)
↔ HDL-C
(MD = −0.59 mg/dL; 95% CI −1.66 to 0.49; p = 0.28)
CAD, coronary artery disease; CO, crossover; COPD, chronic obstructive pulmonary disease; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; DFU, diabetic foot ulcer; ES, effect size; ESRD, end-stage renal disease; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; MAFLD, metabolic (dysfunction)-associated fatty liver disease; MD, mean difference; Mets, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; P, parallel; PCOS, polycystic ovary syndrome; RCTs, randomized controlled trials; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglyceride; WMD, weighted mean difference. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale). ↑, increase; ↓, decrease; ↔ no effect.
Table 5. Meta-analyses of RCTs investigating the effect of curcumin intake on body weight, BMI, and waist circumference.
Table 5. Meta-analyses of RCTs investigating the effect of curcumin intake on body weight, BMI, and waist circumference.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Lukkunaprasit et al. 2023 [160]13 publications [34,35,50,161,164,165,166,167,168,175,176,178,181]MAFLD75625–38P8–1280–1500 mg/day of curcumin,
3000 mg/day of turmeric		↓ BMI
(MD = −0.34; 95% CI −0.62 to −0.05; p < 0.05)		Cochrane risk of bias tool (68.8%)Medline and SCOPUS
Qiu et al. 2023 [22]7 publications [23,25,61,170,171,172,223]Mets36928–64P4–1280–1000 mg/day of curcumin,
2400 mg/day of turmeric		↓ WC
(MD = −2.16; 95% CI −3.78 to −0.54; p = 0.009)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
Rozanski et al. 2023 [173]14 publications [34,35,50,55,161,164,165,166,174,175,176,177,178,179]MAFLD84718–70P8–1270–1500 mg/day of curcuminoids,
80–1000 mg/day of curcumin,
3000 mg/day of turmeric		↓ WC
(MD = −2.6303; 95% CI −4.9350 to −0.3256; p = 0.0253)		Cochrane risk of bias tool (90.8%)PubMed, Web of Science, and Scopus
Ngu et al. 2022 [180]11 publications [34,35,50,161,164,166,175,178,181,196,224]NAFLD70118–70P8–1250–1500 mg/day of curcumin,
2000 mg/day of turmeric		↓ BMI
(MD = −0.41; 95% CI −0.75 to − 0.07; p = 0.02)		Cochrane risk of bias tool (79.5%)Cochrane Central Register of Controlled Trials and PubMed
Sun et al. 2022 [100]15 publications [23,25,38,49,60,61,70,101,126,170,182,183,185,209,223]Mets, obese, hyperlipidemia, hypercholesterolemia, T2DM, IGT, IFG, DSPN99038–62P,
CO		4–1280–2400 mg/day of curcumin↓ BW
(WMD = −0.94 kg; 95% CI −1.40 to −0.47; p < 0.001)		Cochrane risk of bias tool (69.3%) Jadad scale
(77.0%)		PubMed, Embase, Web of Science, CNKI, Wanfang, and CBM
12 publications [23,25,38,49,61,70,170,183,185,188,209,223]Mets, obese, hypercholesterolemia, T2DM, IGT, IFG, DSPN88238–63P,
CO		4–1780–2400 mg/day of curcumin↔ WC
(WMD = −1.41 cm; 95% CI −2.82 to 0.004; p = 0.051)
16 publications [23,25,29,49,60,61,76,101,126,170,182,183,185,188,209,223]Mets, obese, hyperlipidemia, hypercholesterolemia, T2DM, IGT, IFG, DSPN, hemodialysis113538–70P,
CO		4–2480–2400 mg/day of curcumin↓ BMI
(WMD = −0.40 kg/m2; 95% CI −0.60 to −0.19; p < 0.001)
Khalili et al. 2022 [195]9 publications [34,50,161,165,166,176,179,181,196]NAFLD61942–67P4–1280–2000 mg/day of curcumin↔ BMI
(SMD = −0.13; 95% CI −0.29 to 0.02; p = 0.096)		Cochrane risk of bias tool (65.5%)Web of Science, Science Direct, PubMed, and Embase
Nouri et al. 2022 [192]4 publications [58,73,193,194]PCOS19828–31P6–1293.34–1500 mg/day of curcumin↔ BMI
(ES = −0.23 kg/m2; 95% CI −1.46 to 0.99; p = 0.70)		Cochrane risk of bias tool (75.0%)PubMed, Scopus, and ISI Web of Science
Shen et al. 2022 [99]7 publications [58,73,193,194,197,198,199]PCOS44720–38P6–2480–1500 mg/day of curcumin↓ BMI
(WMD = −0.267; 95% CI −0.450 to −0.084; p = 0.004)		Cochrane risk of bias tool (73.5%)PubMed, Embase, Cochrane Library, Web of Science, Scopus, Clinical Trials, Chinese Clinical Trial Registry, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, VIP database, and Wanfang Database
4 publications [58,73,193,197]PCOS22924–35P6–1293.34–1000 mg/day of curcumin↔ BW
(WMD = −0.924; 95% CI −2.009 to 0.162; p = 0.095)
2 publications [73,194]PCOS9724–35P8–1293.34–1500 mg/day of curcumin↔ WC
(WMD = −1.475; 95% CI −4.519 to 1.570; p = 0.342)
Abdelazeem et al. 2021 [115]4 publications [58,73,193,197]PCOS22924–35P6–1280–1000 mg/day of curcumin↔ BW
(MD = −0.15; 95% CI −0.56 to 0.27; p = 0.49)		Cochrane risk of bias tool (73.3%)PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar
2 publications [73,194]PCOS9724–35P8–1293.34–1500 mg/day of curcumin↔ WC
(MD = −1.47; 95% CI −4.52 to 1.57; p = 0.34)
5 publications [58,73,193,194,197]PCOS29624–39P6–1280–1500 mg/day of curcumin↔ BMI
(MD = −0.15; 95% CI −0.56 to 0.27; p = 0.49)
Altobelli et al. 2021 [201]3 publications [49,144,182]T2DM16830–70P8–1280–1500 mg/day of curcumin,
2100 mg/day of turmeric		↔ BMI
(ES = −0.30 kg/m2; 95% CI −0.62 to 0.02; p = 0.067)		Cochrane risk of bias tool (93.8%)Medline, EMBASE, ClinicalTrials.gov, Web of Science, Cochrane Library, and Scopus
Ashtary-Larky et al. 2021 [111]4 publications [23,50,171,185]Mets, T2DM, NAFLD24036–64P6–1240–80 mg/day of nano-curcumin↔ BW
(WMD = −0.51 mg/dL; 95% CI −1.85 to 0.82; p = 0.449)		Cochrane risk of bias tool (55.6%)PubMed, Scopus,
Embase, and Web of Science
6 publications [23,50,71,171,182,185]Mets, T2DM, NAFLD36436–67P6–1240–80 mg/day of nano-curcumin↔ BMI
(WMD = −0.35 mg/dL; 95% CI −0.76 to 0.04; p = 0.079)
4 publications [23,50,171,185]Mets, T2DM, NAFLD24036–64P6–1240–80 mg/day of nano-curcumin↔ WC
(WMD = −1.32 mg/dL; 95% CI −3.89 to 1.23; p = 0.310)
2 publications [23,171]Mets, NAFLD16036–64P6–1240–80 mg/day of nano-curcumin↔ FM
(WMD = −0.86 mg/dL; 95% CI −1.95 to 0.23; p = 0.123)
Mousavi et al. 2020
[225]		8 publications [39,52,124,126,161,223,226,227]Mets, prediabetic, obese, NAFLD, T2DM66738–59P4–3980–200 mg/day of curcumin,
1000–1500 mg/day of curcuminoids		↓ BW
(WMD = −1.14 kg; 95% CI −2.16 to −0.12; p = 0.02)		Jadad scale (81.8%)PubMed, Medline, SCOPUS, Cochrane Library. and Google Scholar
10 publications [52,89,124,126,161,178,182,223,226,227]Mets, obese, NAFLD, T2DM64526–59P4–1380–1000 mg/day of curcumin,
1000–1900 mg/day of curcuminoids		↓ BMI
(WMD = −0.48 kg/m2; 95% CI −0.78 to −0.17; p = 0.002)
6 publications [39,52,89,178,223,226]Mets, prediabetic, obese, NAFLD45626–57P4–39200–1000 mg/day of curcumin,
1000–1500 mg/day of curcuminoids		↔ WC
(WMD = −1.51 cm; 95% CI −4.041 to 1.003; p = 0.23)
Jalali et al. 2020 [203]5 publications [34,50,161,164,165]NAFLD27028–59P8–1250–80 mg/day of curcumin↔ BW
(MD = −0.051; 95% CI −0.271 to 0.170; p = 0.653)		Jadad scale (88.9%)PubMed, Embase, Scopus, Web of Science. and Cochrane Library
7 publications [34,50,124,161,164,165,181]NAFLD45328–59P8–1250–1500 mg/day of curcumin↔ BMI
(MD = −0.179; 95% CI −0.365 to 0.006; p = 0.058)
3 publications [50,124,165]NAFLD26935–58P8–1280–1425 mg/day of curcumin↓ WC
(MD = −1.005; 95% CI −1.304 to −0.706; p < 0.0001)
Baziar et al. 2020 [228]6 publications [34,35,50,161,164,165]NAFLD38542–46P8–1270–1500 mg/day of curcumin,
3000 mg/day of turmeric		↔ BW
(WMD = −0.60 kg; 95% CI −2.07 to 0.87; p = 0.423)		Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) (87.5%)PubMed/Medline, ISI Web of Science, Scopus, EMBASE, Cochrane Library, Google Scholar, Sid.ir, and Magiran.com
8 publications [34,35,50,161,164,165,178,179]NAFLD56742–54P8–1270–1500 mg/day of curcumin,
3000 mg/day of turmeric		↓ BMI
(WMD = −0.34 kg/m2; 95% CI −0.64 to −0.0; p < 0.05)
4 publications [50,165,178,179]NAFLD31842–54P8–1270–1500 mg/day of curcumin,
3000 mg/day of turmeric		↓ WC
(WMD = −2.12 cm; 95% CI −3.26 to −0.98; p < 0.001)
Akbari et al. 2019 [131]12 publications [25,45,52,124,126,161,178,182,208,223,226,229]Mets, obese, T2DM, hyperlipidemia, NAFLD85423–72P4–1280–2400 mg/day of curcumin,
294 mg/day of curcuminoids,
2100 mg/day of turmeric		↓ BMI
(SMD = −0.37; 95% CI −0.61 to 0.13; p < 0.01)		Cochrane risk of bias tool (77.8%)Cochrane Library, EMBASE, PubMed, and Web of Science
13 publications [25,32,39,45,46,52,126,161,178,208,223,226,229]Mets, obese, T2DM, hyperlipidemia, NAFLD123310–72P4–3680–2400 mg/day of curcumin,
294–1500 mg/day of curcuminoids,
2100–2800 mg/day of turmeric		↓ BW
(SMD = −0.23; 95% CI −0.39 to 0.06; p < 0.01)
8 publications [25,31,32,39,52,124,223,226]Mets, obese, T2DM84810–72P4–36200–2400 mg/day of curcumin,
1500 mg/day of curcuminoids		↓ WC
(SMD = −0.25; 95% CI −0.44 to −0.05; p = 0.01)
5 publications [25,32,52,223,226]Mets, obese30110–58P4–8200–2400 mg/day of curcumin↔ hip ratio
(SMD = −0.17; 95% CI −0.42 to 0.08; p = 0.18)
Wei et al. 2019
[230]		2 publications [161,231]NAFLD29941–57P8–24500–3000 mg/day of curcumin↓ BW
(MD = −2.27; 95% CI −3.11 to −1.44; p < 0.0001)		Cochrane risk of bias tool (75.0%)PubMed, EMBASE, and Cochrane Library
Azhdari et al. 2019 [204]4 publications [25,61,172,223]Mets24438–48P4–8800–2400 mg/day of curcumin↔ WC
(WMD = −0.41 cm; 95% CI −1.95 to 1.13; p = 0.6)		Cochrane risk of bias tool (59.2%)Web of Science, MEDLINE, Google Scholar, Scopus, Cochrane, and CINAHL
Jafarirad et al. 2019 [232]7 publications [35,146,161,165,177,227,233]NAFLD42940–65P8–1280–1500 mg/day of curcumin,
2000–3000 mg/day of turmeric		↔ BMI
(WMD = −0.21 kg/m2; 95% CI −0.71 to 0.28; p = 0.39)		Cochrane risk of bias tool (72.9%)PubMed, Scopus, Cochrane Library, and ISI Web of Science
7 publications [35,146,161,163,165,227,233]NAFLD36240–65P8–2480–1500 mg/day of curcumin,
3000 mg/day of turmeric		↔ BW
(WMD = −0.54 kg; 95% CI −2.40 to 1.31; p = 0.56)
4 publications [146,163,165,177]NAFLD22140–54P8–241000–1500 mg/day of curcumin,
2000 mg/day of turmeric		↔ WC
(WMD = −0.88 cm; 95% CI −3.76 to 2.00; p = 0.54)
BMI, body mass index; BW, body weight; CI, confidence interval; CO, crossover; DSPN, diabetic sensorimotor polyneuropathy; ES, effect size; FM, fat mass; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; MAFLD, metabolic (dysfunction)-associated fatty liver disease; MD, mean difference; Mets, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; P, parallel; PCOS, polycystic ovary syndrome; RCTs, randomized controlled trials; SMD, standardized mean difference; T2DM, type 2 diabetes mellitus; WC, waist circumference; WMD, weighted mean differences. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale) or good (GRADE). ↑, increase; ↓, decrease; ↔ no effect.
Table 6. Meta-analyses of RCTs investigating the effect of curcumin intake on blood pressure and endothelial function.
Table 6. Meta-analyses of RCTs investigating the effect of curcumin intake on blood pressure and endothelial function.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Lukkunaprasit et al. 2023 [160]5 publications [50,166,167,168,178]MAFLD35825–36P8–1280–1000 mg/day of curcumin↔ SBP
(MD = −0.29; 95% CI −0.91 to 0.34; p = 0.37)
↔ DBP
(MD = −0.02; 95% CI −0.55 to 0.52; p = 0.95)		Cochrane risk of bias tool (68.8%)Medline and SCOPUS
Qiu et al. 2023 [22]6 publications [23,25,27,61,170,171]Mets40528–61P6–1280–1000 mg/day of curcumin, 1000 mg/day of curcuminoids, 2400 mg/day of turmeric↔ SBP
(MD = −4.82; 95% CI −9.98 to 0.35; p = 0.07)		Cochrane risk of bias tool (71.4%)PubMed, SCOPUS, Cochrane Library, EMBASE, Web of Science, and China Biological Medicine
5 publications [25,27,61,170,171]Mets38328–61P6–1280–1000 mg/day of curcumin,
1000 mg/day of curcuminoids,
2400 mg/day of turmeric		↓ DBP
(MD = −2.8; 95% CI −4.53 to −1.06; p = 0.002)
Ashtary-Larky et al. 2021 [111]4 publications [23,50,76,171]Mets, NAFLD, T2DM, hemodialysis21337–68P6–1240–80 mg/day of nano-curcumin↓ SBP
(WMD = −7.09 mg/dL; 95% CI −12.98 to −1.20; p < 0.001)		Cochrane risk of bias tool (55.6%)PubMed, Scopus,
Embase, and Web of Science
3 publications [50,76,171]Mets, NAFLD, T2DM, hemodialysis18037–68P1240–80 mg/day of nano-curcumin,↔ DBP
(WMD = −0.07 mg/dL; 95% CI −1.12 to 0.97; p = 0.891)
Changal et al. 2020 [234]5 publications [66,235,236,237,238]Healthy, postmenopausal73319–70POne time,
8–12		25–5000 mg/day of curcumin↑ FMD
(SDM = 1.379; 95% CI 0.48 to 2.274; p = 0.003)		Not assessedPubMed, ClinicalTrials.gov, Scopus, and Embase
Hallajzadeh et al. 2019 [239]2 publications [66,235]Healthy6059–71P8–12150–2000 mg/day of curcumin↑ FMD
(WMD = 1.49; 95% CI 0.16 to 2.82; p < 0.05)		Cochrane risk of bias tool (not indicated)Cochrane Library,
EMBASE, PubMed, and Web of Science
4 publications [31,66,89,240]Healthy, postmenopausal, obese, T2DM31922–70P8–24150–2000 mg/day of curcumin↔ PWV
(WMD = −41.59; 95% CI −86.59 to 3.42; p > 0.05)
2 publications [66,240]Healthy, postmenopausal8453–68P8–12150–2000 mg/day of curcumin↔ Aix
(WMD = 0.71; 95% CI −1.37 to 2.79; p > 0.05)
3 publications [33,66,114]Healthy, depressive, T2DM13331–67P8–12150–2000 mg/day of curcumin↔ ET-1
(WMD = −0.30; 95% CI −0.96 to 0.37; p > 0.05)
3 publications [62,120,241]Healthy, perennial allergic rhinitis, dyslipidemia35326–62P4–1280–500 mg/day of curcumin↔ sICAM-1
(WMD = −10.11; 95% CI −33.67 to 13.46; p > 0.05)
Hadi et al. 2019 [242]11 publications [25,50,61,65,66,89,151,178,219,243,244]Mets, obese, lupus nephritis, T2DM postmenopausal, CKD, NAFLD, COPD, diabetic proteinuria, healthy, elderly73421–74P,
CO		8–2480–1000 mg/day of curcumin,
320–2400 mg/day of turmeric		↔ SBP
(ES = −0.69 mmHg; 95% CI −2.01 to 0.64)
↔ DBP
(ES = 0.28 mmHg; 95% CI −1.12 to 1.68)		Cochrane risk of bias tool (69.7%)Medline, EMBASE, SCOPUS, ISI Web of Science, Google Scholar, and Cochrane Library
Azhdari et al. 2019 [204]3 publications [25,27,61]Mets28038–45P81000 mg/day of curcumin,
1000 mg/day of curcuminoids,
2400 mg/day of turmeric		↔ SBP
(WMD = −1.68 mmHg; 95% CI −4.68 to 1.3)
↓ DBP
(WMD = −2.96 mmHg; 95% CI −5.09 to −0.83; p = 0.007)		Cochrane risk of bias tool (59.2%)Web of Science, MEDLINE, Google Scholar, Scopus, Cochrane, and CINAHL
Aix, augmentation index; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; ES, effect size; ET-1, endothelin-1; FMD, flow-mediated dilation; MAFLD, metabolic (dysfunction)-associated fatty liver disease; MD, mean difference; Mets, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; P, parallel; PWV, pulse wave velocity; RCTs, randomized controlled trials; SBP, systolic blood pressure; SDM, standard difference in means; sICAM-1, soluble intercellular adhesion molecule-1; T2DM, type 2 diabetes mellitus; WMD weighted mean differences. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale). ↑, increase; ↓, decrease; ↔ no effect.
Table 7. Meta-analyses of RCTs investigating the effect of curcumin intake on depression and cognitive function.
Table 7. Meta-analyses of RCTs investigating the effect of curcumin intake on depression and cognitive function.
Ref.No. of Studies IncludedHealth Status of SubjectsNo. of SubjectsAge of Subjects (Years)DesignPeriod
(Weeks)		DoseOutcomes
(Effect Size)		Quality of Primary StudiesDatabases
Wang et al. 2021 [245]6 publications [139,246,247,248,249,250]MDD (DSM-IV or Mini 6.0)52040–76P5–12500–1500 mg/day of curcumin↓ Depression
(SMD = −0.35; 95% CI −0.56 to −0.15; I2 = 7%)		Cochrane risk of bias tool (71.7%)EMBASE, PubMed, PsycINFO, Web of Science, Cochrane Library, and ClinicalTrials.gov
4 publications [251,252,253,254]T2DM, obesity, schizophrenia (DSM-IV), systemic lupus erythematosus7725–68P,
CO		4–2480–3000 mg/day of curcumin↔ Depressive symptoms
(SMD = −0.32; 95% CI −0.50 to −0.13; I2 = 15%)
3 publications [139,248,250]MDD (DSM-IV)44023–53P6–12500–1000 mg/day of curcumin↑ Response rates
(OR = 3.20; 95% CI 1.28 to 7.99; I2 = 35%)
Fusar-Poli et al. 2020 [255]9 publications [139,246,247,248,249,250,252,254,256]MDD (DSM-IV), obesity, systemic lupus erythematosus59917–81P,
CO		4–12150–1500 mg/day of curcumin↓ Depression
(Hedge’s g = −0.75; 95% CI −1.11 to −0.39; p < 0.001; I2 = 26.28%)		Cochrane risk of bias tool (71.4%)Web of Science, MEDLINE, KCI, Russian Science Citation Index, SciELO Citation Index, CINAHL, Embase, PsycINFO, and ClinicalTrials.gov
4 publications [248,249,252,256]MDD (DSM-IV), obesity32017–80P4–12500–1000 mg/day of curcumin↓ Anxiety symptoms
(Hedge’s g = −2.62; 95% CI −4.06 to −1.17; p < 0.001)
unNg et al. 2017 [257]6 publications [139,246,249,250,252,256]CGI-S ≥ 4,
HAM-D17 ≥ 21, MADRS ≥ 22, BDI-II, DSM-IV, IDS-SR30 ≥ 14, HAM-D17 ≥ 7, HAM-D17 ≥ 10, MADRS ≥ 14		37730–76P,
CO		4–8500–1000 mg/day of curcumin↓ Depressive symptoms
(SMD = −0.344; 95% CI −0.558 to −0.129; p = 0.002)		Jadad scale (100%)PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety, and Neurosis Group (CCDANTR), and Cochrane Field for Complementary Medicine
Al-Karawi et al. 2017 [258]6 publications [139,246,249,250,252,256]CGI-S ≥ 4,
HAM-D17 ≥ 21, MADRS ≥ 22, BDI, DSM-IV, IDS-SR30 ≥ 14, HAM-D17 ≥ 7 HAM-D17 ≥ 10, MADRS ≥ 14		37730–76P,
CO		4–8500–1000 mg/day of curcumin↓ Major depression (SMD = −0.34; 95% CI −0.56 to −0.13; p = 0.002)Quality Assessment Tool for Quantitative Studies (83.3%)Pubmed, Scopus, Psychinfo, Evidence-Based Medicine Guidelines, DynaMed, JAMA evidence, and Cochrane Library
Tsai et al. 2021 [259]6 publications [260,261,262,263,264,265]Alzheimer’s disease, obese, schizophrenia, healthy older adults26428–82P6–24160–4000 mg/day of curcumin↔ Cognitive function
(Hedges’ g = 0.340; 95% CI −0.353 to 1.033; p = 0.337; I2 = 0.0%)		Cochrane risk of bias tool (89.6%)PubMed, Embase, ClinicalKey, Cochrane CENTRAL, ProQuest, ScienceDirect, and Web of Science
3 publications [261,266,267]Schizophrenia, obese, healthy older adults16028–76P8–1680–180 mg/day of curcumin↑ Working memory
(Hedges’ g = 0.396; 95% CI 0.078 to 0.714; p = 0.015; I2 = 0.0%)
Zhu et al. 2019 [268]3 publications [118,263,269]healthy, elderly, nondemented19654–73P4–7280–1320 mg/day of curcumin↑ Cognitive function in the elderly
(SMD = 0.33; 95% CI 0.05 to 0.62; p = 0.02)		Cochrane risk of bias tool (80.0%)PubMed, Embase,
Web of Science, ClinicalTrials.gov, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, and China Biology Medicine disc
Sarraf et al. 2019 [270]4 publications [172,262,271,272]Mets, premenstrual syndrome, schizophrenia,13918–65P8–12200–1820 mg/day of curcumin↑ BDNF
(WMD = 1789.38 pg/mL; 95% CI 722.04 to 2856.71; p < 0.01; I2 = 83.5%; p < 0.001)		Cochrane risk of bias tool (not indicated)PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar
BDNF, brain-derived neurotrophic factor; BDI-II, Beck Depression Inventory II; CGI-S, Clinical Global Impression Severity Scale; CI, confidence interval; CO, crossover; DSM, diagnostic and statistical manual of mental disorders; HAM-D17, Hamilton Depression Rating Scale, 17-item version; IDS-SR30, Inventory of Depressive Symptomatology—Self-rated; MADRS, Montgomery–Åsberg Depression Rating Scale; MDD, major depressive disorder; Mets, metabolic syndrome; OR, odds ratio; P, parallel; RCTs, randomized controlled trials; SMD, standardized mean difference; T2DM, type 2 diabetes mellitus; WMD, weighted mean differences. The quality of primary studies is indicated as a percentage of low risk (Cochrane risk of bias tool) or ≥3 (Jadad scale). ↑, increase; ↓, decrease; ↔ no effect.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, Y.-M.; Kim, Y. Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials. Nutrients 2024, 16, 1728. https://doi.org/10.3390/nu16111728

AMA Style

Lee Y-M, Kim Y. Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials. Nutrients. 2024; 16(11):1728. https://doi.org/10.3390/nu16111728

Chicago/Turabian Style

Lee, Young-Min, and Yoona Kim. 2024. "Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials" Nutrients 16, no. 11: 1728. https://doi.org/10.3390/nu16111728

APA Style

Lee, Y. -M., & Kim, Y. (2024). Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials. Nutrients, 16(11), 1728. https://doi.org/10.3390/nu16111728

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop